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Multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) and myelin 
oligodendrocyte glycoprotein (MOG) IgG associated disorders (MOGAD) are immune-me-
diated demyelinating diseases of the central nervous system (CNS)1-5. For all three entities, 
disability accumulates due to ongoing brain volume loss and incomplete recovery from 
relapses6. These diseases are presumed to be mediated by pro-inflammatory B and T cells 
and/or antibodies that cross the endothelial cell layer between peripheral blood and the 
CNS (in simplified form called the blood brain barrier, BBB) and target specific parts of the 
CNS. This is most likely the myelin-sheath in MS and MOGAD and the astrocyte in AQP4 IgG-
positive NMOSD. Local inflammation, demyelination and CNS cell death (neurons, oligoden-
drocytes and astrocytes) are seen as typical and probably sequential pathological events2, 
7-10. In contrast to MS, the transfer of peripherally produced autoantibodies into the CNS is 
probably the main pathogenic event in both NMOSD and MOGAD11. In NMOSD, MOGAD and 
MS, (auto)antigen-specific targeting of the CNS is likely the result of pathogenic lymphocytes 
that are inadequately controlled in the periphery. 
Increased understanding of the lymphocyte subsets that drive MS, NMOSD and MOGAD 
may help to better predict the disease course and optimize current treatment regimens in a 
more personalized manner. New insights into their pathogenicity will even provide a ratio-
nale for developing more targeted therapeutic strategies. In the current thesis, the develop-
ment, antigen specificity and local recruitment of disease-relevant lymphocyte subsets will 
be explored in patients with MS, NMOSD and MOGAD. 
Epidemiology and clinical features of MS
The prevalence of MS is 127 per 100,000 in Western Europe and the global number of 
patients exceeds 2 million12. MS affects mostly young people (disease onset most frequently 
between 20 and 40 years of age), resulting in a significant loss of quality-adjusted life years12. 
Although the cause of MS remains elusive, factors that are known to increase MS risk include 
genetic predisposition, infections, female sex and smoking13-15. These factors all can impact 
the immune system as will be discussed later in this chapter. 
A schematic representation of the MS course is displayed in figure 1. For most MS patients, 
the disease starts with an episode of clinical symptoms reflecting subacute demyelination in 
optic nerves, spinal cord or brain stem5, 16. This first episode is called clinically isolated 
syndrome (CIS, Table 1)17. During this episode, lymphocyte subsets infiltrate the central 
nervous system (CNS), predominantly white matter, due to profound leakage of the BBB 
resulting in typical demyelinated plaques18, 19. Most patients with CIS also have oligoclonal 
bands (OCB) composed of immunoglobulins (Ig) in their cerebrospinal fluid (CSF). These CSF 
OCB (identified after correction for bands in peripheral blood) are probably the result of 
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intrathecal Ig production20-22. After CIS, a significant proportion of patients (~60%) will experi-
ence a second demyelinating attack. This most often occurs within the next months or years, 
but intervals of 10-20 years have been reported17, 23. A second clinical relapse can define 
relapsing remitting MS (RRMS). In some patients, MS can be diagnosed without or even 
before second clinical relapse by showing dissemination in lesion location and in time using 
MRI24, 25. It is challenging to foresee whether individual patients will develop RRMS, although 
some risk factors are known including clinical factors (disease dissemination and first lesion 
location26) and exposure to environmental factors (discussed later on)27. Next to patients pre-
senting with CIS and RRMS, some patients (~10-15%) show a gradual increase of neurological 
disability from disease onset onwards. This disease type is referred to as primary progressive 
MS (PPMS)28-30 and is characterized by slow accumulation of lymphocytes in the perivascular 
space without significant BBB leakage19. 
Figure 1. The typical clinical course in an individual MS patient 
In the pre-clinical phase, first typical MRI lesions may be present without any clinical signs (radiologically isolated 
syndrome). In general, MRI-based disease activity is more frequent than clinical disease activity and sometimes 
goes unnoticed. The occurrence and duration of first symptoms caused by inflammation or demyelination defines 
a clinically isolated syndrome. When dissemination in space and in time is detected (via a second relapse or proven 
disease activity on MRI), the diagnosis of MS is clinically definite (relapsing-remitting MS). After a variable period 
(typically between 10-15 years), approximately 60% of the patients progress during which brain volume further 












RRMS patients will experience relapses of which the timing, duration and subsequent 
complaints are hard to predict9, 28, 31. Neuronal loss that occurs gradually from the start of 
disease can further increase due to incomplete relapse recovery. Around 60% of RRMS 
patients32 will develop secondary progressive multiple sclerosis (SPMS)28, 29, 33, who show 
more gradual and progressive deterioration. The pathogenesis of SPMS is more similar to 
PPMS than to RRMS19. Risk factors for developing secondary progressive MS are older age, 
male sex, longer disease duration, high disability score, rapid initial disease progression and 
increased number of relapses in the year prior to SPMS conversion34, 35.
Risk factors for MS
Early detection of individuals who are prone for developing MS would advance prognosis 
and treatment. Furthermore, it would aid in understanding the disease process and provide 
possible options to intervene. Many risk factors have been described for MS, of which the 
most have an impact on the immune system.
Table 1. Clinical phenotype, patient distribution and pathological hallmarks of various MS stages, NMOSD and 
MOGAD. s
Clinical phenotype Patients Pathology
CIS First episode of demyelination Female predominance (60-
70%)




RRMS Lesions have occurred at mul-




BBB leakage. CNS infiltration 
of mononuclear cells
SPMS Gradual progression, relapses 
in some patients can still oc-
cur but are less prominent
Female predominance (60-
70%)
Slow accumulation of mono-
nuclear cells in PVS
PPMS From initiation phase onwards 
progression dominates dis-
ease course
Equal sex ratio Slow accumulation of mono-
nuclear cells in PVS
NMOSD Fierce attacks of demyelina-




AQP-4 Ig produced in periph-
ery infiltrates and damages 
CNS (astrocytes)
MOGAD More often monophasic de-
myelination of optic nerves 
and/or spinal cord
Equal sex ratio MOG-Ig induced pathology
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MS is much more common among women compared to men (3:1 ratio)3, 36. In general, 
females live longer and healthier lives compared to males37 and female immune responses 
are more intense38. This is a double edged sword since females are more prone for most 
autoimmune diseases (AID)39, 40. The sex-based differences may originate from genes 
located at the X-chromosome41-43, harboring the largest number of immune-related genes 
of all chromosomes44. X-inactivation is not successful for about 15% of genes45, resulting in 
a cumulative higher expression of those genes in women. Furthermore, DNA-methylation 
patterns of the X-chromosome are parent-of-origin specific, resulting in reduced expression 
in paternally inherited X-chromosomes. This is female-specific as males always inherit their 
X-chromosome maternally42, 46. Overactivation of the female immune system via these path-
ways might contribute to the shifted sex-ratio in autoimmune diseases, including MS. Also 
sex-associated hormones are known to affect the immune system47-50. Compared to healthy 
males, male MS patients have lower levels of testosterone and these levels correlate with 
increased disability51. Restoring testosterone levels in male patients induces neuroprotec-
tion and reduces brain atrophy52, 53. In vitro testosterone exposure impairs differentiation of 
pathogenic lymphocytes54. In contrast, normal levels of female hormones induce pro-inflam-
matory responses whereas high levels, for instance during pregnancy, reduce the pro-inflam-
matory response40.
Pregnancy
MS disease activity is significantly lowered in the third trimester of pregnancy and MS 
relapse risk rises again after parturition55-58. These differences in MS risk coincide with 
pregnancy-induced shifts in hormone levels such as estrogens that show a peak in the third 
trimester and are reduced postpartum59. During pregnancy, there is need for a delicate bal-
ance between an active immune system providing protection to both mother and fetus and 
simultaneously maintaining a state of immune tolerance towards partly allogenic fetal HLA. 
Previously, it has been shown that the default T cell response in pregnant women switches 
from pro- to anti-inflammatory48. In pregnant healthy women, it has been shown that certain 
lymphocyte subsets of the adaptive part of the immune system alter in frequency during 
pregnancy and recuperate post-partum48, 60. Understanding which exact disease-relevant 
lymphocyte subsets change during the peri-pregnancy period might aid in predicting which 
patients are at increased risk for a post-partum relapse and deserve frequent monitoring or 
prophylactic treatment. 
Smoking
Smoking increases individual MS risk with approximately 50%61, 62 and in individual patients 












pro-inflammatory cytokines like interleukin (IL)-1764-66. Smoking cessation can reduce MS risk 
and reduce disability progression in confirmed cases67. In individuals with genetic suscepti-
bility for MS, smoking increased MS risk much more compared to patients without genetic 
predisposition63, 68, 69. 
Sunlight
The incidence of MS is much lower in countries around the equator. The increased sun 
exposure in these countries results in higher circulating levels of active vitamin D, which is 
likely to protect people from developing MS70-72. Vitamin D is a lipid-soluble precursor of 
active 1,25(OH)2D and can be recognized by the vitamin D receptor (VDR). VDR, a nuclear 
receptor transcription factor, is expressed in a variety of immune cells and binds to VDR 
responsive elements (VDRE) of gene promoter regions, which are enriched in MS risk loci73, 
74. Dendritic cells, involved in both the innate and adaptive parts of the immune system, are 
crucial in mediating the immune modulatory function of 1,25(OH)2D by transporting vita-
min D metabolites to the draining lymph nodes75. 1,25(OH)2D reduces the differentiation of 
pro-inflammatory CD4+ T cells71. Altogether, 1,25(OH)2D shifts the human immune system to 
a more anti-inflammatory profile, which might explain the protective effect of appropriate 
vitamin D levels on MS risk71, 76.
Epstein Barr Virus infection
One of the strongest environmental risk factors for MS development is a history of symp-
tomatic infection with Epstein Barr virus (EBV)77, 78. EBV is a B- and plasma cell-tropic virus 
infecting the majority of individuals (~90%). MS patients are almost universally seropositive 
for EBV78. Primary EBV infection occur most often during childhood and is asymptomatic 
or with minor complaints79. However, with increasing age, primary EBV infection is more 
frequently associated with infectious mononucleosis (IM)80, a symptomatic infection with 
sometimes long lasting complaints of fatigue. It has been reported that IM increases per-
meability of the blood-brain barrier with subsequent infiltration of lymphocytes into the 
CNS81. MS patients more often show a history of IM than healthy individuals82. In light of the 
association between age of primary infection and IM, it is interesting to see that high titers of 
EBV antibodies in mothers during pregnancy increase the risk for MS in the offspring83. Here, 
it might be possible that these Igs delay the child’s own EBV-specific immune response due 
to long lasting maternal protection. Individuals with genetic MS predisposition have higher 
titers of EBV-specific antibodies84, 85. 
Genetics
MS is partly heritable as shown by the increased likelihood of developing MS when a family 
member has been diagnosed86, 87. Concordance in monozygotic twins is around 25-30%88-90 
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and in discordant monozygotic twins, the healthy twins immune system often shows signs of 
aberrant activation91. A significant part of the heritability has been explained almost entirely 
via genes acting on the adaptive immune response. The largest genetic risk allele is found 
in the protein complexes involved in presenting foreign antigens to T cells from the adap-
tive immune system: the human leukocyte antigens (HLA, explained later in more detail). 
The presence of HLA-DRB1*15:01 increases MS risk approximately three times92-95. This 
haplotype increases HLA class II expression on various antigen-presenting cells96, 97, making 
these cells more likely to be involved in immune responses. In HLA-DRB1*15:01-positive MS 
patients, brain homing of cells involved in adaptive immunity (i.e. B and T lymphocytes) is 
induced98. In contrast, certain HLA class I haplotypes are associated with relative protection 
against MS development99, 100. Next to the major HLA haplotypes, minor genetic variants are 
associated with increased MS risk as well. Genome wide association studies (GWAS) with 
large numbers of patients and controls identified 200 additional risk alleles43, of which the 
majority is active in B and T lymphocytes101. 
The role of the immune system in MS 
It has long been considered that the immune system plays an important role in the initi-
ation and progression of MS. The presence of oligoclonal immunoglobulin bands in CSF has 
been known for over 60 years102 and MS is generally recognized as an autoimmune disease 
although this has not been fully proven. In patients with autoimmune diseases (AID), lym-
phocytes specifically recognize and respond to an autoantigen or epitope, eventually result-
ing in tissue damage. The originally defined criteria for AID in Witebksy’s postulates103, 104 
include the presence of circulating antibodies directed against an autoantigen, development 
of comparable clinical phenotype after immunization with this particular antigen and/or dis-
ease induction after transfer of autoantigen-specific immune cells or serum containing auto-
antibodies22. In MS, however, the target antigen(s) of lymphocytes still has to be uncovered 
and therefore does not fulfil these criteria. Multiple studies have been trying to identify the 
antigenic targets of B cells and T cells in MS immunopathology, until now without satisfying 
results. 
Further evidence of the role of the immune system in MS comes from the fact that most 
of the various drugs that exist for reducing MS disease activity and preventing relapses, 
target the adaptive arm of the immune system105. For instance, anti-CD20 and -CD52 ther-
apy is highly effective in MS by reducing both B- and T-cell responses106, 98. Interferon-β, the 
oldest approved drug for MS treatment, is a cytokine likely to suppress interferon-γ activity 
and by doing so shifts the T cell response to a more anti-inflammatory one107. Congruently, 
glatiramer acetate108, a compound containing four amino acids found in myelin basic pro-
tein (MBP), reduces T cell pro-inflammatory cytokine responses. Furthermore, natalizumab, 












is an effective treatment in MS, preventing relapses and disease progression109, 110. Finally, 
fingolimod, an agent blocking lymphocyte egress from lymph nodes, reduces frequencies of 
circulating immune cells, including B and T cells111, 112.
Elucidating the role the immune system plays in MS, therefore, remains an important 
aspect of unravelling the complex pathophysiology of MS.
Adaptive immunity: specific protection against infections
The human immune system protects the body against pathogens via innate and adap-
tive responses. The innate response is initiated after the detection of pathogen-associated 
molecular patterns (PAMPs) which are recognized by pattern recognition receptors (PRR) 
expressed on macrophages and dendritic cells (DC)113, 114. PRR-mediated signaling triggers 
microbicidal and pro-inflammatory responses that are required to eliminate infectious 
agents115, 116. Furthermore, PRR enable detection cellular debris116. DC are professional anti-
gen-presenting cells (APC) that internalize, process and present antigens on the cell surface 
via human leukocyte antigen (HLA) molecules75. HLA-molecules are encoded by the highly 
polymorphic major histocompatibility complex (MHC) gene complex117. Two HLA classes 
exist, both with three different HLA loci: HLA-A, HLA-B and HLA-C for class I118, 119 and HLA-DR, 
HLA-DP and HLA-DQ for class II120-122. DC, like other antigen-presenting cells (macrophages, 
thymocytes, B cells), express HLA class II molecules enabling the presentation of exogenously 
derived and phagocytosed antigens (e.g. bacteria or fungi) to CD4+ T helper (Th) cells121. HLA 
class I molecules are expressed on every nucleated cell in the human body and classically 
present peptides generated within a cell, for example viral antigens123, to CD8+ cytotoxic T 
cells (CTLs). DCs also have the ability to present exogenously derived antigens on HLA class I 
molecules, a process termed cross presentation124. 
Development of T and B cells
All T and B cells develop from the common lymphocyte progenitor cell (fig 2). The anti-
gen-specific receptors are generated via a process of relatively random DNA rearrangements 
of variable, joining and in some cells also diversity gene segments, a process called V(D)J 
recombination125-127, resulting in a broad repertoire of antigen-specific T and B cell receptors 
(TCR and BCR respectively). 
After the development in the bone marrow, T lineage cells transmigrate into to the thymus 
and mature into pro-thymocytes. Via TCR rearrangements, cells expressing a functional TCR 
differentiate into common thymocytes. Double-negative thymocytes evolve in double posi-
tive thymocytes, expressing both CD4 and CD8 receptors. These undergo positive selection 
in the thymic cortex, eliminating cells with non-responsive TCRs. Cells become either CD8+ or 
CD4+ T cells based on the affinity of the TCR for HLA class I and II molecules, respectively128. 
After positive selection, thymocytes are directed into the medulla. where cells that show 
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high affinity to autologous peptides presented by thymic antigen-presenting cells are deleted 
(negative selection)129. Alternatively, autoreactive cells can become regulatory T cells130. 
Naive CD4+ and CD8+ T cells eventually leave the thymus and enter the circulation. 
B cells emerge from common hematopoietic cells in the bone marrow. BCR repertoire 
diversities are further increased via random nucleotide deletions, which can result in read-
ing frame shifts131. Comparable to TCR, BCR selection occurs, first via the central tolerance 
checkpoint132-134. B cells with strong responses to autologous peptides undergo apoptosis. 
Alternatively, BCR can be edited via secondary recombination to alter their specificity134. 
After passing this checkpoint, immature B cells undergo positive selection and become tran-
sitional IgM+ B cells that can no longer edit their BCR134. These cells enter the circulation. In 
Figure 2. Lymphocyte development and maturation within lymphoid organs. 
Common hematopoietic cells reside in the bone marrow and can give rise to various types of lymphocytes in the 
human blood. Pro-thymocytes enter the thymus and, after positive and negative selection, leave the thymus as a 
naive T cell. In secondary lymphoid organs, they are activated by dendritic cells and develop into effector and mem-
ory cells. B cells develop in the bone marrow and, after passing central tolerance checkpoints, enter the circulation 
as transitional B cells. At the follicular border within secondary lymphoid organs, naive mature B cells interact with 
CD4+ T cells and subsequently become short lived plasmablasts (not shown) or enter the germinal center (GC). After 
GC-dependent interaction with T cells, B cells can become effector memory cells or plasma cells. For responses to 
T-cell independent antigens, B cells can become natural effector B cells and plasmablasts without any T cell help, 












the circulation, autoreactive B cells will go through peripheral tolerance checkpoints in the 
secondary lymphoid organs135-137. These checkpoints prevent the activation of naive mature B 
cells recognizing peptides derived from self-antigens in the absence of T cell help135-138.
Generation of a T-cell response
After DC have engulfed and processed an exogenous antigen, they migrate into secondary 
lymphoid organs. Here, the DC present peptides on HLA molecules to naive T cells, a process 
called priming139. Primed CD4+ T cells will proliferate, produce cytokines, express activation 
markers and become effector CD4+ T cells. These cells can in turn can help macrophages in 
killing engulfed pathogens by producing cytokines and provide B cell help for proliferation 
and antibody production140, 141. Different effector CD4+ T-cell subsets can be distinguished 
based on their cytokine secretion and receptor expression, as will be discussed later in this 
chapter. Like CD4+ T cells, primed cytotoxic CD8+ T cells undergo clonal expansion142. When 
effector CD8+ T cells encounter their HLA-peptide complex, they release substances that 
induce cell lysis (perforin)143 or apoptosis (granzymes)144. If the infection is cleared, most 
CD4+ and CD8+ T cells undergo apoptosis. However, some will develop into memory cells, 
providing protection when the same pathogen is encountered later in life. 
Generation of a B-cell response
BCR can recognize soluble and membrane bound peptides. Soluble forms of the BCR are 
known as antibodies8, 145, 146. Antibody binding to target cells induces cellular cytotoxicity or 
apoptosis (activation of death receptors, antigen-crosslinking or blockade of cell survival 
pathways)147. Naive B cells can be activated in a T cell dependent and independent manner. 
A T cell-independent (TI) antigen can activate B cells via BCR crosslinking or triggering of 
Toll-like receptors (TLRs), a subtype of PRRs recognizing structures that are common on 
micro-organisms148. In response to TI antigen, B cells can become natural effector cells or 
short lived plasmablasts. TI immune responses are generally characterized by low avidity and 
the absence of memory formation149, 150. In contrast, a T cell-dependent B-cell response is 
initiated in the follicular border within secondary lymphoid organs. After antigen processing 
and presentation by HLA class II molecules, naive mature B cells are activated by T follicu-
lar helper (TFH) cells via costimulatory receptors and cytokine production. B cells can then 
either leave the follicle and differentiate into short-lived plasmablasts or further mature 
within so-called germinal centers (GC)151. Increased strength and duration of the interaction 
between B and TFH cells facilitates their entry into the GC
151. The GC is composed of two 
zones: the light zone (affinity selection via interaction with TFH cells) and the dark zone (B cell 
receptor diversification and clonal expansion)145. Cells circulate between these zones until 
they leave the GC as switched memory (IgG+ or IgA+), unswitched memory (IgM+) or long-
lived plasma cells145 (fig 2). 
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In MS, antigenic targets of pathogenic B and T cells have not yet been elucidated. It is a 
matter of debate whether their pathogenicity is induced via infection with common viruses 
or bacteria, leading to bystander inflammatory demyelination152-154. In general, adaptive 
immune responses will give rise to tissue-resident memory lymphocytes that can respond 
quickly upon recognition of their target antigen. These cells are also found in the CNS of both 
healthy individuals and MS patients155-157. 
The concept of CNS immune privilege
Historically, the CNS was considered an immune privileged site with the BBB preventing 
entrance of infectious agents and potential harmful lymphocytes. However, during CNS infec-
tions, lymphocyte migration is necessitated and can therefore still occur158-161. More recently, 
the concept of immune privilege has been re-evaluated. It is now generally accepted that 
immune cells in meninges and parenchymal perivascular space (PVS) provide CNS immune 
surveillance159. The PVS has been shown to be an important location for T and B cell interac-
tion and tissue resident lymphocytes found here are phenotypically distinct from populations 
in the peripheral blood81. PVS tissue resident cells show reduced expression of differentiation 
markers and transcription factors as well as increased tissue homing markers156. Within the 
CNS, T cell populations differ greatly as well, as indicated by the predominance of CD4+ T cells 
in CSF, whereas brain parenchyma harbors significantly more CD8+ T cells155. Immune cells 
and large particles drain via CSF and interstitial fluid to deep cervical lymph nodes, using a 
functional lymphatic system originating from meninges162. 
Peripheral lymphocytes can enter the CNS using different routes: via the choroid plexus, 
meningeal vessels or the PVS163. Lymphocytes expressing certain chemokine receptors 
migrate towards their cognate chemoattractant in the CNS164, 165. For instance, C-X-C chemo-
kine receptor 3 (CXCR3) facilitates migration towards C-X-C motif chemokine ligand 10 
(CXCL10)166 whereas C-C chemokine receptor 6 (CCR6) induces attraction towards CCL20167. 
Interestingly, increased proportions of CSF T cells expressing CXCR3164 as well as CCR6168 have 
been shown. Other proteins like integrins169, 170, and adhesion molecules171 can facilitate cell 
migration as well. For instance, very-late antigen 4 (VLA-4) is an integrin involved in lym-
phocyte homing to various site of inflammation, including the gut, skin and the brain172-174. 
VLA-4 on lymphocyte cell surface interacts with vascular cell adhesion molecule 1 (VCAM-1), 
expressed by endothelial cells composing blood vessels175. Blocking this interaction is the 
rationale behind natalizumab treatment: an antibody targeting VLA-4, shown to be effective 
in reducing MS disease activity109, 170, 176, 177. Lymphocytes can recirculate between CNS and 
periphery178, 179. Due to selective migration it seems worthwhile to compare relative lym-
phocyte subset distribution in periphery and CNS in MS. Furthermore, it would be favorable 












disease compartment, since antigen-specific cells are likely to be enriched in the disease 
compartment.
Altered adaptive immunity and MS
A frequently used animal model to study neuroinflammation in MS is experimental 
autoimmune encephalomyelitis (EAE)180, 181. In this mouse model, CNS antigens (most often 
myelin-derived) are intrathecally injected, with or without an adjuvant to boost the immune 
system. This procedure gives rise to CD4+ T cells that carry TCR specific for myelin epitopes, 
which induce CNS lesions that are comparable to those found in MS patients182, 183. Adoptive 
transfer of these antigen-specific CD4+ T-cells to naive animals causes similar lesions184. 
Although EAE provides a valuable model studying neuroinflammatory processes, this model 
has its limitations. For example, the absence of genetic diversity due to use of inbred mouse 
stains185 and the known target of the antigen-specific response due to active immunization186 
differ with respect to MS. Since there are also differences in the immune system between 
men and mice187, one should be reserved when interpreting results in patients with MS.  
CD4+ T cells
From historical perspective, CD4+ T cells have been considered the main drivers behind 
MS pathology9, 188, 189, which is supported by the major risk locus HLA-DRB1*15:01190, 191 and 
observations in EAE93-95. Multiple Th subsets exist that can be distinguished based on cyto-
kine production and corresponding chemokine receptor expression128 (fig 3). Th1 (mainly 
producing interferon (IFN)-γ) and Th17 (mainly producing IL-17A and -F) cells are involved 
in pro-inflammatory responses such as in EAE and MS192-194. IFN-γ has been shown to induce 
oligodendrocyte cell death195 and is abundant in MS white matter lesions196. IL-17A has been 
reported to be associated with breakdown of the BBB in RRMS197. Th1 cells express tran-
scription factor T-bet, which triggers surface expression of CXCR3198. Th17 cells express tran-
scription factor RORγT199 and chemokine receptor CCR6200. In contrast, Th2 cells classically 
help B-cells to differentiate and proliferate and thereby facilitate antibody production194. 
This subset provides protection to parasitic infections and, via typical adaptive responses 
in atopic individuals, can contribute to asthma pathology201. Th2 cells express transcription 
factor GATA-3202 and can be identified by surface expression of CCR3, CCR4 and CCR8203. In 
MS, Th2 cells were found in type II brain lesions, characterized by antibody and complement 
disposition204. Tregs highly express FoxP3 and CD25205 and are critical for maintaining periph-
eral tolerance, limiting chronic inflammation and preventing autoimmune responses. Their 
most important cytokines are IL-10, TGF-β and IL-35206, 207. In MS, it has been shown that 
Tregs have reduced immune suppressive capacities208, 209 and adoptive transfer of this subset 
has been proposed as a therapeutic option210. Follicular T helper cells (TFH) convey a separate 
subset mainly helping B cells to produce antibodies and can be identified by the expression 
22





of CXCR5211-213. Follicular T helper cells are subdivided into TFH1, TFH2, TFH17 and TFHregs based on 
similar cytokine and transcription factor expression profiles as other Th subsets214. 
Multiple studies have been focused on addressing antigen specificity of CD4+ T cells in 
MS. Myelin peptides were most frequently assessed, but antigens derived from other cells 
in the CNS (i.e. neuronal or glial proteins) have been proposed as well215-218. Myelin-reactive 
CD4+ T cells have been shown to be present in MS patients and healthy individuals219-221. 
However, such T cells in healthy individuals were much less frequent222. Furthermore, in 
healthy individuals these cells showed a reduced activation status221 and produced anti-in-
flammatory IL-10 in contrast to pro-inflammatory IFN-γ, IL-17 and GM-CSF223. Recently, CD4+ 
T cells recognizing self-peptides and EBV antigens have been identified in MS patients car-
rying HLA-DRB1*15:0198, 224. Other reports indicate that EBV-reactive CD4+ T cells can cross 
react with myelin peptides78, 225. 
CD8+ T cells
Next to CD4+ T cells, cytotoxic CD8+ T cells are involved in MS immunopathology and 
activated CD8+ T cells are found in MS brain lesions155, 157, 226. CD8+ T cells could damage CNS 
tissue directly via cytotoxic responses since HLA class I is upregulated in the MS brain, most 
profound in severe and active lesions185, 227-229. Apoptotic-epitope specific CD8+ T cells with 
Figure 3. Classical T helper subsets with associated transcription factors, cytokines and chemokine receptors. 












strong inflammatory potential were found in MS CSF230, possibly aggravating newly formed 
lesions. Furthermore, oligoclonal expansion of CSF-derived memory CD8+ T cells has been 
observed231, 232 and granzyme B levels produced by these cells correlate to disease activ-
ity233, providing evidence for a local immune response. Certain proteins are associated with 
increased pathogenicity and CNS migration of CD8+ T cells in MS, like CCR6234 and melanoma 
cell adhesion molecule (MCAM)235. Expression of VLA-4, another protein enabling CNS migra-
tion discussed earlier, is upregulated on effector CD8+ T cells236, 237. The exact target of CNS-
infiltrating CD8+ T cells in MS patients remains unknown. Antigen-specific CD8+ reactivity 
towards myelin basic protein (MBP) was shown in a small cohort using CSF-derived T cells238. 
Myelin reactive CD8+ T cells expressing low levels of CD20 have been described recently239. 
These cells disappeared after anti-CD20 therapy and it cannot be ruled out that this con-
tributes to success of this therapy. More recently, EBV-responsive CD8+ T cells were found 
in higher frequencies in MS patients with active disease compared to patients with stable 
disease or healthy controls155, 240-242. 
B cells
In MS, in contrast to other AID like NMOSD133, only peripheral and not central B-cell 
tolerance checkpoints are impaired, which suggests MS-specific alternations in the selec-
tion of autoreactive naive B cells. As a result, not transitional but naive mature B cells show 
increased numbers of autoreactive clones and have an activated phenotype in the blood of 
MS patients136. These autoreactive B cells can contribute to MS immunopathology in distinct 
ways.
Antibody-dependent function
B cells are abundant in MS cerebrospinal fluid243, often harboring OCB244, and clonally 
expanded memory B and plasma cells are present in white matter demyelinated lesions245, 
246. Since short lived plasmablasts are the most predominant lymphocytes in MS CSF and 
abundance of these cells correlates with disease severity247, 248, it seems likely that these 
cells produce the OCB-IgG. Successful natalizumab treatment frequently omits OCB after 
two years244. However, although successful in reducing MS disease activity106, 249, 250, B cell 
depletion therapy via anti-CD20 therapy fails to omit the OCB106, even when applied intra-
thecally251. Until now, no clear universal target for MS OCB-IgG has been shown. Previously, 
OCB-IgG specificity for myelin epitopes has been reported252, 253. More recently, reactivity 
was shown to be rather patient specific254, targeting ubiquitous intracellular proteins255 or 
debris as result of cellular damage256. However, due to the high prevalance of OCB in MS 
and the correlation with different clinical characteristics, intrathecal antibody production by 
antibody secreting cells (ASC) can not be ruled out as pathogenic factor in MS. 
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In addition to antibody production, B cells can alter T-cell responses via antigen presenta-
tion, costimulation and cytokine production122, 257-259. After CD20-directed antibody therapy, 
pro-inflammatory and autoproliferative T cells were reduced in MS patients260. Furthermore, 
successful treatment of MS patients with glatiramer acetate affects B cell antigen-presen-
tation resulting in reduced differentiation of pro-inflammatory T cells and simultaneous 
induction of regulatory T cell differentiation261. Ectopic B cell follicle-like structures, enabling 
local B cell and T cell interaction, have been described in MS leptomeninges262-264. The pres-
ence of these structures correlates with subpial demyelination, advocating their pathological 
relevance263-265. Together these observations imply an important role for the antibody-in-
dependent B cell functions in MS immunopathology. An interesting hypothesis on B cell 
involvement in MS immunopathology has been put forward recently266. B-cell activation in 
peripheral lymph nodes enables CNS migration via expression of chemokine receptors and 
integrins. In the CNS, memory B cells can activate local T cells to mediate local inflammation 
and demyelination. Furthermore, memory B cells in the CNS can be re-activated and differ-
entiate into professional ASC after interaction with pathogenic Th cells, producing antibodies 
directed against yet unknown antigens112, 266. 
Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glyco-
protein antibody associated disease
Epidemiology and clinical features of NMOSD and MOGAD
Compared to MS, NMOSD are rare, with a disease prevalence of about 1 in a million267. 
The spectrum conveys a broad range of severe clinical presentations that are caused by 
(relapsing) inflammation of the optic nerve(s) and/or myelum1, 2, 268. Disease exacerbations 
are generally accompanied with greater disability compared to MS269, 270. Complaints of optic 
nerve involvement can be visual field defects, loss of visual acuity or loss of color vision. 
Spinal cord involvement can induce a relative acute paralysis of legs and sometimes arms 
together with disturbances in the sensory pathways, quite often accompanied by bladder 
dysfunction1, 2. An important difference between NMOSD and MS is the undisputed role of 
pathogenic antibodies with known specificity in most NMOSD patients and NMOSD’s com-
plete fulfillment of the Witebsky criteria for AID103, 104. In ~75% of patients with NMOSD-like 
symptoms, antibodies are found that target aquaporin-4 (AQP4), a water channel protein 
expressed on astrocytes within the CNS271. Transfer of AQP4 antibodies to animal models 
yields NMOSD-like disease272, demonstrating their pathogenicity and confirming the Witebsky 
criteria103, 104. About 10% of NMOSD patients are seropositive for antibodies targeting myelin 
oligodendrocyte glycoprotein (MOG). These antibodies have been shown to cause brain 












(MOGAD) with an NMOSD phenotype274. In 60% of patients with MOGAD, MOG-specific B 
cells are detected in the peripheral blood275. Clinical features of AQP4-IgG-positive NMOSD 
and MOGAD patients are significantly different276-278, including a different sex distribution, 
more relapses and increased need for immune modulatory medication for AQP4 seroposi-
tive patients279. The frequency of other AID in patients with NMOSD is 20-30%280, whereas 
MOGAD patients showed no elevated risk for these diseases281. Due to this difference in 
clinical characteristics, it is tempting to speculate that the immunopathogenesis is different 
between NMOSD and MOGAD. 
Immunopathogenesis
Recently, it has been reported that in patients with AQP4-IgG-positive NMOSD, both 
central and peripheral B tolerance checkpoints are defective133, 282. This enables autoreactive 
B cells to differentiate into ASC in a germinal center-dependent but also an antigen-indepen-
dent manner10, 133, 282. Whether similar checkpoint deficits are involved in MOGAD pathol-
ogy remains unknown. Plasmablast frequencies in the blood have been shown to increase 
during a NMOSD relapse, whereas it remains stable during an exacerbation in patients with 
MOGAD. This suggests the peripheral B-cell development is differentially regulated in these 
two diseases283. Some reports provide evidence for Th17 cell involvement in NMOSD and 
MOGAD immunopathology284-289. High IL-17 levels are associated with severe disability289. T 
cell involvement is further indicated by the IgG1 subclass of most AQP4- and MOG-specific 
antibodies285, 288. It is also not surprising that TFH subsets favoring B-cell differentiation and 
antibody production are more prominent in NMOSD290. In brain biopsies and post-mortem 
tissues, activated CD4+ cells were found in NMOSD286 and MOGAD287 patients. 
Adaptive immunity in NMOSD and MOGAD, the unknowns
Individual patient based fine-tuning of current treatment is warranted. At present, ste-
roids are given to treat acute disease relapses in both NMOSD and MOGAD, but their use is 
also accompanied by serious side effects291. Furthermore, due to these effects they can only 
be prescribed for a limited time frame, and thus they are not suitable for preventing relapses 
in NMOSD patients292. Adequate prediction of which patients will benefit from steroid treat-
ment and at which specific moment in time is currently not possible. Since most previous 
research has been performed using patients receiving immunomodulatory treatment, the 
determination of essential B cell subsets involved in NMOSD/MOGAD immunopathology can 
be hampered. Development of a prediction model defining optimal starting and cessation 
points for steroid treatment would benefit patients to a great extent. Furthermore, if patho-
genic lymphocyte subsets can be identified in NMOSD and MOGAD, it might be possible to 
develop compounds that selectively interfere with their development in the periphery. 
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SCOPE OF THIS THESIS
This thesis focusses on the development, specificity and local recruitment of lympho-
cytes in different central nervous system autoimmune diseases (AID): multiple sclerosis 
(MS), neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte 
glycoprotein (MOG)-antibody associated disease (MOGAD) with a clinical presentation of 
NMOSD. Chapter 1 will provide an introduction based on relevant current understanding 
of both diseases. MS is most the most prevalent AID of the CNS whilst NMOSD is relatively 
rare. Both disorders however can provide distinct knowledge about protective immunity and 
alterations that can yield pathogenic immunity contributing to neurological disease. In this 
thesis, we aimed to uncover the identity, specificity and effector function of lymphocytes 
involved in CNS inflammatory demyelinating disease. Furthermore, we tried to find markers 
predicting individual clinical courses. The first part focusses on T-lymphocytes in MS, histori-
cally thought as most important in its disease pathology; Chapter 2 studies antigen-specific-
ity of intrathecal CD4+ and CD8+ T cells derived from the cerebrospinal fluid against a panel 
of candidate auto-antigens. In chapter 3 we examine a newly discovered type of CD4+ T cell: 
the Th17.1 cell, and compare its presence and activation status in MS blood, cerebrospinal 
fluid and brain tissue. In chapter 4, we address a functionally distinct B cell subset known to 
be involved in autoimmunity: the T-bet+ B cell. We compare its presence in early MS (CSF 
and blood) as well as different post-mortem CNS compartments from end-stage MS donors, 
and perform in vitro assays to study its development and CNS infiltration capacity. Chapter 5 
focusses on the impact of pregnancy, a naturally occurring modifier of MS disease activity, on 
GC-dependent B-cell differentiation both ex vivo and in vitro. Finally, in chapter 6, we study 
how B-cell differentiation can be linked to relapses and steroid treatment in patients with 
NMSOD and MOGAD. The composition of the peripheral B-cell compartment is compared 
to patients with MS. In chapter 7, the main findings of this thesis are brought together and 
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MS pathology is potentially orchestrated by autoreactive T-cells, but the 
antigens recognized remain unknown. A novel APC/T-cell platform was devel-
oped to determine intrathecal CD4+ and CD8+ T-cell responses to candidate 
MS-associated autoantigens (cMSAg) in clinically isolated syndrome (CIS, n=7) 
and MS (n=6) patients. Human cMSAg encoding open reading frames (n=8) 
were cloned into an Epstein–Barr virus (EBV)-based vector to express cMSAg 
at high levels in EBV-transformed B-cells (BLCLs). Human cMSAg cloned were 
myelin-associated MAG) and -oligodendrocyte glycoprotein (MOG), myelin 
basic protein (MBP), proteolipid protein (PLP), ATP-dependent potassium chan-
nel ATP-dependent inwards rectifying potassium channel 4.1 (KIR4.1), S100 cal-
cium-binding protein B (S100B), contactin-2 (CNTN2), and neurofascin (NFASC). 
Transduced BLCLs were used as autologous APC in functional T-cell assays to 
determine cMSAg-specific T-cell frequencies in cerebrospinal fluid derived 
T-cell lines (CSF-TCLs) by intracellular IFN-γ flow cytometry. Whereas all CSF-TCL 
responded strongly to mitogenic stimulation, no substantial T-cell reactivity to 
cMSAg was observed. Contrastingly, measles virus fusion protein-specific CD4+ 
and CD8+ T-cell clones, used as control of the APC/T-cell platform, efficiently 
recognized transduced BLCL expressing their cognate antigen. The inability to 
detect substantial T-cell reactivity to eight human endogenously synthesized 
cMSAg in autologous APC do not support their role as prominent intrathecal 




















MS is a chronic neurological disorder characterized by inflammation, demyelination, 
and axonal loss leading to accumulative disability1. MS immunopathology has been widely 
studied in EAE models2. EAE is induced by immunization of animals using various, mainly 
myelin-derived CNS proteins, or by adoptive transfer of autoreactive T-cells. Autoreactive 
CD4+ and CD8+ T-cells are analogously assumed to orchestrate MS pathology, but candidate 
MS autoantigen (cMSAg) targets remain enigmatic1,2.
Several cMSAgs have been proposed including oligodendrocyte-specific proteins like 
myelin-associated glycoprotein (MAG), myelin basic protein (MBP), myelin oligodendrocyte 
glycoprotein (MOG) and proteolipid protein (PLP), glia-specific proteins like inwards rectify-
ing potassium channel (KIR4.1, ATP-dependent inwards rectifying potassium channel 4.1) and 
S100 calcium-binding protein (S100B) and neuron-specific proteins like contactin-2 (CNTN2) 
and neurofascin 155kD isoform (NFASC)1,2. The majority of studies detailing cMSAg-specific 
T-cells in MS patients assayed peripheral blood with conflicting outcome1,2. Some observed 
increased auto-reactive T-cell frequencies in MS, while others described equivalent numbers 
in patients and controls questioning their role in MS3. The poor correlation between blood 
and intrathecal T-cell phenotypes, and TCR repertoires4 dispute extrapolation of systemic 
T-cell data to MS immunopathology.
Most studies assayed intrathecal cMSAg-specific T-cell responses using autologous PBMC, 
pulsed with synthetic peptides or recombinant (animal) cMSAg, as APC2. This strategy has 
several limitations2,3. First, cMSAg of different species and bacterial-produced antigens have 
a different amino acid composition and conformation compared with native human cMSAg, 
respectively, which potentially affect processing and presentation of the cognate epitope5.
Second, peptide binding is highly HLA allele-specific. Distinct HLA alleles are dominant MS 
risk or even protective factors1. Thus, differences in cMSAg T-cell responses in MS patients 
and controls may be due to intercohort HLA genotype disparity1 ensuing mandatory HLA 
matching of patients and controls. Third, CD8+ T-cells preferentially recognize endogenously 
synthesized proteins. This is only partially overcome using cMSAg-spanning synthetic pep-
tides as corresponding epitopes may not be presented when processed intracellularly and 
might need length optimization5. Finally, previous studies commonly used superphysiological 
peptide concentrations, typically in the 10–250 µM range, which may lead to activation of 
disease-irrelevant T-cells expressing low-avidity TCR6. 
To overcome the aforementioned limitations we developed a novel APC/T-cell platform 
that facilitates high and stable expression of individual cMSAgs in Epstein–Barr virus (EBV)-
transformed B-cells (BLCL), an easy to generate and efficient APC system to assay CD4+ and 
CD8+ T-cell responses simultaneously by flow cytometry. This APC system was used to deter-
mine the frequency of CD4 and CD8 T-cells directed to eight different human cMSAgs in 
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short-term cerebrospinal fluid (CSF)-derived T-cell lines (CSF-TCLs) obtained from MS (n=6) 
and clinically isolated syndrome (CIS; n=7) patients.
RESULTS AND DISCUSSION
BLCL express and present recombinant proteins to CD4 and CD8 T-cells 
efficiently
The advantage of using immortalized BLCL as APC is their high expression of HLA class I 
and II (HLA-I/II) and costimulatory molecules crucial for T-cell activation. Ectopic expression 
of EBV nuclear antigen 1 facilitates episomal replication of the origin of latent replication 
(oriP) containing EBV genomes. We optimized an eukaryotic EBV-based vector, containing 
the EBV OriP and a geneticin transferase expression cassette, facilitating stable plasmid 
maintenance in BLCL7. The original pNS vector was modified to clone and express human 
cMSAg proteins more efficiently (Fig. 1A).
To validate that stable transduction of BLCL leads to efficient processing and presentation 
of endogenously expressed antigen by both HLA-I and II, we cloned measles virus fusion pro-
tein (MVF) into the pNS vector (pNS.MVF). The pNS.MVF-transduced BLCL grown for several 
weeks under geneticin selection showed uniform MVF surface expression (Fig. 1B; left panel) 
(Supplementary Fig. 1A). Next, we assayed recognition of transduced HLA-matched BLCL 
(GR-BLCL) by well-defined MVF-specific CD4+ (4-F99) and CD8+ T-cell clones (2-F40; TCCs)8,9.
Both TCC showed a dose-dependent response to BLCL pulsed with their cognate peptides 
(Fig. 1C). TCCs cultured alone or cocultured with mock-transduced GR-BLCL secreted neg-
ligible IFN-γ amounts, whereas both TCCs stimulated with phorbolmyristate-acetate and 
ionomycin (P/I) secreted high IFN-γ levels. Notably, both TCCs efficiently recognized pNS.
MVF-tranduced GR-BLCL, but not empty vector (pNS.empty)-transduced BLCL (Fig. 1C). Thus, 
the pNS/BLCL-system facilitates high expression and efficient presentation of CD4+ and CD8+ 
T-cell epitopes of an endogenously expressed antigen.
No evidence for intrathecal T-cell responses to cMSAg in CIS and MS patients
No consensus exists on autoantigens specifically recognized by systemic and intrathe-
cal T-cells in MS. Limited studies have addressed cMSAg-specificity of CSF-derived T-cells in 
MS10–12. Ideally, antigen specificity of CSF-derived T-cells is determined ex vivo. However, lim-
ited cell numbers in surplus CSF samples, particularly in CIS cases, prohibited functional T-cell 
assays for multiple cMSAgs directly (Table 1). Therefore, we generated short-term CSF-TCLs 
by stimulating CSF-derived cells from CIS and MS patients in a single round of mitogenic stim-
ulation to characterize intrathecal human cMSAg-specific CD4+ and CD8+ T-cell responses 



















The coding sequences of human cMSAg for oligodendrocyte (i.e. MAG, MBP1, MOG, and 
PLP), glia (i.e. KIR4.1 and S100B) and neuronal origin (i.e. CNTN2 and NFASC) were cloned 
in the pNS vector and subsequently used to nucleofect autologous BLCL (autoBLCL). Flow 
cytometry showed that all viable transduced BLCLs uniformly expressed the respective cMSAg 
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EBV-based episomal pNS vector enables stable expression and efficient presentation of a cloned gene in BLCL to 
CD4+ and CD8+ T cells. (A) Schematic representation of pNS expression vector containing EBV origin of latent repli-
cation P (EBV oriP) for episomal replication in EBV-transformed B-cell lines (BLCLs). Combined kanamycin/neomycin 
transferase under control of the prokaryotic transposon Tn5 and eukaryotic herpes simplex type 1 (HSV-1) promoter 
enabled positive geneticin selection of transduced BLCL. Antigens of interest were cloned in BamHI site and ex-
pressed under control of SRα promoter and SV40 polyadenylation signal (poly A). (B) Histograms of flow cytometry 
analyses of cells gatedfor lymphocytes, based on forward and side scatter and viability using fluorescent viability 
staining of representative BLCL transduced with pNS encoding measles virus fusion protein (MVF) and seven indi-
vidual candidate human MS-associated autoantigens (cMSAg) cultured under gentamycin selection for >2 weeks. 
Dark area represents antigen-specific staining and the dotted line represents the respective isotype control staining. 
Vertical axis shows cell counts normalized to mode. Histograms are representative of two independent experiments. 
(C) HLA-matched BLCL pulsed with increasing synthetic peptide concentrations encompassing epitopes of MVF-spe-
cific CD4+ (4-F99) and CD8+ (2-F40) T-cell clones (TCCs) and stably pNS.MVF-transduced BLCL expressing MVF protein 
were cocultured for 24 h with respective TCC. IFN-γ levelswere determined by ELISA. As controls, TCC were non-
stimulated (TCC), stimulated with phorbolmyristate-acetate and ionomycin (P/I) or cocultured with untransfected 
BLCL (mock) and BLCL transduced with empty pNS vector (pNS.empty). Data are shown as mean + SD (n = 4) and are 
pooled from two independent in-duplo experiments.
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except MBP1 and S100B, are transmembrane proteins only MOG- and CNTN2-specific mAb 
target extracellular domains of the protein. Transmembrane localization of MOG and CNTN2 
was confirmed by extracellular staining. Unfortunately, no MBP1-specific mAb was available.
To determine the lower level of detection of antigen-specific CD4 and CD8 T-cells in T-cell 
lines using the APC/T-cell platform developed, we spiked a T-cell mixture consisting of two 
irrelevant varicella zoster virus-specific CD4+ (TCC 146) and CD8+ (TCC 38) with increasing 
numbers of the MVF-specific CD4+ and CD8+ TCCs and measured the response to pNS.MVF-
transduced GR-BLCL by intracellular IFN-γ flow cytometry8,9. The estimated detection limit 
of CD4+ and CD8+ T-cells directed to endogenously expressed protein, here represented by 
MVF, in transduced GR-BLCL was 1 and 3%, respectively (Supplementary Figs. 1B and 2). 
Next, the frequency of cMSAg-specific CSF-derived CD4+ and CD8+ T-cells was determined 
by coculturing CSF-TCL with human cMSAg-transduced autoBLCL. P/I stimulation of all CSF-
TCL showed that the majority of CD4 and CD8 T-cells produced high levels of IFN-γ indicating 
that the CSF-derived T-cells cultured were immunecompetent and not exhausted (Fig. 2A). 
To correct for background T-cell reactivity (e.g. intrathecal EBV-specific T-cells recognizing 
BLCL)13, cMSAg-specific CD4+ and CD8+ T-cell responses were normalized for reactivity 
toward pNS.empty-transduced autoBLCL (Supplementary Fig. 3). Interassay variation for 
CD4+ and CD8+ T-cell responses was determined by calculating the SD of all mean netto 
cMSAg-specific responses. The variation was lower for CD4+ T-cells (0.33%) as compared 



















  1  37; F  CIS    10    5  no  0.5  50  no 
  2  34; F  CIS    22    5  no  0.5    3  no 
  3  21; F  CIS      8    5  multiple  0.7  46  yes, to RRMS 
  4  25; M  CIS      1  12  multiple  0.9  42  yes, to RRMS 
  5  37; M  CIS      4    3  no  0.5  25  no 
  6  37; M  CIS      2    2  no  0.5  24  no 
  7  42; M  CIS      4    3  multiple  0.7  30  no 
  8  51; F  PPMS    54  11  multiple  0.9    2  n.a. 
  9  36; F  RRMS  102    4  multiple  1.4  29  n.a. 
10  34; F  RRMS      9  14  multiple  1.0  26  n.a. 
11  29; F  RRMS    30  25  multiple  1.0  32  n.a. 
12  41; F  RRMS    36    7  multiple  2.1  51  n.a. 
13  38; F  RRMS    18    5  n.d.  0.5  51  n.a. 
Table 1. Patient demographics and diagnosis
a) Age in years; F, female; M, male.
b) CIS, clinical isolated syndrome and PP, primary progressive MS; RRMS, relapsing remitting MS.
c) Disease duration in months at time of lumbar puncture.
d) White blood cell count (WBC) per mL cerebrospinal fluid (CSF).
e) Presence and number of oligoclonal bands (OCB) in CSF only; n.d. not determined
f) IgG index was determined by the following formula: (CSF [IgG] ∕ CSF [albumin]) ∕ (serum [IgG] ∕ serum [albumin]).



















CD4+ T-cells and 2.9% for CD8+ T-cells allowing a one-tailed 0.1% false discovery rate, respec-
tively14. This closely resembles the detection limit determined using titrated MVF-specific 
TCCs and MVF-transduced GR-BLCL as APC (Supplementary Fig. 2). Notably, the only positive 
call for cMSAg reactivity was the CSF-TCL of patient #13 containing a median 1.4% (range 
0.3–2.5%) frequency of NFASC-specific CD4 T-cells. However, no significant variation was 
observed between pMSAg for CD4+ (p = 0.74) and CD8+ T-cells (p = 0.30, one-way analysis 










CD4+ and CD8+ T cell reactivity to candidate MS-associated human autoantigens in CSF-derived T-cell lines from 
CIS and MS patients. (A) CSF-derived T-cell lines (CSF-TCLs) generated from patients diagnosed for clinically isolated 
syndrome (CIS; n = 7) and MS (n = 6) were stimulated with phorbolmyristate-acetate and ionomycin (P/I). Phenotype 
and frequency of responding T cells was determined by flow cytometry. Cells were gated on viable lymphocytes 
using fluorescent viability staining, expression of CD3, subdivided on CD4 and CD8 and subsequently intracellular 
IFN-γ expression. Colored dots and vertical bars represent median reactivity and range of individual CSF-TCL. (B) Au-
tologous BLCL (autoBLCL) were nucleofected with pNS vector encoding candidate MS-associated antigens (cMSAgs; 
n = 8) and positively selected in culture for >2 weeks with geneticin to generate stable cMSAg expressing BLCLs. 
CSF-TCLs were cocultured with cMSAg-transduced autologous BLCLs. The netto frequency of cMSAg-specific T cells, 
corrected for reactivity toward pNS.empty-transduced BLCL, is shown as percentage of IFN-γ+ CD4 (left panels) or 
CD8 T cells (right panels). Threshold for positive cMSAg T-cell reactivity, indicated by a horizontal dashed line, was 
calculated as 3.09-times SD of all mean netto cMSAg-specific CD4+ and CD8+ T-cell responses, allowing a 0.1% one-
tailed false discovery rate. Significance of variation in T-cell reactivity per cMSAg was determined by one-way analy-
sis of variance for CD4+ and CD8+ T cells independently. CSF-TCL T-cell reactivity to cMSAg-transduced autoBLCLs was 
performed in monoplo and determined at least twice, except for RRMS patient #9 (red dots) and #12 (gray dots), 
which were measured only once.
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Intrathecal autoreactive T-cells are anticipated to be involved in MS pathology, but we 
were unable to detect substantial CD4+ and CD8+ T-cell reactivity to a broad panel of cMSAgs 
(n=8) in short-term cultures of CSF-derived T-cells of seven MS and six CIS patients. Few 
studies enumerated intrathecal antigen-specific CD4+ and CD8+ T-cells responses simulta-
neously using endogenously processed antigen2,3. Whereas antigen processing and presen-
tation may differ between BLCL and the currently undefined local APC in MS lesions, the 
use of cMSAg-transduced autoBLCL as artificial APC represents a reasonable compromise to 
detect intrathecal cMSAg-specific T-cells. Congruent to our findings, Wuest and colleagues 
also did not observe significant reactivity of CSF-derived T-cells toward self-antigens using 
cell-, myelin-, and brain-derived lysate pulsed autologous dendritic cells used as APC12.
Still, a cautious interpretation of our data is warranted, as there are a few limitations. First, 
the assay format is not well equipped to detect low frequencies of cMSAg-specific T-cells, 
as the overall background was 1.1±0.3% and 2.6±0.9% (mean±SD) reactive CD4+ and CD8+ 
T-cells, respectively. Nevertheless, local frequencies of Ag-specific T-cells observed by others 
typically exceeded our detection limit in compartmentalized T-cell mediated diseases like 
Chronic Chagas’ Cardiomyopathy15 and autoimmune thyroiditis16,17. Moreover, using BLCL as 
APC we have previously detected profound frequencies (>5%) of intralesional T-cells. T-cells 
directed to the triggering herpes virus in patients with herpetic ocular diseases18,19. Second, 
a limited number of 13 patients were included in this study, which warrants further studies 
on larger cohorts of patients and disease controls. However, we included patients early in 
disease development, particularly seven CIS patients. Notably, two of them progressed to 
RRMS during clinical follow-up, suggesting that intrathecal reactivity against the explored 
antigens did not contribute to their disease evolution.
In conclusion, the inability to detect substantial intrathecal T-cell reactivity to eight 
human cMSAgs in CIS and MS patients do not support their role as prominent target antigen 
for intrathecal T-cell responses in CIS and MS patients.
MATERIALS AND METHODS
Patients and clinical specimens
Paired blood and CSF samples from CIS (n=7) and MS (n=6) patients were obtained as 
part of diagnostic workup at the Erasmus MC (Rotterdam, the Netherlands) (Table 1). No 
patient received immunomodulatory therapy at time of lumbar puncture, except one CIS 
patient (patient #2) who received Avonex treatment. CSF was always obtained >1 month 



















Helsinki declaration, approved by the local medical ethical committee and written informed 
consent was obtained from all participants.
Generation of BLCL and CSF-TCL
Isolation of PBMC and generation of autoBLCL were performed as described previ-
ously8,13. CSF-TCL were generated from surplus CSF cells by stimulation with 1 µg/mL phy-
tohemagglutinin-L (Roche, Branfort, CT) in the presence of 30 Gray γ-irradiated allogeneic 
PBMC used as feeder cells13. Cells were grown in RPMI-1640 supplemented with antibiotics 
and 10% heat-inactivated bovine (B-cells) or pooled human (T-cells) serum. T-cells received 
recombinant human IL-2 (25 U/mL) and IL-15 (25 ng/mL; Myltenyi biotec, Bergisch Gladbach, 
Germany) every 3–4 days and were harvested around day 14, aliquoted and stored frozen13.
Generation, characterization, and maintenance of MVF-specific CD4+ and CD8+ TCC was 
described8.
Cloning of human cMSAg in the EBV-based episomal pNS vector
The eukaryotic expression vector pNS.CD8α described by Mazda et al.7 was modified 
to the current pNS vector by removing murine CD8α by PvuII/HindIII digestion, gener-
ation of blunt ends using T4 DNA polymerase and subsequent self-ligation (all from New 
England Biolabs, Ipswich, MA) (Fig. 1A). ORFs encoding human MAG, MBP1, MOG, PLP1, 
S100B, CNTN2, and NFASC were PCR amplified from cDNA clones obtained from Darmacon 
(Lafayette, CO) and cloned in pCR4.1-TOPO (Invitrogen). Restriction endonuclease target 
sequences engineered into amplification primers were used to shuttle ORFs to pNS vector’s 
BamHI site (Supplementary Table 1). ORFs encoding MVF were cloned from pEC12.MVF20 
and human KIR4.1 (Damacon) from a cDNA clone by SacI or SacII/SmaI digestion into pNS 
vectors’s BamHI site after generating blunt ends using T4 DNA polymerase, respectively. 
DNA sequences of all cloned vectors were verified by Sanger sequencing using an ABI prism 
3130XL genetic Analyzer (Applied Biosystems, Foster City, CA) with pNS vector specific 5′- 
and 3′-end cMSAg flanking primers and if no overlapping sequences were obtained internal 
cMSAg-specific primers (data not shown).
Generation of BLCL expressing MVF and candidate MS-associated 
neuroantigens
BLCL were nucleofected using Amaxa Cell line nucleofection kit V (Lonza; Bazel, 
Switzerland) per manufacturer’s instructions and transduced cells positively selected using 
500 µg/mL geneticin (Life Technologies; Carlsbad, CA) for >2 weeks. Expression of cMSAgs 
and MVF were determined by extracellular and intracellular flow cytometry on a FACSCanto 
II (BD Biosciences; San Jose, CA) using specific antibodies. Intracellular staining was per-
formed using Cytofix/Cytoperm Kit (BD Biosciences) per manufacturer’s instructions. The 
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following mAbs were used at predefined concentrations: Mouse-anti-MVF (clone F3-5), 
mouse-anti-MAG (clone 513) (Millipore; Darmstadt, Germany), mouse-anti-MOG (clone 
8–18C5; Millipore), mouse-anti-PLP1 (clone sc-73336) (Santa Cruz; Dallas, TX), mouse-anti-
KIR4.1 (clone 1C11) (Sigma-Aldrich; St. Louis, MO), mouse-anti-S100B (clone 19/S100B; BD 
Biosciences), mouse-anti-CNTN2 (clone 372913) (R&D systems; Minneapolis, MN), and rab-
bit-anti-NFASC (ab31457) (AbCAM; Cambridge, UK). Secondary fluorescein-conjugated goat-
anti-mouse IgG (BD Pharmingen; San Diego, CA) or swine-anti-rabbit IgG (Dako; Glostrup, 
Denmark) were used. Respective mouse IgG1, IgG2a, IgG2b, or Rabbit IgG isotypes were 
used as negative controls. Data analysis on viable stained cells was performed using FlowJo 
software version 10 (Ashland, OR). Gating strategy for BLCL is shown in Supplementary Fig. 
1A.
T-cell reactivity to endogenously expressed MVF in BLCL
CD4+ and CD8+ MVF-specific TCCs were incubated with pNS.MVF-transduced HLA-
matched BLCL (GR-BLCL). Negative controls included TCC alone, TCC cocultured with BLCL or 
BLCL nucleofected with the pNS vector without insert. Positive control for T-cell stimulation 
included stimulation with phorbolmyristate-acetate (50 ng/mL) and ionomycin (500 ng/
mL) (Sigma-Aldrich). Additionally, TCC were incubated with GR-BLCL pulsed overnight with 
increasing concentrations of synthetic peptide, range 0.01–10 µM, representing minimal 
T-cell epitopes8. In all assays, 5 × 104 BLCL were cocultured with either TCC at a 1:1 ratio for 
24 h. Secreted IFN-γ was quantified by ELISA in conditioned culture medium (eBioscience; 
San Diego, CA). Experiments were performed twice.
The detection limit of T-cell responses toward endogenously expressed antigen was 
determined by titrating the MVF-specific CD4+ (4-F99) and CD8+ TCC (2-F40) into a T-cell 
mixture, consisting of VZV-specific CD4+ (TCC 146; patient 4) and CD8+ TCC (TCC 38; patient 
3)9, ranging from 0.1 to 10% of either MVF-specific TCC in the T-cell mixture. T-cell mixtures 
(total 105 cells) were cocultured with pNS.MVF-transduced GR-BLCL in a 1:1 ratio for 6–8 
h in the presence of Golgistop per manufacturer’s instructions (BD Biosciences). GR-BLCL 
transduced with pNS.empty and GR-BLCL pulsed overnight with 3 µM of aforementioned 
synthetic peptides were used as negative and positive control APC, respectively. T-cells 
were phenotyped with fluorochrome-conjugated mAbs directed to CD3 (clone SP34-2) (BD 
Pharmingen; San Diego, CA), CD4 (clone SK3; BD Biosciences), and CD8α (clone RPA-T8; 
eBioscience) stained for viability (violet live/dead stain; Invitrogen), fixed, permeabilized, 
and subsequently stained for intracellular IFN-γ (clone B27; BD Pharmingen) followed by 
flow cytometry. Lymphocytes were first gated based on forward and side scatter character-
istics and viability using violet live/dead staining and subsequently on differential expression 



















expression was defined for both gated T-cell subsets (Supplementary Fig. 2). Experiment was 
performed twice.
Intrathecal T-cell reactivity to endogenously expressed human cMSAg 
expressed in autologous BLCL
CSF-TCL (105 cells) were cocultured with autoBLCL stably transduced with aforemen-
tioned cMSAg (n=8) in a 1:1 ratio for 6–8 h in the presence of Golgistop per manufacturer’s 
instructions (BD Biosciences). Negative and positive controls included CSF-TCL incubated 
with pNS.empty-transduced autoBLCL and CSF-TCL solely stimulated with P/I, respectively. 
T-cells were stained and analyzed using flow cytometry as described above (Supplementary 
Fig. 3). Experiments were performed at least twice, except for RRMS patient #9 and #12 
where limited numbers of CSF-TCL cells were available.
Statistical analysis
Netto T-cell reactivity toward cMSAg-transduced BLCL was calculated by subtracting 
reactivity toward pNS.empty-transduced BLCL. Threshold for positive cMSAg T-cell reactiv-
ity was calculated as 3.09-times SD of all mean netto cMSAg-specific CD4+ and CD8+T-cell 
responses, allowing a 0.1% one-tailed false discovery rate14. Significance of variation in T-cell 
reactivity per cMSAg was determined by one-way analysis of variance for CD4+ and CD8+ 
T-cells independently.
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Supplementary Figure 1. Gating strategy for EBV-transformed B-cells and T-cell subsets. 
(A) Cultures of EBV-transformed B-cells (BLCL) were stained for viability with the violet live/dead buffer and sub-
sequently for intra-cellular or surface expression of candidate multiple sclerosis-associated antigens as depicted 
in Figure 1B. Viable BLCL were identified based on lymphocyte forward and side scatter characteristics and cell 
viability. (B) Cell cultures, consisting of T-cells and BLCL, were stained for surface markers CD3, CD4 and CD8 and 
viability using violet live/dead buffer. Viable T-cells were identified based on lymphocyte forward and side scatter 
characteristics, live cells and subsequently CD3 expression. Finally, viable CD3+ cells were separated into CD4+ (pink) 
and CD8+ (blue) viable T-cells.
GenBank  Length  Primer sequencec  Restriction site ORFd 
Genea  Accession No  (aa)b  5'‐end forward (5'‐3')  3'‐end reverse (5'‐3')  5'‐end  3'‐end 
MAG  BC053347     626  CTCTTAAGTACAGAATGATATTCCTCAC  CTATGCATACTTGACCCGGATTTCAG  AflII (T4)  NsiI (T4) 
MBP1  BC065248     197  CTCTTAAGATTCAGGATGGGAAACCAC  CTATGCATGCTACGTGCCAGTTCTTCC  AflII (T4)  NsiI (T4) 
MOG  BC035938     295  CTCTTAAGTAGAGATGGCAAGCTTATC  CTATGCATTCTAACAGCTGGCTTCTTTGC  AflII (T4)  NsiI (T4) 
PLP  NM_000533     277  CTGGATCCCAAAGACATGGGCTTGTTAG  CTGGATCCGAACTTGGTGCCTCGGC  BamHI  BamHI 
KIR4.1  BC131627     379  n.a.  n.a.  SacII (T4)  SmaI 
S100B  BC001766       92  CTGGATCCGAGGATGTCTGAGCTGGAGAAGGCC  CTGGATCCTCAAAGAACTCGTGGCAGGCAG  BamHI  BamHI 
CNTN2  BC129986   1040  CTGGATCCATCCACCATGGGGACAGCCAC  CTGGATCCGAAGGGGCTGGCTGTGTCCG  BamHI  BamHI 
NFASC  BC137013   1169  GAGGATCCGGGCCAGGTGCCGAGGATG  GAGGATCCGTGGTTTTGTCTCCCCTTCTC  BamHI  BamHI 
MVF  AM237414     553  n.a.  n.a.  SacI (T4)  SacI (T4) 
a. MAG; myelin associated glycoprotein, MBP1; myelin basic protein isoform 1, MOG; myelin oligodendrocyte 
protein, PLP; proteolipid protein, KIR4.1; inward rectifying potassium channel 4.1, S100B; S100 calcium binding 
protein B, CNTN2; contactin-2, NFASC; neurofascin, and MVF; measles virus fusion protein.
b. aa, amino acid.
c. Primer sequence annotation: restriction site, start codon; n.a. not applicable. 
d. ORF, open reading frame; T4, restriction site blunted using T4 DNA polymerase.






























































Percentage CD4+ T-cell clone (4-F99) Percentage CD8+ T-cell clone (2-F40)
Supplementary Figure 2. Estimation of CD4+ and CD8+ T-cell detection limit recognizing recombinant protein 
expressing EBV- transformed B-cells used as antigen presenting cells. 
EBV-transformed B-cells (BLCL) were nucleofected with a eukaryotic expression vector (pNS) encoding measles virus 
F (MVF) protein to generate stable high MVF protein expressing BLCL. Indicated percentages of two different MVF- 
specific T-cell clones (TCC), one CD4+ (clone 4-F99) and one CD8+ (clone 2-F40) TCC, were spiked into a T-cell popu-
lation consisting of two irrelevant varicella zoster virus-specific CD4+ and CD8+ TCC. T-cell mixtures were co-cultured 
with MVF-expressing BLCL in a 1:1 ratio for 6 to 8 hrs at 37oC in the presence of Golgistop and subsequently stained 
for intracellular IFNg and surface CD4 and CD8 followed by flow cytometry analysis (black bars). Cells were gated 
for viable lymphocytes, based on forward and side scatter and cell viability using violet live/dead buffer, expressing 
CD3 and subsequently subgated for viable CD4+ and CD8+ T-cells expressing IFNg. Frequencies of reactive T-cells are 
shown as percentage of IFNg+ CD4+ or CD8+ T-cells. T-cell reactivity towards non-transduced BLCL pulsed overnight 
with 3 µM synthetic peptide encompassing the MVF- specific TCC cognate MVF epitopes were included as positive 
control (white bars). BLCL transduced with the empty pNS vector were used as negative control (grey bars). Data of 
an experiment, performed in monoplo, are shown. The experiment was performed twice.
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Supplementary Figure 3. T-cell reactivity towards endogenously synthesised cMSAg of a cerebrospinal fluid-
derived T-cell line (CSF-TCL) of multiple sclerosis (MS) patient #11. 
Autologous EBV-transformed B-cells (BLCL) were nucleofected with the eukaryotic expression vector pNS encoding 
candidate human MS-associated antigens (cMSAg; n=8) and positively selected in vitro with geneticin for >2 weeks 
at 37oC to generate stable cMSAg expressing autologous BLCL. CSF-TCL generated from surplus CSF of patient #11 
were co-cultured with cMSAg-transduced autologous BLCL in a 1:1 ratio for 6 to 8 hrs at at 37oC in the presence of 
Golgistop and subsequently stained for intracellular IFNg and surface CD3, CD4 and CD8 followed by flow cytometry 
analysis. Cells were gated for lymphocytes forward and side scatter characteristics, viability using violet live/dead 
buffer and subsequently CD3 expression. Finally, viable CD3+ cells were subgated for CD4+ (pink) and CD8+ (blue) 
T-cells and subsequently intracelIular IFNg expression. Frequency of reactive T-cells are shown as percentage of 
IFNg+ CD4+ (pink) or CD8+ (blue) T-cells. The normalized frequency of cMSAg-specific T-cells, corrected for reactiv-
ity towards autologous BLCL transduced with the empty pNS vector (pNS.empty, is shown as netto percentage of 
IFNg+ CD4+ or CD8+ T-cells (bold). CSF-TCL alone and co-cultured with non- transduced autologous BLCL served as 
negative controls. CSF-TCL stimulated solely with phorbolmyristate-acetate and ionomycin (P/I) served as positive 
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Interleukin-17-expressing CD4+ T helper 17 (Th17) cells are considered as 
critical regulators of multiple sclerosis disease activity. However, depending on 
the species and pro-inflammatory milieu, Th17 cells are functionally heteroge-
neous, consisting of subpopulations that differentially produce interleukin-17, 
interferon-gamma and granulocyte macrophage colony-stimulating factor. In 
the current study, we studied distinct effector phenotypes of human Th17 cells 
and their correlation with disease activity in multiple sclerosis patients. Th 
memory populations single- and double-positive for C-C chemokine receptor 
6 (CCR6) and CXC chemokine receptor 3 (CXCR3) were functionally assessed 
in blood and/or cerebrospinal fluid from a total of 59 clinically isolated syn-
drome, 35 untreated and 24 natalizumab-treated patients with relapsing-re-
mitting multiple sclerosis, and nine patients with end-stage multiple sclero-
sis. Within the clinically isolated syndrome group, 23 patients had a second 
attack within 1 year and 26 patients did not experience subsequent attacks 
during a follow-up of >5 years. Low frequencies of T helper 1 (Th1)-like Th17 
(CCR6+CXCR3+), and not Th17 (CCR6+CXCR3-) effector memory populations in 
blood strongly associated with a rapid diagnosis of clinically definite multiple 
sclerosis. In cerebrospinal fluid of clinically isolated syndrome and relapsing-re-
mitting multiple sclerosis patients, Th1-like Th17 effector memory cells were 
abundant and showed increased production of interferon-gamma and gran-
ulocyte macrophage colony-stimulating factor compared to paired CCR6+ and 
CCR6- CD8+ T cell populations and their blood equivalents after short-term cul-
turing. Their local enrichment was confirmed ex vivo using cerebrospinal fluid 
and brain single-cell suspensions. Across all pro-inflammatory Th cells analyzed 
in relapsing-remitting multiple sclerosis blood, Th1-like Th17 subpopulation 
T helper 17.1 (Th17.1; CCR6+CXCR3+CCR4-) expressed the highest very late 
antigen-4 levels and selectively accumulated in natalizumab-treated patients 
who remained free of clinical relapses. This was not found in patients who 
experienced relapses during natalizumab treatment. The enhanced potential 
of Th17.1 cells to infiltrate the central nervous system was supported by their 
predominance in cerebrospinal fluid of early multiple sclerosis patients and 
their preferential transmigration across human brain endothelial layers. These 
findings reveal a dominant contribution of Th1-like Th17 subpopulations, in 
particular Th17.1 cells, to clinical disease activity and provide a strong rationale 





















Multiple sclerosis (MS) is mediated by effector T cells trafficking from the periphery into 
the central nervous system (CNS) to trigger local inflammation, demyelination and neurode-
generation1. Although current T cell-directed treatment attenuates disease activity, it often 
causes serious complications and does not prevent disease progression in MS2. To improve 
treatment efficacy and risk management, more in-depth insight into human effector T cells 
during MS onset is warranted. In the earliest clinical presentation of MS, clinically isolated 
syndrome (CIS), increased peripheral CD4+ T cell activation is linked to the occurrence of a 
second attack3. However, substantial knowledge has been gained about specific human T 
helper (Th) functions, and the exact nature of the pro-inflammatory Th subsets involved in 
MS is incompletely understood. 
Both Th1 and Th17 cells are known to be encephalitogenic, but use distinct transmi-
gration routes to enter the CNS. In experimental autoimmune encephalomyelitis, Th1 cells 
preferentially migrate into the spinal cord, while Th17 cells mainly infiltrate the brain4. This 
is facilitated by their differential expression of pro-inflammatory cytokines, chemokine 
receptors and integrins5-7. Interleukin-17 (IL-17) and C-C chemokine receptor 6 (CCR6) are 
key determinants for Th17 transmigration across the blood-brain barrier7, 8. IL-17 is generally 
considered as the signature cytokine produced by CCR6-positive Th17 cells. However, this 
greatly underestimates Th17 effector function, since subpopulations also (co-)produce inter-
feron-gamma (IFN-γ) and granulocyte macrophage colony-stimulating factor (GM-CSF). Next 
to IL-17, also IFN-γ and GM-CSF are strongly produced by myelin-specific CCR6-positive Th 
cells in MS9. Th17 polyfunctionality is differently regulated between species, as reflected by 
the antagonistic regulation of IL-17 and GM-CSF expression in human compared to murine 
Th cells10-12. Particularly GM-CSF produced by Th cells is implicated as a critical mediator of 
MS onset13, 14. 
The surface expression of another chemokine receptor, CXCR3, defines Th17 cells with 
Th1-like features15. CCR6 and CXCR3 expression on CD4+ T cells is controlled by transcrip-
tion factors RORγt and T-bet, respectively, which were originally associated with IL-17/IFN-γ 
double-production15. However, recent findings demonstrate more heterogeneous IL-17, 
IFN-γ and GM-CSF expression profiles in Th17 cells, depending on the inflammatory milieu16. 
Besides CCR6 and CXCR3, also the presence of the α4β1 integrin very late antigen-4 (VLA-4), 
which is abundant on Th17 cells in MS cerebrospinal fluid (CSF)17, determines T-cell transmi-
gration capacities. Anti-VLA-4 monoclonal antibody natalizumab is currently one of the most 
effective therapies in MS, but relapses are still encountered after one year in about one-third 
of treated patients18. Understanding which distinct pro-inflammatory Th subsets are targeted 
by natalizumab will help to better predict treatment response in MS19.
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Here, blood and CSF samples from CIS and both untreated and natalizumab-treated 
relapsing-remitting MS (RRMS) patients were assessed for distribution, memory phenotype, 
activation and pro-inflammatory capacity of Th17 subsets. We reveal that IFN-γ-/GM-CSF-
producing (CCR6+CXCR3+), but not IL-17-producing (CCR6+CXCR3-) Th17 effector cells are key 
regulators of MS onset. A Th1-like Th17 subpopulation termed Th17.1 (CCR6+CXCR3+CCR4-) 
is selectively targeted by natalizumab in MS patients who remained free of clinical relapses. 
This work supports the design and early use of therapeutic strategies against Th17.1 cells to 
prevent relapses in MS.
MATERIALS AND METHODS
Patients
Characteristics of patients and controls in the screening cohorts are summarized in Table 
1. Main experimental results were confirmed using additional cohorts (Supplementary Table 
1). All CIS and RRMS patients as well as controls were included at Erasmus MC (Rotterdam, 
The Netherlands), which is a national tertiary referral center for patient with MS (MS Center 
ErasMS). All primary material was collected between 2007 and 2017. 
For blood analyses, we selected 23 patients with CIS who did not experience a second clin-
ical attack for at least 5 years of follow-up (CIS-CIS) and 26 CIS patients who were diagnosed 
with clinically definite MS (CDMS) within 1 year after CIS (CIS-CDMS) from our prospective 
cohort. None of these patients were treated with disease-modifying therapies before or at 
time of sampling. CIS was defined as a first clinical attack of demyelination in the CNS20. 
CDMS diagnosis was made when a patient experienced two attacks with clinical evidence 
of two separate lesions according to the Poser criteria21. A relapse was defined as sub-acute 
worsening of existing symptoms, or new symptoms after at least 30 days of improvement 
or stable disease22. Fatigue scores were acquired at time of the first attack using the self-ad-
ministered Krupp’s Fatigue Severity Scale (FSS), as shown previously23. Anti-EBNA1 IgG levels 
were determined in plasma using a well-validated chemiluminescent assay and analyzer 
(Liaison XL; both Diasorin, Saluggia, Italy) according to manufacturers’ instructions at our 
local referral center for virus diagnostics (Erasmus MC). 
Patients with RRMS were diagnosed according to the McDonald 2010 criteria24. Blood Th 
cell analyses were performed for 31 treatment-naive RRMS patients, as well as for 24 RRMS 
patients before the start and after both 6 and 12 months of natalizumab therapy. The median 
time between the last clinical attack and first administration of natalizumab was 2.8 months 
[interquartile range (IQR): 1.7-6.3]. Seventeen of these patients (70.8%) were treated with 
disease-modifying therapy before initiation of natalizumab (14 with IFN-β, one with both 




















CSF with and without paired blood samples were obtained from 14 patients with ear-
ly-stage MS (ErasMS) and nine with late-stage MS (Netherlands Brain Bank, Amsterdam). 
In the early-stage MS group, 10 patients were CIS at the time of lumbar puncture and four 
patients were diagnosed with RRMS within 6 months before sampling. The median time 
between sampling and the last clinical attack was 2.8 months (IQR: 1.3-5.8). Additional 
autopsied brain tissues were obtained from five patients with late-stage MS and two non-de-
mented control subjects (Netherlands Brain Bank). All study protocols were approved by 
the medical ethics committee of the Erasmus MC (Rotterdam) and VUmc (Amsterdam, 
Table 1. Characteristics of patients and controls in screening cohorts
aRRMS according to the McDonald (2010) criteria. 
bFourteen patients were included for in-depth analysis of Th17 subpopulations in blood. For three patients, Th sub-
sets were only used for analysis of pro-inflammatory cytokine expression. 
cAt the time of sampling.
dAt the time of pre-treatment sampling. 
eTime from CIS diagnosis to sampling.
fSamples obtained from either CIS and RRMS patients (‘early’) or deceased patients with MS and non-demented 
control subjects (‘late’). 
gThree patients were also used for ex vivo CSF/brain T cell analysis. 
HC = healthy control; MS = multiple sclerosis; NA = not applicable or available; NAT = natalizumab; NDC = non-de-
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The Netherlands). Written informed consent was obtained from all included patients and 
controls. 
Mononuclear cell isolation from blood, CSF and brain tissue 
Blood from patients and matched controls was collected using Vacutainer CPT tubes (BD 
Biosciences, Erembodegem, Belgium) containing sodium heparin. Peripheral blood mono-
nuclear cells (PBMC) were isolated according to manufacturer’s instructions. After centrif-
ugation, cells were taken up in RPMI1640 (Lonza, Verviers, Belgium) containing 40% fetal 
calf serum (FCS) and 20% dimethyl sulfoxide (Sigma-Aldrich, Saint-Louis, MO) and stored in 
liquid nitrogen until further use. Surplus CSF of patients with early-stage MS was obtained 
through lumbar puncture for diagnostic purposes. Blood and CSF samples from patients with 
late-stage MS were acquired post-mortem through heart puncture and ventricle drainage, 
respectively. Collection tubes with CSF were centrifuged for 10 min at 500g. Paired blood 
and blood from buffy coats were diluted in phosphate-buffered saline (PBS), after which 
mononuclear cells were isolated by density gradient centrifugation using Ficoll® Paque 
Plus (GE Healthcare, Freiburg, Germany). CSF and blood mononuclear cell fractions were 
resuspended in RPMI 1640 containing 10% heat inactivated human AB serum (Sanquin, 
Rotterdam, The Netherlands) and 1% Pen/Strep (Lonza) and left to rest at 37oC until fur-
ther use. Brain tissue samples were processed and single-cell suspensions were obtained as 
described previously25. 
Short-term CSF and blood T-cell cultures
Short-term culturing of CSF-derived T cells was required to obtain sufficient cell num-
bers for fluorescence-activated cell sorting (FACS) and intracellular cytokine staining of the 
Th subsets of interest. CSF and blood T cells were cultured as previously described26. In 
short, mononuclear cell fractions were treated for 13 to 15 days with γ-irradiated feeder 
cells (10×106 PBMC and 1×106 EBV- B-cell lines HAL-02 and RS-411), phytohemagglutinin-L 
(1 ng/ml; Sigma-Aldrich), IL-2 (25 U/ml; Erasmus MC) and IL-15 (12.5 ng/µl; Miltenyi Biotec, 
Leiden, The Netherlands) in RPMI1640 containing L-glutamine (Lonza), 1% Pen/Strep and 
10% heat-inactivated human AB serum. IL-2 and IL-15 were added every 3 to 4 days. Post-
mortem CSF samples were re-stimulated using the same protocol. 
Antibodies and flow cytometry
Multicolor flow cytometric analysis was performed using the following fluorochrome-la-
beled monoclonal anti-human antibodies: CD3 BV785 (SK7), CD8 FITC (SK1), CD45RA 
APC-H7 (HI100), HLA-DR FITC and BB515 (G46-6), VLA-4 BV711 and APC (9F10), CD45RO 
PerCP-Cy5.5 (UCHL1), CD25 BV605 and APC-R700 (2A3), CD226 BB515 (DX11), MCAM 




















Biosciences), CD4 BV510 (OKT4), CD38 BV711 and PerCP-Cy5.5 (HIT2), CXCR3 BV421, PE-Cy7 
and APC (G025H7), CCR6 PE (G034E3), CCR7 PE-CF594 (150503), CCR4 PE-Cy7 and PE-Dazzle 
(L291H4), CD161 BV605 (HP-3G10), IFN-γ BV421 and BV711 (4S.B3), and IL-17A APC (BL168; 
all Biolegend, London, UK). Cells were stained for 30 min at 4oC, measured with an LSRII-
Fortessa flow cytometer and analyzed using FACSDiva 6.1.2 software (both BD Biosciences). 
Th1, Th17 and Th1-like Th17 cells were defined based on markers CCR6 and CXCR3 with and 
without the use of CCR4. For analyses without CCR4, total CD4+ T cells were subdivided into 
CCR6-CXCR3+ (Th1), CCR6+CXCR3- (Th17) and CCR6+CXCR3+ (Th1-like Th17) subsets. In each 
Th subset, the proportion of effector memory (CCR7-CD45RA-) and central memory (CCR7-
CD45RA+) cells was analyzed. CCR4 was used as a marker to discriminate CCR6-CXCR3+CCR4- 
(Th1), CCR6+CXCR3-CCR4+ (Th17), CCR6+CXCR3+CCR4- (Th17.1) and CCR6+CXCR3+CCR4+ (Th17 
double-positive, DP) subpopulations27. 
Intracellular cytokine staining
Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-), Th1-like Th17 (CCR6+CXCR3+), as well as CCR6- 
and CCR6+ CD8+ T cells were sorted from blood and CSF T cell memory pools (CD3+CD25-/int 
CD45RO+CD45RA-) using a BD FACSAria™ III cell sorter. Prior to isolation of Th memory sub-
sets from buffy coats, CD4+ cells were purified from the mononuclear cell fraction using CD4 
microbeads and the autoMACS Pro Separator (both Miltenyi Biotec). Cells were stimulated 
with phorbol 12-myristate 13-acetate (PMA; 1:2000) and ionomycin (1:500; both Sigma-
Aldrich) for 5 h. GolgiStop™ (1:1500; BD Biosciences) was added during the last 2.5 h of 
stimulation. Stimulated cells were fixed and permeabilized using the BD Cytofix/CytopermTM 
kit (BD Biosciences) according to the provided protocol, and stained for IFN-γ, GM-CSF and 
IL-17A within the same tube. 
RNA isolation and quantitative PCR
Sorted T-cell subsets were washed with PBS and resuspended in RNA lysis solution with 
1% 2-ME. Total RNA was extracted using the GenElute™ Total RNA Purification kit (Sigma-
Aldrich) and treated with DNase I (Invitrogen, Carlsbad, CA). Complementary DNA (cDNA) 
was synthesized from total RNA using a reaction mix containing Tris-aminomethane (200 
mM), KCl (500 mM), MgCl2 (0.2M; Sigma-Aldrich), DTT (100mM; Invitrogen), random hexam-
ers (50µM; Invitrogen), oligo(dT) 15 primer (100 µg/ml; Promega, Madison, WI), dNTP mix 
(10 mM; Promega), RNAsin® (40 U/µl; Promega) and superscript™ II (200 U/µl; Invitrogen). 
After incubation at 42oC for 50 min and inactivation at 99oC for 3 min, cDNA was diluted and 
stored at -20oC until use. For quantitative PCR, 0.2µM forward and reverse primer (Sigma-
Aldrich), 10 µM probe (Universal Probe Library; Roche Applied Science, Penzberg, Germany) 
and diluted cDNA were added to Taqman® Universal PCR Master Mix. Target gene expression 
was measured using optimal primer/probe assays and Taqman® 7900HT (Applied Biosystems, 
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Foster City, CA). We used the following thermal cycle protocol: 2 min at 50ºC and 10 min at 
95ºC followed by 40 cycles of 15 s at 95ºC and 1 min at 60ºC. CT values were analyzed using 
SDS 2.4.1 software (Applied Biosystems). Expression levels of target genes were normalized 
using 18S rRNA as a reference. Primer sequences are provided in Supplementary Table 2.
T-cell transmigration assays
CD4+CD25-/int memory T cells depleted from naive populations (CCR7+CD45RA+) were 
sorted by FACS and added at 2×105 cells/well to 3 μm pore size transwell plates (Corning, 
Amsterdam, The Netherlands). Migration of Th17 subsets towards medium or CXCL10 
(900ng/ml; R&D Systems, Abingdon, UK) was analyzed after 3 h incubation at 37°C using 
FACS. To assess trans-endothelial migration of Th17 subsets, migration experiments were 
performed across confluent monolayers of human brain endothelial cells (hCMEC/D3 cell 
line)28 on collagen-coated 5 μm pore size Transwell® plate, as previously described29. In this 
system, 5×105 Th memory cells were added per well and migration was assessed after 4 h.
Statistical analyses
Statistical analyses were carried out using Graphpad Prism Software, version 5.04. 
We used the two-tailed Mann-Whitney U test to compare two independent groups and 
the Wilcoxon matched-pairs signed rank test to compare samples of the same persons. 
Correlations were tested using Spearman’s rank. A logistic regression model was used to 
correct for MRI measurements in the multivariate analyses. Experimental data are depicted 
as mean and standard error of the mean. P-values < 0.05 were considered significant.
RESULTS
Low frequencies of Th1-like Th17 and not Th17 effector cells in CIS blood 
associate with rapid MS onset
To search for pro-inflammatory Th subsets that are critically involved in early diagnosis 
of CDMS, we used peripheral blood mononuclear cells at time of CIS from age- and gen-
der-matched patients who remained monophasic for at least 5 years (CIS-CIS, n = 16) and 
from patients who experienced a second attack within 1 year (CIS-CDMS, n = 16; Table 1). 
Flow cytometric analysis of CD4+ T cells showed decreased Th1-like Th17 (CCR6+CXCR3+) 
frequencies in the CIS-CDMS group compared to the CIS-CIS group (median: 5.9% versus 
11.2%, p = 0.011; Fig. 1A). After correction for lesion load on MRI at baseline, using a logistic 
regression model, the association remains significant (OR: 0.78 per percent increase in Th1-
like Th17; p = 0.026). In CIS-CDMS, additional reductions in effector memory (EM) to central 




















1B). Similar but less strong reductions were observed for Th1 (CCR6-CXCR3+; 10.0% versus 
12.5%, p = 0.070 and mean EM/CM ratio: 0.21 versus 0.29, p = 0.021). Frequencies and EM/
CM ratios for Th17 (CCR6+CXCR3-) did not differ between CIS-CIS and CIS-CDMS (Fig. 1A and 
B). Th subset distribution in CIS patients was not affected after stratification for methylpred-
nisolone treatment in the last 3 months prior to sampling (data not shown). Finally, Th1-like 
Th17 EM/CM ratios in CIS blood inversely correlated to anti-EBNA1 IgG titers (p = 0.013; Fig. 
1C) and fatigue (p = 0.001; Fig. 1D), which were reported as independent predictive markers 
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Figure 1. Reduction of Th1-like Th17 effector cells in the blood of CIS patients with short time to CDMS.
CIS patients were selected based on blood sampling within 4 months after diagnosis and time between CIS and 
CDMS. ‘CIS-CDMS’ patients were diagnosed with CDMS within 1 year (n = 16; filled bars), while ‘CIS-CIS’ patients 
were not diagnosed with CDMS for at least 5 years (n = 16; shaded bars). CD4+ T cells in the blood were compared 
for (A) Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-) and Th1-like Th17 (CCR6+CXCR3+) cell distribution, as well as (B) ef-
fector memory (EM; CCR7-CD45RA-) to central memory (CM; CCR7+CD45RA-) cell ratios within each of these subsets, 
as determined by flow cytometry. Th1-like Th17 effector to central memory cell ratios were correlated to reported 
predictors of early CIS to CDMS transition, anti-EBNA1 IgG blood titer (C) and fatigue severity scale (FSS; D). * p < 
0.05; ** p < 0.01.
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Effector populations of highly activated Th1-like Th17 cells are reduced in 
blood after MS diagnosis
To verify that these selective differences in Th subsets are associated with MS diagnosis, 
we explored total frequencies of blood Th1 EM and Th1-like Th17 EM cells in treatment-naive 
RRMS patients (n = 18, Table 1), and age-/gender-matched healthy controls (n = 19). Strongly 
reduced frequencies were found for both these subsets in RRMS (median: 1.1% and 0.7%) 
compared to CIS-CIS (1.9%, p < 0.001 and 2.8%, p < 0.0001 respectively) and healthy con-
trols (2.8%, p < 0.001 and 3.3%, p < 0.0001 respectively; Fig. 2A). These frequencies did not 
significantly differ between the RRMS and CIS-CDMS (1.0% and 1.3%, respectively) group. In 
RRMS, a significant proportion of blood Th1-like Th17 cells was positive for both CD38 and 
HLA-DR (Fig. 2B), indicating a highly activated phenotype after MS diagnosis. This was not 
seen for Th1 cells (Fig. 2B). These data suggest that Th1-like Th17 effector cells are selectively 
activated in the periphery and recruited to the CNS during MS onset. 
Predominant expression of T-bet, RORγt, IFN-γ and GM-CSF, but not IL-17A 
by activated blood Th1-like Th17 cells
Human CCR6+ CD4+ T cells are not only strong producers of IL-17, but also express 
IFN-γ and GM-CSF9, 27. To explore how these pro-inflammatory cytokines are co-regulated 
in our phenotypically defined Th1-like Th17 (CCR6+CXCR3+) cells, T-bet and RORγt, as well 
as IFN-γ, GM-CSF and IL-17A expression was compared to paired Th1 (CCR6-CXCR3+) and 
Th17 (CCR6+CXCR3-) populations from healthy blood donors. Th1-like Th17 expressed both 








































































































Figure 2. Th1-like Th17 effector cells are highly activated and less present in the blood after MS diagnosis.
(A) Th1 and Th1-like Th17 effector memory (EM) frequencies in CD4+ T cells from CIS-CIS (n = 14) and CIS-CDMS (n = 
16) as well as RRMS (n = 18) and both age- and gender-matched healthy control (HC; n=19) blood. (B) Highly activat-
ed fractions of blood Th1 and Th1-like Th17 cells in CIS-CIS (n = 14), CIS-CDMS (n = 16) and RRMS (n = 18) patients 
as well as HC (n = 19), as defined by co-expression of late T-cell activation markers HLA-DR and CD38. * p < 0.05; ** 

















































































































































































































































































































Figure 3. Blood Th1-like Th17 cells predominantly express T-bet and RORγt, and are high IFN-γ and GM-CSF, but 
low IL-17A producers.
Buffy coats from nine healthy blood donors were used to assess gene expression of TBX21, RORC and FOXP3 (A), as 
well as IFNG, CSF2, IL17A and TNF (B) in sorted Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-) and Th1-like Th17 (CCR6+CX-
CR3+) memory populations. Cells were stimulated with PMA and ionomycin and mRNA levels were measured using 
quantitative PCR. (C) Flow cytometric analysis of intracellular IFN-γ, GM-CSF and IL-17A expression in PMA- and 
ionomycin-stimulated Th1, Th17 and Th1-like Th17 memory cells from the same blood donors (n = 7). (D) Repre-
sentative dot plots and quantification of co-expression of IFN-γ with GM-CSF and IL-17A in Th1-like Th17 memory 
cells (n = 7). * p < 0.05; ** p < 0.01. 
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and Th17 (p = 0.008 and p = 0.039, respectively; Fig. 3A). IFNG/IFN-γ mRNA levels were 
similar between Th1 and Th1-like Th17, while CSF2/GM-CSF mRNA levels in Th1-like Th17 
were higher than in Th1 (p = 0.008) and Th17 (p = 0.020). Th1-like Th17 cells only moderately 
expressed IL17A mRNA (Fig. 3B). Differences in IFN-γ, GM-CSF and IL-17A expression were 
verified at the protein level (Fig. 3C). The percentage of GM-CSF-positive cells was 2- to 3-fold 
higher in Th1-like Th17 than in Th1 and Th17. IL-17A-positive cells were ~4-fold less present 
in Th1-like Th17 compared to Th17. At the single-cell level, IFN-γ was mainly co-expressed 
with GM-CSF and not with IL-17A in Th1-like Th17 cells (Fig. 3D). These cytokine profiles 
were the same for Th subsets from CIS and RRMS blood (data not shown). TNF expression 
was comparable between Th1, Th17 and Th1-like Th17 subsets (Fig. 3B). CD226 was higher, 
while CD25 and FoxP3 were lower expressed by Th1-like Th17 as compared to Th17 (Fig. 3A 
and Supplementary Table 3), which supported their pro-inflammatory potential31, 32. Th1-like 
Th17 cells also showed sustained CD161 expression (Supplementary Table 3), reflecting an 
ex-Th17 phenotype33. 
Pro-inflammatory Th1-like Th17 cells are abundant in CSF T cell cultures of 
MS patients 
To explore the local pro-inflammatory capacity of Th1-like Th17 cells in early MS, CSF 
(n = 10) and paired blood (n = 4) T cell subsets from early-stage MS patients (Table 1) were 
analyzed after short-term culturing. Th1 and Th1-like Th17 were the main populations in 
the CSF CD4+ T cell pool (Fig. 4A). Proportions of Th1-like Th17 were higher than those of 
Th1 (p = 0.020) and their equivalents in blood (2- to 3-fold increase; Fig. 4B). Similar results 
were obtained with EM/CM ratios, which were high for both subsets but most prominent in 
Th1-like Th17 cells in CSF (Fig. 4C). Within the total CSF T cell pool, Th1-like Th17 cells were 
enriched and co-produced more IFN-γ and GM-CSF compared to CCR6- and CCR6+ CD8+ T 
cells, and paired blood counterparts (Fig. 4D to G). The percentage of IFN-γ-positive cells 
was increased in CSF Th1-like Th17 versus Th1 (Fig. 4E). The enrichment of Th1-like Th17 in 
CSF compared to blood (Fig. 4A and B) was also found in T cell cultures from late-stage MS 
patients (n = 7, p = 0.016; Table 1 and Fig. 4H), suggesting that Th1-like Th17 recruitment to 
the CNS also occurs at later stages of the disease.
Ex vivo Th1-like Th17 cells are enriched in the CNS and accumulate in the 
blood after natalizumab treatment
To confirm their recruitment to the CNS, we compared ex vivo Th1 and Th1-like Th17 
frequencies in single-cell suspensions of 10 brain tissues and paired CSF and blood samples 
of five patients with late-stage MS (Table 1, Fig. 5A and B). Th1 and Th1-like Th17 cells were 
over-represented, while Th17 cells were hardly seen in MS brain tissues and CSF, in contrast 




















from two non-demented controls (Fig. 5B), suggesting that enhanced infiltration of Th1-like 
Th17 cells into the brain parenchyma is associated with MS34-36. 
In addition to chemokine receptors and pro-inflammatory cytokines6, 7, adhesion mole-
cules play a key role in migration of peripheral Th cells into the CNS, including VLA-4, MCAM 
and PSGL-137. Interestingly, VLA-4 but not MCAM and PSGL-1 was the most abundant on 
Th1-like Th17 cells (Supplementary Table 3). In patients with RRMS (n = 14), blood Th1-like 
Th17 proportions were elevated after 6 months of treatment with natalizumab (anti-VLA-4 
monoclonal antibody; median pre- versus post-treatment: 7.7% versus 10.4%, p = 0.006; 
Fig. 5C and Table 1). Th1-like Th17 cells did not show differences in EM/CM ratio (data not 
shown), but their activation state (see also Fig. 2B) was significantly reduced after natal-























































































































































































































































































































Figure 4. Prevalence of pro-inflammatory Th1-like Th17 cells in CIS and MS CSF compared to blood T cell cultures.
(A-D) Presence of Th1-like Th17 (CCR6+CXCR3+) subsets in short-term CSF T cell cultures from 10 early-stage MS 
patients (CIS, n = 7; RRMS, n = 3). CSF Th1-like Th17 were compared to Th1 cells and their equivalents in blood for 
percentages in the total CD4+ T cell pool (A and B) and for effector memory (EM) to central memory (CM) ratios (C) 
from the same patients. Similar analyses were performed for CSF Th1-like Th17 and both CCR6- and CCR6+ CD8+ T cell 
subsets within the total T cell pool (D). These T cell subsets were separated, stimulated with PMA and ionomycin and 
assessed for intracellular expression of (E) IFN-γ, (F) GM-CSF and (G) IFN-γ with GM-CSF. For each analysis, Th1-like 
Th17 subsets were compared between paired CSF and blood T cell cultures. (H) Th1-like Th17 frequencies in T cell 
cultures from paired blood and CSF of late-stage MS patients (n = 7). * p < 0.05; ** p < 0.01.
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Figure 5. Th1-like Th17 recruitment to the CNS and targeting by natalizumab in MS patients.
(A) Presence of Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-) and Th1-like Th17 (CCR6+CXCR3+) cells in single-cell suspen-
sions from brain tissue, CSF and blood of a patient with MS, as determined by FACS. (B) Th1-like Th17 frequencies 
in 10 brain tissues and paired CSF and blood samples from five different MS patients (filled shapes). Similar analyses 
were performed for two non-demented controls (NDC; open shapes). Each shape represents a different donor. For 
Th1-like Th17 cells in MS blood, frequencies (n = 14; C), activation (n = 14; D) as well as pro-inflammatory capacities 
(n = 6; E and F) were determined before and 6 months after natalizumab treatment. T-cell activation was assessed 
by surface expression of both HLA-DR and CD38. To determine their pro-inflammatory capacity, Th1-like Th17 mem-
ory cells were isolated from pre- and post-treatment blood, stimulated with PMA and ionomycin, and stained for 




















GM-CSF in post- versus pre-treatment blood samples (Fig. 5E and F). These results show that 
the effects of natalizumab in MS are associated with an accumulation of Th1-like Th17 cells 
in the blood. 
Targeting of VLA-4high Th17.1 cells by natalizumab in MS patients who 
respond to treatment
To assess the selectivity of natalizumab effects on pro-inflammatory Th populations in 
MS patients, CCR4 was included as a surface marker in our flow cytometric panels for sub-
division of Th1-like Th17 into recently described pathogenic Th17.1 (IFN-γhighGM-CSFhighIL-
17low) and Th17 double-positive (DP; IFN-γlowGM-CSFlowIL-17int) subpopulations27, 38. Th17.1 
(CCR6+CXCR3+CCR4-) frequencies were significantly increased in RRMS blood samples after 
both 6 and 12 months of treatment (median: 5.3% and 6.1%) versus pre-treatment (3.7%; n 
= 14, both p = 0.0002; Table 1; Fig. 6A and B). No significant differences were found in Th1 
(CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+) and Th17 DP (CCR6+CXCR3+CCR4+) cells (Fig. 
6A and B). Importantly, this accumulation of Th17.1 was most pronounced in natalizum-
ab-treated patients who were free of clinical relapses (n = 9; pre-treatment, 3.8% versus 6m 
post-treatment, 6.5% and 12m post-treatment, 6.8%; p = 0.008 and p = 0.004, respectively). 
As compared to patients who had relapses during treatment (n = 5; pre-treatment, 3.2% 
versus 6m post-treatment, 4.0% and 12m post-treatment, 4.1%; Fig. 6C). The accumula-
tion of Th17.1 cells in the blood of clinical responders was validated using a second cohort 
(Supplementary Table 1; Supplementary Fig. 1A). 
In pre-treated RRMS blood, VLA-4 surface expression on Th17.1 (mean MFI: 2603) was 
the highest of all pro-inflammatory Th subsets analyzed, including Th1 (MFI: 1328, p = 0.001), 
Th17 (MFI: 1255, p = 0.0001) and Th17 DP (MFI: 2038, p = 0.002; Fig. 6D and Supplementary 
Fig. 1B). After natalizumab treatment, VLA-4 was downregulated on all subsets analyzed, 
but this was most prominent for Th17.1 (mean reduction: 6m post-treatment, 56%, 12m 
post-treatment, 58%), as compared to Th1 (6m post-treatment, 52%, p = 0.038; 12m 
post-treatment, 54%, p = 0.005), Th17 (6m post-treatment, 37%, p = 0.003; 12m post-treat-
ment, 38%, p = 0.0009) and Th17 DP (6m post-treatment, 49%, p = 0.002; 12m post-treat-
ment, 50%, p = 0.002; Fig. 6E). This indicates that Th17.1 cells are preferentially targeted by 
natalizumab treatment, preventing their transmigration into the CNS of MS patients. 
Pathogenic Th17.1 cells have a superior capacity to transmigrate into the 
CNS in early MS
To study the CNS transmigration potential of Th17.1 in MS further, we performed differ-
ent in vitro transwell migration assays using total Th memory cell fractions. Th17.1 was the 
main Th17 subpopulation migrating across transwell filters towards inflammatory mediator 
CXCL1039 (Fig. 7A and B). No migration was observed towards medium only (data not shown). 
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Figure 6. Selective accumulation of Th17.1 cells in natalizumab-treated MS patients who do not experience clin-
ical relapses.
Using CCR4 as an additional marker, Th1-like Th17 cells were subdivided into Th17.1 (CCR6+CXCR3+CCR4-) and Th17 
DP (CCR6+CXCR3+CCR4+) subsets and analyzed in natalizumab-treated RRMS patients by flow cytometry (A). Th1 
(CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+), Th17.1 and Th17 DP cells were monitored in pre- and both 6 and 
12 months post-treatment blood samples (n = 14; B). Th17.1 proportions were separately evaluated in relapse-free 
(n = 9) and relapsing (n = 5) treatment groups (C). VLA-4 surface expression levels were determined on these Th 
subpopulations before (D) and both 6 and 12 months after (E) natalizumab treatment. * p < 0.05; ** p < 0.01; *** p 







































































































































































































































































































Figure 7. Enhanced CNS transmigration potential of Th17.1 cells and their recruitment to CSF in early MS.
Total Th memory cells were sorted from healthy blood and used to assess the in vitro transmigration capacities of 
Th17, Th17.1 and Th17 DP cells across transwell membranes (A and B; n = 6) and monolayers of human brain en-
dothelial cells (BEC; C and D, n = 4) towards CXCL10. Each experiment was performed in quintuplicate. Th17 subset 
distribution was assessed before (‘control’) and after migration towards medium or CXCL10 using FACS. (E and F) Ex 
vivo Th17, Th17.1 and Th17 DP frequencies of CCR6+ Th cells in paired CSF and blood from four early MS patients. (G) 
The presence of Th17.1 cells in blood samples from 21 CIS-CIS, 26 CIS-CDMS and 13 treatment-naive RRMS patients, 
as well as 12 healthy controls (HC), as determined by FACS. * p < 0.05.
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Particularly Th17.1 cells did show spontaneous transmigration across human brain endothe-
lial layers (hCMEC/D3), which was enhanced under CXCL10-attracting conditions (Fig. 7C and 
D).
In addition, ex vivo flow cytometric analysis revealed an enrichment of Th17.1 versus Th17 
and Th17 DP cells in CSF versus paired blood samples from four patients with early-stage MS 
(three CIS and one RRMS; Table 1; Fig. 7E and F). Consistently, lowered Th17.1 frequencies 
were found in the blood from 26 CIS-CDMS versus 21 CIS-CIS patients (p = 0.019), as well as 
13 RRMS patients versus 12 matched healthy controls (p = 0.031; Fig. 7G and Supplementary 
Table 1). Both Th17.1 and Th17 DP cells were abundant in CSF compared to blood from late-
stage MS patients (Supplementary Fig. 2). 
Finally, to confirm that Th17.1 is a distinct pro-inflammatory Th17 subset, we evaluated 
the expression of key regulators of Th17 differentiation and pathogenicity. Along with VLA-4 
(see also Fig. 6D), CD161, CD226, ABCB1 (MDR1), IL23R, STAT4, FCMR (TOSO) and GZMB 
(granzyme B; all upregulated), as well as CD25 and BATF (downregulated) were discrimina-
tive markers for Th17.1 (Supplementary Table 3 and Supplementary Fig. 3). The abundant 
expression of T-bet, RORγt, IFN-γ and GM-CSF in Th17.1 cells (Supplementary Fig. 4) con-
firmed the pronounced Th1 features of this Th17 subset27. 
Collectively, these data demonstrate the propensity of Th17.1 cells to recruit to the CNS 
and mediate disease activity in early MS. 
DISCUSSION
In this study, we demonstrate that IFN-γ- and GM-CSF-expressing Th1-like Th17 
(CCR6+CXCR3+) cells are selectively associated with early disease activity in patients with MS. 
During disease onset, highly activated and effector memory Th1-like Th17 cells are markedly 
reduced in the peripheral blood and represents the main pro-inflammatory T-cell popula-
tion within CSF. This local recruitment seemed to be preferentially targeted by natalizumab 
treatment to prevent subsequent MS relapses, since a Th1-like Th17 subpopulation termed 
Th17.1, and no other Th subsets, predominantly accumulated in the blood of relapse-free 
patients. The current work provides in-depth insights into the pro-inflammatory capacity of 
distinct CCR6+ Th subpopulations during the course of MS9, and offers new possibilities to 
fine-tune currently approved T-cell directed treatment for patients with MS. 
The use of both CCR6 and CXCR3 as discriminating markers for Th17 cells does not only 
reflect their pro-inflammatory state, but also their capability to migrate into local inflamma-
tory sites. Previous studies on Th17 cells in experimental autoimmune encephalomyelitis 
and MS primarily focused on single expression of CCR69, or IL-17, which is increased in blood 




















expression of CXCR3 subdivides human CCR6+ Th17 into high (CXCR3-) and low (CXCR3+) pro-
ducers of IL-17A. In these IL-17low producers, which were over-represented in early-stage 
MS CSF compared to blood T cell cultures, GM-CSF is the major pro-inflammatory cytokine 
expressed together with IFN-γ. This is likely caused by their elevated levels of T-bet, and 
not RORγt, as previously reported for human Th cells11. The association of Th1-like Th17 
(T-bet-dependent) and not Th17 (RORγt-dependent) with a short time to CDMS diagnosis is 
supported by the expression of T-bet, and not RORγt in CD4+ T cells during rapid MS onset40. 
Th1-like Th17 cells were also highly activated after MS diagnosis, which links to the import-
ant role of CD4+ T-cell activation in CIS progression3 human. This suggests that during MS 
disease onset, the loss of T regulatory function41 results in the activation of peripheral Th1-
like Th17 subsets, which infiltrate the CNS to mediate local inflammation. Indeed, memory 
Th cells of relapsing MS patients were more capable of differentiating into Th1-like Th17 
cells, albeit co-producing IFN-γ and IL-1735. These Th cells were cultured in the presence of 
IL-23, prompting RORγt and subsequently IL-17 expression11. In our CCR6- and CXCR3-based 
approach, we defined pro-inflammatory cytokine profiles of Th17 and Th1-like Th17 popu-
lations directly from the blood. This could explain why we identified IFN-γ/GM-CSF- and not 
IL-17-producing Th17 cells as the most pro-inflammatory subset in early MS, and also agrees 
with the minimal influence of IL-17 and strong impact of GM-CSF on experimental auto-
immune encephalomyelitis induction13, 42, 43. For proper analysis of cytokine production by 
Th1-like Th17 cells in CSF, we had to add IL-2 to short-term T cell cultures, inducing GM-CSF 
expression11. Th1-like Th17 subsets co-produced more IFN-γ and GM-CSF than other T cell 
subsets in CSF and their counterparts in blood. Our finding that pro-inflammatory Th1-like 
Th17 and especially Th17.1 cells were highly enriched in CSF of patients with early-stage MS 
is in line with their reduced frequencies in the blood (this study), and the increased CSF CD4 
to CD14 ratios in CIS patients with a short time to CDMS44. Consistent with in situ observa-
tions in MS brain tissue35, a small fraction of blood and CSF Th1-like Th17 and Th17.1 cells did 
co-produce IFN-γ and IL-17, but this was considerably less than their co-production of IFN-γ 
and GM-CSF. Besides Th17.1, Th17 DP (IL-17int) cells were also enriched in CSF of patients 
with late-stage MS, suggesting that local IL-17 production is mainly involved in disease pro-
gression. Nevertheless, the predominance of Th1-like Th17 cells in MS CSF and brain tissues 
as observed in this study corresponds to more recent findings that CNS inflammation in MS 
is largely mediated by infiltrating IFN-γ- and not IL-17-producing Th cells34, 36, 45.
Th1-like Th17 cells contain several features promoting their selective intrusion into the 
CNS, although local Th17 plasticity cannot be completely ruled out46. Th1-like Th17 cells pro-
duce high levels of IFN-γ, triggering CXCL10 expression by endothelial cells to favor CXCR3-
mediated migration into the CNS36, 47, and thereby MS disease activity48, which is supported 
by our in vitro and ex vivo transmigration results. Additional expression of GM-CSF by this 
subset may further dysregulate the blood-brain barrier, as described for monocytes49. Prior 
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to their extravasation, Th17 cells make use of distinct molecules involved in the rolling on 
and adhesion to endothelial cells, which are activated by pro-inflammatory cytokines and 
chemokines37, 50, 51. One of these molecules is the α4β1-integrin VLA-4, which is targeted by 
natalizumab to cause a strong reduction of lymphocytes in MS CSF52. In addition to previ-
ous work53, we now show that only a particular Th1-like Th17 subpopulation termed Th17.1 
accumulates in the blood from MS patients who clinically respond to natalizumab treatment. 
These selective effects may thus be useful for predicting freedom from MS activity19, and 
understanding the potential lethal MS rebounds that occur in patients who have to stop this 
treatment due to increased risk of progressive multifocal leukoencephalopathy (PML)54, 55. 
MS rebounds are characterized by a rapid influx of pro-inflammatory cells into the CNS to 
cause excessive inflammation, potentially resulting in PML-immune reconstitution inflam-
matory syndrome (IRIS)56. Although not proven yet, the marked accumulation of Th17.1 in 
natalizumab-treated MS blood puts forward their transmigration into CNS as a critical pro-
cess during these complications. Out of all pro-inflammatory Th subsets defined by CCR6, 
CXCR3 and CCR4, Th17.1 revealed the strongest VLA-4 surface expression levels in MS blood, 
which explains their restricted targeting by natalizumab. Consistent with our results, VLA-4 
levels were found to be higher on Th17 than on Th1 cells in MS patients, probably mediating 
their trafficking into the CNS17. However, when we compared individual Th17 subpopula-
tions, i.e. CCR6+ Th17 (CXCR3-CCR4+; IL-17high), Th17 DP (CXCR3+CCR4+; IL-17dim) and Th17.1 
(CXCR3+CCR4-; IL-17low)27, VLA-4 surface expression seemed to be inversely associated with 
their ability to produce IL-17, as also described for mice57. The predominant expression of 
VLA-4 on Th17.1 cells closely parallels the dependence of IFN-γ- and not IL-17-producing Th 
cells on this integrin for their entry into the CNS during experimental autoimmune enceph-
alomyelitis57, 58. However, adhesion molecules other than VLA-4 must be taken into account 
for alternative transmigration routes of pro-inflammatory Th17 cells as well50, especially con-
sidering the rebound effects after natalizumab discontinuation in MS. 
This cross-sectional study exemplifies that a more refined evaluation of chemokine sur-
face receptors, pro-inflammatory cytokines and adhesion molecules is warranted to better 
understand the contribution of human Th1 and Th17 to MS and other autoimmune and neu-
roinflammatory diseases. Based on CCR6/CXCR3, IFN-γ/GM-CSF and VLA-4 expression, we 
identify Th1-like Th17 as a clinically relevant CD4+ T cell population during disease onset and 
treatment in MS patients. Future work on the localization and antigen specificity of these 
subsets in human brain lesions will be critical to determine their local impact on myelin and 
axonal loss in MS. The prominent association of Th1-like Th17 cells, in particular Th17.1, with 
MS activity suggests the possibility for more specific T cell-targeted therapies, and pleads for 
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Supplementary Table 1. Characteristics of patients and controls in additional cohorts
a14 CIS-CIS and 16 CIS-CDMS were also included in the screening cohorts (see Table 1).
b2 natalizumab-treated RRMS patients were also used for analysis of pro-inflammatory cytokine expression only 
(Table 1).
cAt the time of sampling.
dAt the time of pre-treatment sampling. RRMS according to the McDonald 2010 criteria. 
eTime from CIS diagnosis to sampling.
HC = healthy control; MS = multiple sclerosis; NA = not applicable or available; NAT = natalizumab.






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(A) Validation of Th17.1 accumulation in the blood of nine MS patients after natalizumab treatment. Frequencies of 
Th1 (CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+), Th17.1 (CCR6+CXCR3+CCR4-) and Th17 DP (CCR6+CXCR3+CCR4+) 
cells within the CD4+ T cell pool were compared pre- and 12m post-treatment using multicolor flow cytometry. (B) 
Representative gating and percentages of VLA-4+ cells within Th1, Th17, Th17.1 and Th17 DP subpopulations in 







































































Supplementary Figure 2. Flow cytometric analysis of Th17 subpopulations in paired ex vivo CSF and blood samples 
of three late-stage MS patients. 
90






































































































Supplementary Figure 3. Validation of Th17.1 as a distinct Th17 subset based on the expression of key genes 
involved in Th17 differentiation and pathogenicity.
We sorted memory Th17 (CCR6+CXCR3-CCR4+), Th17.1 (CCR6+CXCR3+CCR4-) and Th17 DP (CCR6+CXCR3+CCR4+) cells 
of seven healthy blood donors and compared the relative expression levels of ABCB1 (MDR1), IL23R, STAT4, BATF, 
FCMR (TOSO) and GZMB (granzyme B). For FCMR and GZMB expression analyses, Th subsets were activated with 



































































































































































































































































Supplementary Figure 4. Validation of Th17.1 as a distinct Th17 subset based on the expression of Th1- and 
Th17-associated pro-inflammatory cytokines and transcription factors.
Th1 (CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+), Th17.1 (CCR6+CXCR3+CCR4-) and Th17 DP (CCR6+CXCR3+CCR4+) 
cells were sorted from seven healthy blood donors and compared for mRNA (A) and protein (B) expression of IFN-γ 
(IFNG), GM-CSF (CSF2), IL-17A (IL17A), T-bet (TBX21) and RORγt (RORC).
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Objective: Results from anti-CD20 therapies demonstrate that B- and T-cell 
interaction is a major driver of multiple sclerosis (MS). The local presence of 
B-cell follicle-like structures and oligoclonal bands in MS patients indicates that 
certain B cells infiltrate the central nervous system (CNS) to mediate pathology. 
Which peripheral triggers underlie the development of CNS-infiltrating B cells 
is not fully understood. 
Methods: Ex vivo flow cytometry was used to assess chemokine receptor 
profiles of B cells in blood, cerebrospinal fluid, meningeal and brain tissues of 
MS patients (n = 10). Similar analyses were performed for distinct memory 
subsets in the blood of untreated and natalizumab-treated MS patients (n = 
38). To assess T-bet(CXCR3)+ B-cell differentiation, we cultured B cells from MS 
patients (n = 21) and healthy individuals (n = 34) under T helper 1- and TLR9-
inducing conditions. Their CNS transmigration capacity was confirmed using 
brain endothelial monolayers. 
Results: CXC chemokine receptor 3 (CXCR3)-expressing B cells were 
enriched in different CNS compartments of MS patients. Treatment with the 
clinically effective drug natalizumab prevented the recruitment of CXCR3high 
IgG1+ subsets, corresponding to their increased ability to cross CNS barriers 
in vitro. Blocking of interferon-γ (IFN-γ) reduced the transmigration potential 
and antigen-presenting function of these cells. IFN-γ-induced B cells from MS 
patients showed increased T-bet expression and plasmablast development. 
Additional TLR9 triggering further upregulated T-bet and CXCR3, and was 
essential for IgG1 switching.
Interpretation: This study demonstrates that T-bethigh IgG1+ B cells are 
triggered by IFN-γ and TLR9 signals, likely contributing to enhanced CXCR3-



























B cells are one of the main contributors to chronic autoimmune pathology in multiple 
sclerosis (MS), as supported by results from large genome-wide association studies1. B-cell 
repertoires in the central nervous system (CNS) and the periphery are closely connected, 
suggesting that disease-relevant B-cell networks interact at both sides of the blood-brain 
barrier2-5. There is evidence that the beneficial effects of anti-CD20 monoclonal antibody 
therapy are related to the ablation of functional B cells interacting with T cells6, 7. The menin-
ges of MS patients contain tertiary lymphoid structures that are filled with B and T cells, close 
to cortical lesions8. This strongly suggests that B- and T-cell interaction is a major event in 
triggering and sustaining inflammation in the CNS. 
In MS, autoreactive (naive) B cells escape peripheral selection and probably receive spe-
cific signals from CD4+ T cells within secondary lymphoid organs to differentiate into memory 
populations before entering the CNS5, 9, 10. The presence of oligoclonal bands (OCBs) in the 
cerebrospinal fluid (CSF) of MS patients implies that these memory B cells undergo local 
reactivation (with the help of CD4+ T cells) to further develop into immunoglobulin (Ig)-
producing plasmablasts and plasma cells8, 11. Although memory B cells have been recently 
shown to promote the differentiation of CNS-infiltrating CD4+ T cells in MS, little is known 
about how and which functional B-cell subsets are triggered in the periphery to infiltrate the 
CNS and contribute to MS pathology.
In mice, the T helper 1 (Th1) cytokine interferon-γ (IFN-γ) induces the interaction 
between autoreactive B cells and CD4+ T cells to form tertiary lymphoid structures and 
promote systemic autoimmune diseases such as systemic lupus erythematosus (SLE)12. In 
these cases, IFN-γ induces the expression of the T-box transcription factor T-bet, resulting in 
enhanced Ig class switching and CXC chemokine receptor 3 (CXCR3) expression in murine B 
cells13, 14. Interestingly, B-cell-intrinsic T-bet expression associates with increased pathogenic 
responses14, 15 and is induced by systemic infections16, a major environmental trigger in MS17. 
Toll-like receptor 9 (TLR9), which binds to pathogen-related CpG-DNA, integrates with the 
B-cell receptor (BCR), CD40 and cytokine signals to stimulate T-bet+ B-cell development18, 
19. Additionally, B cells from MS patients were previously reported to exhibit an enhanced 
pro-inflammatory phenotype when activated with IFN-γ and TLR9 ligand CpG-DNA7.
Here, we aimed to explore the CNS transmigration capacity of T-bet(CXCR3)-expressing 
B cells and which peripheral triggers are involved in the development of such populations in 
MS patients. We explored the recruitment of human CXCR3+ B cells to the CNS both ex vivo 
and in vitro. Furthermore, the susceptibility of blood-derived B cells from MS patients and 
healthy individuals to T-bet-inducing stimuli and how this influences their differentiation into 
CXCR3+ memory subsets was determined using different T-cell-based culture systems.
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Post-mortem CSF, meninges, brain tissues and blood samples were freshly obtained from 
MS brain donors (Netherlands Brain Bank, Amsterdam, the Netherlands). The main cause of 
death was legally granted euthanasia (8 of 10 donors). The two other donors died from pneu-
monia or MS. These tissues had a very short post-mortem delay of 8.92 hours (interquartile 
range [IQR] = 8.50 – 9.50 hours) and pH of the CSF was 6.59 (IQR = 6.44 – 6.87). All other 
MS patients and healthy controls were included at Erasmus Medical Center (Rotterdam, The 
Netherlands), which is a national tertiary referral center for MS patients (MS Center ErasMS). 
Patients and controls were age- and gender-matched per study group. Patient characteris-
tics are summarized in Table 1. Primary material was obtained between 2007 and 2018. All 
patients gave written informed consent, and study protocols were approved by the medical 
ethics committee of the Erasmus Medical Center (Rotterdam) and VU University Medical 













































































Table 1. Characteristics of patients and controls used in this study 
aAt time of sampling
bTime from MS diagnosis to sampling
cAt time of pre-treatment sampling
dIgG subclass instead of total IgG analysis
CNS = central nervous system; MS = multiple sclerosis; HC = healthy control; NAT = natalizumab, Tx = treatment; IQR 


























Mononuclear cell isolation from blood and CNS compartments
Peripheral blood mononuclear cells (PBMCs) were isolated according to the manufactur-
er’s instructions from blood of MS patients and matched controls with the use of vacutainer 
CPT® tubes containing sodium heparin (BD Biosciences, Erembodegem, Belgium). PBMCs 
were frozen and stored in liquid nitrogen until use as previously described20. Mononuclear 
cells were isolated from buffy coats using Ficoll-Paque Plus (GE Healthcare, Freiburg, 
Germany) and density gradient centrifugation. Blood and CSF samples from MS brain 
donors were acquired post-mortem through heart puncture and ventricle drainage, respec-
tively20. Heart blood mononuclear cells were isolated as described for buffy coat material. 
Collection tubes with CSF were centrifuged for 10 min at 500g. CSF and blood mononuclear 
cell fractions were resuspended in RPMI 1640 (Lonza, Verviers, Belgium) containing 10% 
heat-inactivated human AB serum (Sanquin, Rotterdam, The Netherlands) and 1% penicillin/
streptomycin (Lonza) and left to rest at 37oC until further use. Meninges were washed in 
phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin (BSA) 3 times, cut 
into pieces and incubated with Liberase (Roche Applied Science, Penzberg, Germany) for 1h 
at 37oC, after which the meninges were filtered through a cell strainer (45µm) and cells were 
washed using Ficoll-Paque Plus (GE Healthcare). Single-cell suspensions from the meninges 
were resuspended in PBS containing 0.1% BSA until further use. Brain tissue samples were 
processed and single-cell suspensions were obtained as previously reported21. 
Antibodies and flow cytometry
Multicolor flow cytometric analysis was performed using fluorochrome-labeled mono-
clonal anti-human antibodies (mAbs; Table 2). PBMCs were stained extracellularly for 30 min 
at 4oC. Cultured B cells were stained with a fixable viability stain (FVS 700) for 15 min at 4oC 
and subsequently stained for either extracellular only or both extracellular and intracellu-
lar markers. For intracellular staining, cells were fixed with 2% paraformaldehyde (Merck, 
Schipol-Rijk, The Netherlands) and permeabilized with PBS pH 7.4 containing 0.3% BSA and 
0.5% saponin (Sigma-Aldrich, Saint-Louis, MO) and stained with T-bet for 60 min at 4oC. All 
measurements were conducted with an LSRII-Fortessa flow cytometer and analyzed using 
FACS Diva software, version 8.0.1 (both BD Biosciences). Ex vivo Th17.1 (IFN-γhighIL-17low) and 
Th17 (IFN-γneg) cells in blood were defined as CCR6+CXCR3+CCR4- (Th17.1) and CCR6+CXCR3-
CCR4+ (Th17), described recently20. 
Human B-cell migration assays
Flow-activated cell sorting (FACS)-sorted CD27- and CD27+ memory CD19+ B cells from 
buffy coat-derived PBMCs were placed on 96 wells permeable transwell plates with a 0.3 µm 
pore size (2×105 cells/well; Corning, Amsterdam, the Netherlands). B-cell migration towards 
medium or CXC chemokine ligand (CXCL)10 (900 ng/ml; R&D Systems, Abingdon, UK) was 
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analyzed after 3h in 37°C. In addition, 2,5-5×105 memory B cells were placed on confluent 
monolayers of human brain endothelial cells (hCMEC/D3) on 5 μm pore size transwell plates 
(Corning) coated with collagen, and migration was analyzed after 5 hours22. Percentages of 
memory B-cell subsets were compared before and after transmigration using flow cytometry.
Antigen-primed autologous B- and Th-cell co-cultures 
BCR-mediated uptake and presentation of Salmonella typhimurium (S. typhimurium) 
SL1344 was used as a model for antigen presentation, as previously demonstrated23. mAb 
anti-human IgG (MH16-1, Sanquin, Amsterdam, The Netherlands) was mixed with mAb 
against S. typhimurium lipopolysaccharide (LPS; 1E6, Invitrogen, Paisley, UK) and rat anti-
mouse IgG1 antibody (RM161.1, Sanquin) to generate BCR-LPS tetrameric antibody com-
plexes. Exponentially grown bacteria were washed twice with PBS, incubated with BCR-LPS 
tetrameric antibody complexes for 30 min at room temperature, and washed twice to remove 
  
 
































































































Table 2. Monoclonal anti-human antibodies used for FACS
aBiolegend, London, UK
b BD Biosciences, Erembodegem, Belgium
cMiltenyi Biotech, Leiden, The Netherlands 


























unbound antibodies. B cells were incubated with viable anti-IgG coated S. typhimurium23 at 
20 bacteria per cell for 45 min at 37oC without antibiotics. Next, cells were washed 3 times 
and cultured for 60 min in medium containing 100 µg/ml gentamicin (Invitrogen) to elimi-
nate non-phagocytosed bacteria. B cells were co-cultured in RPMI supplemented with 5% 
fetal calf serum, 1% (100 U/ml) penicillin, 1% (100 µg/ml) streptamycin (Lonza), 1% (2 mM) 
ultraglutamine (Lonza), 0.1% (50 µM) beta-mercaptoethanol (Sigma Aldrich), 0.1% (20 µg/
ml) apotransferrin (depleted for human IgG with protein-G sepharose; Sigma Aldrich; further 
referred to as B-cell medium) and 10 µg/ml gentamicin together with autologous CD4+ T 
cells (magnetic activated cell sorted). B cells (1×105) and T cells (0.5×105) were cultured in 
200 µl at 37°C in the presence of 5% CO2 in 96-well round-bottom plates (Greiner Bio-One; 
Alphen Aan Den Rijn, The Netherlands) for 6 days. Cultures were performed in the pres-
ence of recombinant interleukin (IL)-21 (50 ng/ml; Thermo Fisher Scientific, Landsmeer, The 
Netherlands), recombinant IL-2 (50 IU/ml, Miltenyi Biotec, Bergisch Gladbach, Germany), 
and with or without an anti-IFN-γ blocking antibody (MD-1, 10 µg/ml, U-CyTech Biosciences, 
Utrecht, The Netherlands). 
IL-21/3T3-CD40L assay for human B-cell differentiation 
To mimic B-cell differentiation in vitro, murine NIH3T3 fibroblasts expressing human 
CD40L (3T3-CD40L)23 were irradiated at 30 Gy using a RS320 X-ray (Beckhoff, Eindhoven, 
The Netherlands), taken up in B-cell medium, and seeded on flat bottom 96-wells plates 
(10×103 cells per well; Greiner Bio-One) to allow adherence overnight. CD19+ (total) B cells 
were isolated from buffy coat-derived PBMCs using CD19 microbeads and the autoMACS Pro 
Separator (both Miltenyi Biotec). Total, naive (CD38-/dimCD27-IgG-IgA-) and memory (CD38-/
dimCD27+IgG+) B cells were isolated from healthy and MS blood using a BD FACSAriaTM III cell 
sorter. These fractions were resuspended in B-cell medium and 20-25×103 cells were co-cul-
tured with irradiated 3T3-CD40L cells and stimulated with a combination of IL-21 (50 ng/
ml; Thermo Fisher), IFN-γ (50 ng/ml; Peprotech/Bio-connect, Huissen, The Netherlands) and 
CpG-ODN (2006-G5; 10 µg/ml; InvivoGen/Bio-connect) at 37oC and 5% CO2. After 6 and 11 
days of culture, supernatants were collected and stored at -80oC until use for enzyme-linked 
immunosorbent assay (ELISA). The cells were stained and assessed using flow cytometry as 
described above. 
IgG1 ELISA
Nunc MaxiSorp plates (Sanbio BV, Uden, The Netherlands) were coated overnight 
with anti-human IgG1 monoclonal capture antibody (1µg/ml; clone MH161-1, Sanquin, 
Amsterdam, The Netherlands) in PBS. After washing with PBS-0.02% Tween-20, the super-
natants from in vitro B-cell cultures (described above) were diluted in high-performance 
ELISA buffer (HPE; Sanquin) and incubated for 60 min. Subsequently, plates were washed 
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and incubated for 60 min with anti-human IgG conjugated with horseradish peroxidase, a 
monoclonal detection antibody (1 µg/ml; clone MH16-1, Sanquin). After washing, the ELISA 
was developed with MQ containing 0.11M sodium-acetate (pH 5.5), 100 µg/ml tetramethyl-
benzidine and 0.003% (vol/vol) H2O2 (all from Merck). The reaction was stopped by addition 
of 2M H2SO4 (Merck). Optical densities at 450nm were measured with a BioTek (Winooski, 
VT) Synergy 2. Background readings at 540nm were subtracted. Results were related to a 
titration curve of a serum sample of a healthy donor in each plate.
Statistical analyses
All data sets were analyzed with Graphpad Prism Software, version 7 (GraphPad Software, 
San Diego, CA) and compared using two sided Mann-Whitney U tests, Wilcoxon matched-
pairs signed rank test, 1- or 2-way analysis of variance with Tukey post hoc test, Friedman 
paired with Dunn post hoc test, and Spearman correlation coefficients (as indicated in each 
figure legend). Experimental data are depicted as the mean ± standard error of the mean 
(SEM). Prior to statistical analyses, datasets were tested for normal distribution. Probability 
values <0.05 were considered significant. 
RESULTS
CXCR3-expressing B cells are selectively enriched in distinct CNS 
compartments of MS patients 
Enhanced chemotaxis is one of the key mechanisms by which B cells can enter distinct 
CNS compartments of MS patients11. Production of the chemoattractants CXCL10, CXCL13 
and CCL20 in the CNS has been associated with B-cell recruitment, distribution and reactivity 
in MS24-26. We compared the presence of B cells that express the chemokine receptors that 
correspond to these ligands, CXCR3+ (CXCL10), CXCR5+ (CXCL13) and CCR6+ (CCL20), between 
paired blood, CSF, meningeal and brain tissues from 10 MS patients (Table 1). To realize this, 
single-cell suspensions were obtained from autopsied brain compartments using a standard-
ized protocol21. From these fractions, viable CD45+CD3-CD19+ B cells were gated and analyzed 
for chemokine receptor expression using flow cytometry (Fig. 1A). We were able to measure 
sufficient numbers of viable B cells from each compartment for all donors (mean [range]: 
blood, 21,509 [610-98,562]; CSF, 12,629 [50-59,499]; meninges, 13,819 [91-36,644]; brain 
tissue, 2,889 [26-18,050]. The frequency of CXCR3+, and not CXCR5+ or CCR6+ B cells was 
strongly increased in ex vivo cell suspensions from MS brain tissues (p < 0.0001), meninges 
(p = 0.0003), and CSF (p < 0.0001) compared to blood (Fig. 1B). CXCR3-expressing T cells, 
including Th17.1, were also enriched in the CNS compartments of these donors (data not 


























Reduced frequencies of CXCR3+IgG(1)+ B cells in the blood of MS patients 
are abrogated after natalizumab treatment 
To determine how CXCR3 is involved in the local attraction of different B-cell populations 
in MS, we assessed the proportions of CXCR3-expressing naive (CD27-IgM+; IgMnaive) and both 
IgM+ memory (CD27+IgM+; IgMmem) and IgG
+ memory (CD27+IgG+) B cells in the peripheral 
blood of untreated MS patients (n = 10) and age- and gender-matched healthy controls (HC, 
n = 10; Table 1 and Fig. 2A). CXCR3-expressing IgG+ cells were reduced (p = 0.007), whereas 
no differences were seen for IgMnaive and IgMmem cells in MS versus HC blood (Fig. 2B). 
Figure 1. CXCR3+ B cells are abundant in the CNS compared to blood of MS patients. 
(A) Representative FACS plots and gating of CXCR3-expressing CD19+ B cells within viable CD45+CD3- lymphocyte 
fractions derived from the blood, CSF, meninges and brain tissue of an MS patient. (B) Frequencies of CXCR3+, 
CXCR5+ and CCR6+ B cells in distinct paired compartments from MS patients. For blood, CSF and meningeal samples 
each dot represents a different patient. A total of 10 brain tissues from 7 different MS patients were used for the 
analysis of CXCR3+ B cells. Any samples with <25 viable B cells were excluded from these analyses. Data are pre-
sented as the mean ± SEM. *p < 0.05, ***p < 0.001, ****p < 0.0001. The p values for B were calculated by a 1-way 











































































































To address this potential migration of CXCR3+IgG+ memory B cells into the CNS, we ana-
lyzed the distribution of these B-cell subsets in the blood of MS patients treated with the 
anti-α4β1 integrin (VLA-4) antibody natalizumab (Table 1), a drug that effectively reduces 
MS disease activity by blocking lymphocyte recruitment to the CNS27. VLA-4 was most abun-
dantly expressed on blood IgG+ B cells from MS patients prior to natalizumab treatment 
(Fig. 2C). Elevated frequencies of both IgMmem (pre-treatment versus 6m post-treatment p 
= 0.042 and 12m post-treatment p = 0.011) and IgG+ (pre-treatment versus 6m post-treat-
ment p = 0.022 and 12m post-treatment p < 0.001) B cells were found in the blood of MS 
patients both 6 and 12 months after versus before treatment (Fig. 2D). However, only IgG+ 
and not IgMnaive or IgMmem B cells from MS patients treated with natalizumab for 12 months 
showed increased expression levels of CXCR3 (p < 0.01; Fig. 2E), and not CXCR5 or CCR6 
(Fig. 2F). These findings were validated in a second cohort of nine MS patients treated with 
natalizumab (Table 1; data not shown). Notably, CD20 expression levels were increased on 
IgG+ B cells and higher on CXCR3+ compared to CXCR3- counterparts in the blood of natali-
zumab-treated MS patients (Fig. 2G).
Because intrathecally synthesized OCBs are restricted to the IgG1 subclass in the CSF of 
MS patients28, we also analyzed IgG1+ B cells for their frequencies and CXCR3 expression in 
the blood of a third cohort of natalizumab-treated MS patients (Fig. 2H). IgG1+ B cells not 
only expressed higher levels of CXCR3 (p = 0.007; Fig. 2I), but also showed increased frequen-
cies in post-treatment samples (p = 0.027; Fig. 2J) compared to IgG2+ B cells. The selective 
accumulation of CXCR3high IgG(1)+ B cells in the blood of natalizumab-treated patients under-
lines the potency of this subset to transmigrate into the CNS to mediate MS disease activity. 
Figure 2 (see right page). Reduced frequencies and natalizumab-mediated accumulation of CXCR3+IgG(1)+ B cells 
in MS blood.
(A) FACS gating strategy used to define IgMnaive (CD27
-IgM+), IgMmem (CD27
+IgM+) and IgG+ (CD27+IgG+) B-cell subsets. 
(B) Gating and quantification of CXCR3-expressing IgMnaive, IgMmem and IgG
+ B-cell frequencies in the blood of un-
treated MS patients (n = 10; dark blue dots) and both age-/gender-matched healthy controls (HC; n = 10; grey dots, 
see Table 1). (C) VLA-4 surface expression on IgMnaive, IgMmem and IgG
+ B cells from blood of MS patients before natal-
izumab treatment (n = 9). (D) The percentage of IgMnaive, IgMmem and IgG
+ B cells in MS blood before (black dots) and 
both 6 months (marine blue dots) and 12 months (light blue dots) after natalizumab treatment (paired samples; n = 
10; see Table 1). Surface expression levels of (E) CXCR3, (F) CXCR5 and CCR6 on IgMnaive, IgMmem and IgG
+ B cells in MS 
patient blood before and after natalizumab treatment (n = 7-10). (G) CD20 expression on IgMnaive, IgMmem and IgG
+ B 
cells as well as paired CXCR3- and CXCR3+ IgG+ populations in blood of MS patients treated with natalizumab for 12 
months (n = 8). (H-J) Gating example and quantifications of IgG1+ and IgG2+ B cells expressing CXCR3 in MS patients 
treated with natalizumab for 12 months (n = 9). Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p 
< 0.001, ****p < 0.0001. The p values were calculated by Mann-Whitney U (B), 2-way analysis of variance (C and G), 
Friedman paired (D-F), and Wilcoxon matched-pairs signed rank (G, I and J) tests. MFI = mean fluorescence intensity; 











































































































































































































































































































































CXCR3+IgG1+ B cells have an enhanced capacity to transmigrate across the 
blood-brain barrier in vitro
To functionally test the transmigration potential of CXCR3+IgG1+ B cells into the CNS, we 
sorted memory B cells from the blood and assessed in vitro migration of subsets towards 
CXCL10. Fractions of CXCR3-expressing IgMmem, IgG1
+ and IgG2+ B cells were assessed within 
the total memory pool before and after migration through transwell filters. In contrast 
to IgMmem and IgG2
+ populations, IgG1+ B cells showed prominent recruitment to CXCL10 
(p < 0.0001 before versus after migration; Fig. 3A and B). This was not seen using medium 
only (Fig. 3B). To mimic B-cell transmigration across the blood-CNS barrier, these experiments 
were repeated using cultured confluent monolayers of human brain endothelial cells22. We 
found a similar CXCL10-mediated migratory advantage of IgG1+ B cells (p < 0.0001; Fig. 3A 
and C), which is consistent with the abundance of CXCR3 on IgG1+ compared to IgMmem and 
IgG2+ B cells in MS patients (Fig. 2G-I). These data demonstrate that CXCR3high IgG1+ B cells in 
the blood have a heightened ability to infiltrate the CNS, probably accounting for the local 
IgG1 subclass restriction of OCBs in MS patients28.
IFN-γ promotes CXCR3 expression and CD4+ T-cell activation by human 
T-bet+ B cells under T follicular helper-like culture conditions 
In MS blood, the proportion of CXCR3+IgG+ B cells correlated to Th17.1 (IFN-γhighIL-17low; 
r = 0.566, p = 0.0003) and not to Th17 (IFN-γneg) cells (Fig. 4A)20. Th cell-derived IFN-γ is known 
as a central driver of autoreactive B cells in mice10 and also induces CXCR3 expression on 
human memory B cells29. Therefore, we aimed to better understand how the differentiation 
and function of human CXCR3+ memory B cells is influenced by IFN-γ before entering the 
CNS. To address this, we mimicked the effects of IFN-γ-producing T follicular helper (Tfh) cells 
on B-cell subsets in vitro. First, an IL-21-based human B- and T-cell co-culture system was 
used to assess whether Th1-derived IFN-γ influenced CXCR3 expression on IgG+ B cells in an 
antigen-specific manner. Because antigen uptake by B cells is limited by the selectivity of the 
BCR, surface IgG was crosslinked with Th1-associated pathogen S. typhimurium for efficient 
internalization, processing and presentation to autologous Th cells (Fig. 4B)23, 30. After 6 days 
of co-culture, we found that the induced expression of CXCR3 on Salmonella-containing IgG+ 
and not IgMnaive or IgMmem B cells was abrogated by the addition of an IFN-γ blocking antibody 
(p < 0.0001; Fig. 4C). Furthermore, blocking of IFN-γ impaired B cell-induced T-cell prolif-
eration, activation and effector memory formation (Fig. 4D and E). This implies that IFN-γ 
additionally stimulates the antigen-presenting function of CXCR3+IgG+ B cells, in parallel with 
previous findings in mice31.
CXCR3 expression is under the direct control of IFN-γ-inducible transcription factor 
T-bet, a critical regulator of memory B-cell differentiation in mice13, 14. Consistent with 


























Figure 3. Enhanced migration of CXCR3+IgG1+ B cells across transwell filters and human brain endothelial mon-
olayers in vitro. 
Sorted memory B cells from healthy donor blood were assessed for selective in vitro transmigration towards 
CXCL10. (A) Representative FACS plots and (B and C) quantifications of viable CXCR3-expressing IgMmem, IgG1
+ and 
IgG2+ B-cells migrating across transwell filters with and without confluent monolayers of human brain endothelial 
cells (BEC). Percentages of subsets within the total memory pool were compared before and after migration, both 
to medium and to CXCL10 (-BEC, n = 8; +BEC, n = 6). These experiments were performed in duplicate for each donor 
for which the average is shown. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01, ****p < 0.0001. The 






























































































































































































































































































































































































































Figure 4. T helper 1 cytokine IFN-γ is a major trigger of CXCR3+(T-bet+) B-cell differentiation in MS. 
(A) Correlation of ex vivo CXCR3+IgG+ B cells with Th17.1 (IFN-γhighIL-17low) and Th17 (IFN-γneg) cells in MS blood before 
and after natalizumab treatment (pre-Tx and post-Tx; n = 12). (B) Experimental model of Salmonella-primed autolo-
gous B- and T-cell co-cultures. (C-E) B cells from healthy donor blood were primed with S. typhimurium through BCR 
crosslinking using a tetrameric antibody complex, as described in Subjects and Methods. This allows BCR-mediated 
Salmonella uptake, processing and presentation on MHC II molecules to Th cells. IL-21 was added with and without 
an IFN-γ blocking antibody to analyze the effects on CXCR3 expression by B cells (C), and on the proliferation, activa-
tion and effector memory phenotype of Th cells (D and E). These experiments were performed in two independent 
experiments and in duplicate for (C) four and (D and E) two different blood donors. (F) Correlation of surface CXCR3 
and intracellular T-bet expression in ex vivo B cells of MS patients before and after natalizumab treatment (pre-Tx 
and post-Tx; n = 9). (G and H) Total B cells from the blood of MS patients (n = 9) and both age-and gender-matched 
healthy controls (HC; n = 10) were cultured in vitro under Tfh-like conditions with IL-21, 3T3-CD40L cells, and with 
or without IFN-γ for 11 days. Representative FACS plots and quantification of in vitro-induced T-bet+ B cells (G) and 
correlation of CXCR3 and T-bet expression in these cultured B cells (H) are shown. Data are presented as the mean ± 
SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. The p values were calculated by 2-way analysis of variance 
(ANOVA) (C), 1-way ANOVA (D and E) and Wilcoxon matched-pairs signed rank (G) tests. The correlation coefficients 
and p values for A, F and H were calculated by Spearman rank. m = months; MFI = mean fluorescence of intensity; 


























(r = 0.644, p = 0.0003) and showed a similar association with Th17.1 (IFN-γhighIL-17low) cells 
in MS patients (Fig. 4F and data not shown)20. To further explore the susceptibility of B cells 
to IFN-γ in MS7, we compared B cells from MS and matched healthy control blood for IFN-
γ-mediated T-bet induction under Tfh-like culture conditions. After 11 days of stimulation 
with 3T3-CD40L cells, IL-21 and IFN-γ, T-bet was predominantly upregulated in B cells of 
MS patients (p = 0.021; Fig. 4G), whereas conditions without IFN-γ did not show this. This 
in vitro-induced T-bet was co-expressed with surface CXCR3 (r = 0.766, p = 0.0001; Fig. 4H), 
in line with our ex vivo results (Fig. 4F). These findings reveal that Th cell-derived IFN-γ is a 
major trigger of peripheral CXCR3(T-bet)+ B cells in MS.
IFN-γ stimulates plasmablast formation and synergizes with CpG-DNA to 
establish IgG1 switching during human Tfh-like B-cell cultures
Besides IFN-γ, TLR9 ligand CpG-DNA has also been reported to induce T-bet in murine B 
cells14, 18 and promote pro-inflammatory cytokine responses of B cells from MS patients7. To 
assess how TLR9 signals integrate with IFN-γ to regulate human T-bet+ B-cell development, 
we first determined whether naive or memory B cells are more prone to this type of co-ac-
tivation. Naive (CD27-IgG-) and memory (CD27+IgG+) B cells were sorted from healthy donor 
blood and stimulated with 3T3-CD40L cells, IL-21, IFN-γ and/or CpG-DNA. After 11 days of 
naive B-cell cultures, both T-bet and CXCR3 expression was induced by IFN-γ, and further 
enhanced after addition of both IFN-γ and CpG-DNA (p = 0.001 and p = 0.021; Fig. 5A). This 
additional effect of CpG-DNA was not found when using sorted memory B cells (Fig. 5B). 
Both IFN-γ- and CpG-DNA-induced T-bet(CXCR3)+ B cells also showed strongly reduced CD21 
expression (data not shown), a typical feature seen for T-bet-expressing B cells31. 
During a germinal center response, naive B cells can either differentiate into plasmablast 
or memory populations, depending on the local inflammatory environment10, 32. We investi-
gated the effects of IFN-γ and CpG-DNA on plasmablast formation and IgG subclass switching 
during IL-21-/CD40L-induced naive B-cell differentiation. After 11 days of culture, sorted 
naive B cells from healthy donors developed into plasmablasts under IFN-γ stimulatory con-
ditions only (p = 0.034; Fig. 5C). IFN-γ and CpG-DNA together did not induce plasmablast for-
mation, but instead triggered IgG1 and not IgG2 expression on differentiating B cells (IFN-γ 
only versus IFN-γ + CpG-DNA: p = 0.002; Fig. 5D). Interestingly, this in vitro-induced IgG1 
switching was subjected to differentiation of sorted naive (Fig. 5D) and not memory (data not 
shown) B cells. CpG-DNA alone did not upregulate CXCR3, T-bet and IgG1 in differentiating 
naive B cells (data not shown), indicating that both IFN-γ and TLR9 signaling are required for 
enhanced expression of these markers. To verify that B-cell intrinsic expression also corre-
sponds with secretion of IgG1, we performed ELISAs on culture supernatants of these B cells. 
The percentage of IgG1+ B cells positively correlated to IgG1 secretion (r = 0.640, p = 0.016; 
Fig. 5E). 
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Figure 5. IFN-γ induces plasmablast differentiation, whereas both IFN-γ and CpG-DNA further upregulate T-bet 
and trigger IgG1 switching in B cells of MS patients.  
(A-D) Naive (IgG-CD27-; dots) and memory (IgG+CD27+; squares) B cells were sorted from peripheral blood of healthy 
donors and were cultured under Tfh-like conditions with IL-21, 3T3-CD40L cells, with or without IFN-γ and/or CpG-
DNA. Frequencies of T-bet+ and CXCR3+ B cells after 11 days of culture using (A) naive B cells (n = 12) and 6 days of 
culture using (B) memory B cells (n = 10-12) are shown. The frequencies of (C) plasmablasts (CD38highCD27+; n = 12) 
and (D) membrane-bound (m) mIgG1+ and mIgG2+ B cells were analyzed after culturing naive populations for 11 
days (n = 12). (E) Correlation between cellular expression and secretion of IgG1 was determined by FACS and ELISA 
(pooled stimulation conditions for 5 donors). Naive B cells from the blood of MS patients (n = 6; dark blue dots) 
and healthy controls (HC; n = 6; grey dots) were cultured under the same Tfh-like conditions and analyzed for (F) 
plasmablast (CD38highCD27+) and (G and H) CXCR3+mIgG1+ and CXCR3+mIgG2+ B-cell differentiation after 11 days of 
culture. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. The p values for A-D and F-H 
were calculated by the Wilcoxon matched-pairs signed rank test. The correlation coefficient and p value for E was 



















































































































































































































































































































Finally, to address how this is regulated in MS, we isolated naive B cells from MS patients 
and performed similar culture experiments. IFN-γ-mediated plasmablast formation was 
more induced after 11 days of culture compared to matched controls (p = 0.031; Fig. 5F). This 
was not seen after stimulation with both IFN-γ and CpG-DNA. Instead, this type of triggering 
resulted in a robust induction of CXCR3+IgG1+, and not CXCR3+IgG2+ subsets in MS (Fig. 5G 
and H). Collectively, these data demonstrate that TLR9 signaling potentiates IFN-γ-induced 
T-bet and CXCR3 expression during naive B-cell differentiation in vitro, and that this is import-
ant for IFN-γ-mediated formation of IgG1+ memory B cells rather than plasmablasts under 
Tfh-like circumstances in MS. 
DISCUSSION 
Evidence has accumulated that at least in the periphery, antibody-independent roles of 
B cells are driving the pathology of MS7. However, local production of autoantibodies should 
not be ruled out as an underlying B-cell mechanism in this disease33. Although autoreactive 
naive B cells are highly active in MS blood9, the vast majority of B cells identified in the MS 
brain have undergone further maturation into antibody-producing cells34, 35. It has also been 
demonstrated that memory B cells of MS patients are the most potent antigen-presenting 
cells and likely have specific pro-inflammatory propensities, including the capacity to express 
enhanced levels of immune activating molecules35. This is of special interest considering the 
presence of meningeal B cell-rich follicle-like structures in MS and the adjacent subpial cor-
tical demyelinating injury8, which probably contributes to progressive loss of neurological 
function in patients with MS. Thus, identification of the particular B-cell subsets that can 
preferentially migrate into the CNS and clarification of how they may contribute to propa-
gating local injury responses are of considerable interest in such an organ-specific disease. 
In this study, we demonstrate that integrating IFN-γ and pathogen-associated TLR9 signals 
are critical for the development of human T-bet+ memory B cells, probably underlying their 
selective recruitment to the CNS of MS patients. 
Recent studies have shown that in MS identical B-cell clones are present in both the 
periphery and CNS2-4. The fact that these B-cell populations further undergo somatic hyper-
mutation in the brain implies the presence of functional germinal centers within the CNS. 
Such structures have been identified in the meninges of MS patients and are obvious local-
izations to play a role here8. The enrichment that we observe of CXCR3+ B cells in paired 
CSF, meninges and brain tissue compartments compared to blood of MS patients is in line 
with studies that show higher levels of CXCR3 ligand CXCL10 in the CSF of MS patients24. 
These results are also consistent with our previous findings that CXCR3+ T cells, including 
Th17.1, are abundant within the CNS20, 24, suggesting a common CXCR3-driven lymphocyte 
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recruitment pathway in MS24, 36, 37. Other studies have also put forward CXCR5 and its ligand 
CXCL13 as important contributors to B-cell recruitment to the CNS3, 38. We did not find differ-
ences in CXCR5-expressing B cells between CNS tissues and paired blood. Hence, the CXCR5/
CXCL13 axis is probably related to local organization rather than recruitment of pathogenic 
B (and T) cells39, 40, in a process similar to that in secondary lymphoid organs41. Although 
these studies indicate a role for germinal center B cells within the CNS, little is known about 
which peripheral mechanisms underlie their development and local recruitment. In mice, it 
has been shown that in an autoimmune setting, IFN-γ, likely produced by activated Tfh cells, 
induce germinal centers10, which can be found in meningeal follicle-like structures8. In these 
situations, IFN-γ induced B cell-intrinsic expression of T-bet, possibly resulting in enhanced 
Ig class switching and CXCR3 expression13, 14. This points to a central role of IFN-γ-associated 
CXCR3+ B-cell subsets in the meningeal process10, 12.
While the inducing effects of peripheral B cells on autoreactive Th1 cells are currently 
being elucidated37, far less is known about the impact of Th1 cells on peripheral B-cell differ-
entiation and function in MS patients. Therefore, we were interested in the signals needed 
for B cells to differentiate into T-bet+ cells and postulated that IFN-γ- and IL-21-producing 
Tfh1 cells in germinal centers can trigger development of such B cells. In MS patients, B cells 
were found to express higher T-bet levels under Tfh1-like culture conditions. Furthermore, 
IL-21-based B- and T-cell co-cultures revealed that CXCR3-expressing IgG+ memory B cells 
were less induced after blocking of IFN-γ, which corresponds to studies that show IFN-γ 
regulates CXCR3 expression in human B cells29. Th cell proliferation, activation and effector 
memory formation were also affected in these cultures. In line with our findings, a recent 
study demonstrated that memory B cells induce proliferation of CNS-infiltrating Th1 cells in 
MS, which was inhibited after IFN-γ abrogation37. Therefore, in MS patients, peripheral inter-
action of CXCR3(T-bet)+ B and IFN-γ-producing Th cells probably generates a feedforward 
loop, in which IFN-γ enhances the potency of B cells as antigen-presenting cells, resulting in 
the activation of (IFN-γ-producing) pathogenic Th cells.
Furthermore, we found that naive B cells from MS patients developed into plasmab-
lasts rather than IgG1-switched memory B cells under IFN-γ-only conditions. Because T-bet 
mediates class-switching in murine B cells13, we expected that an additional signal would 
be required for triggering such a mechanism in human B cells. Besides Tfh1 cells, innate 
TLR signaling is also critical for naive B-cell differentiation42. Especially pathogen-associated 
TLR9 and its ligand CpG-DNA have been shown to promote the development of T-bet+ B cells 
in mice19, 31, 42. Correspondingly, we found that the induction of MS-blood derived naive B 
cells with both IFN-γ and CpG-DNA resulted in the development of IgG1-switched, T-bethigh B 
cells during Tfh-like cultures. Likewise, CXCR3 surface expression was more enhanced under 
these conditions, reflecting the high CXCR3 levels on ex vivo IgG1+ B cells. This additional 


























neuroinflammatory responses, including increased production of chemokines in the CNS43. 
Moreover, CXCR3+IgG1+ B cells showed an enhanced transmigration potential over brain 
endothelial layers, and selectively accumulated in MS blood after natalizumab therapy. The 
importance of pathogenic immune cells in contributing to MS disease progression, such 
as CXCR3+ memory B cells, has been put forward by the recurrence of often-fatal clinical 
relapses in MS patients when discontinuing the use of natalizumab27, 44, 45. During these 
rebounds, Epstein-Barr virus-infected memory B cells that have accumulated in the blood 
show massive influx into brain tissues of MS patients45. Furthermore, persistent viral infec-
tions are suggested to sustain the development of T-bet-expressing B cells15, which further 
supports the enhanced differentiation and local recruitment of CXCR3(T-bet)high memory B 
cells in an organ-specific autoimmune disease such as MS (Fig. 6). 
Although the exact role of (local) autoantibody production in MS is not clear, the ques-
tion whether and how T-bet+ B cells are involved this process deserves further attention. 
In SLE, T-bet+ B cells have autoreactive BCRs and are prone to differentiate into IgG auto-
antibody producing plasmablasts46. Inappropriate T-bet expression in B cells also impaired 































Figure 6. IFN-γ and TLR9 signaling upregulate T-bet in peripheral B cells, likely driving CXCR3-mediated recruitment 
and IgG1 production in the CNS of MS patients. 
Our findings suggest that in the secondary lymphoid organs of MS patients, IFN-γ triggers naive B cells to differen-
tiate into T-bet-expressing populations in a Tfh-dependent manner. Human T-bet+ B cells either can develop into 
plasmablasts or undergo further differentiation into IgG1+ memory B cells mediated by TLR9 ligation. The enhanced 
CXCR3 expression on both IFN-γ- and TLR9-induced IgG1+ B cells makes these subsets highly capable of transmigrat-
ing across the blood-brain barrier and mediate local pathology in MS.
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production13. In our study, IFN-γ-induced and CpG-DNA-induced human CXCR3(T-bet)high B 
cells showed increased IgG1 expression and secretion. This strongly suggests that after pref-
erential recruitment and re-activation in the CNS, CXCR3(T-bet)highIgG1+ B cells are respon-
sible for local production of IgG1 in MS (Fig. 6)28. Although B cells within the CNS of MS 
patients show characteristics of an antigen-driven response, the specific antigens driving 
this response remain unknown. MS disease heterogeneity is reflected by the identification 
of several candidate target antigens, including non-myelin proteins such as neurofilament 
light and RAS guanyl releasing protein 2 (RASGRP2)33, 37. In addition to this, increased Epstein-
Barr nuclear antigen 1 (EBNA1)-specific IgG1 titers have been found in active MS, which 
may be explained by the interaction of B cells with pathogen-associated TLR ligands and 
EBNA1-specific, IFN-γ-producing T cells that cross-recognize myelin antigens47. Therefore, we 
propose that the relevant antigen specificity of B cells in MS can be found within this subset, 
which should be further explored in the near future. 
Taken together, not only a disrupted blood-brain barrier, but also peripheral T-bet-
mediated differentiation and transmigration of IgG1+ memory populations could explain how 
B cells are eventually able to mediate CNS pathology in MS patients (Fig. 6). The relevance of 
T- and B-cell interaction in tolerance breakthrough is stressed by the finding that antigen-spe-
cific B cells are potentially 1,000 to 10,000 times better presenters of autologous peptides 
to T cells than non-specific B cells48. We here reveal that human CXCR3(T-bet)+ B cells are a 
product of T- and B-cell interaction. Similar to SLE, such populations probably serve as potent 
antigen-presenting cells in CNS-specific autoimmune diseases such as MS31. Anti-CD20 ther-
apy exerts immediate effects and is assumed to predominantly affect this function of B cells 
in MS patients35. The potential role of CXCR3(T-bet)+ B cells as prime targets of this therapy 
is further supported by their abundant CD20 expression, as shown in the current study. 
The development of new targeted strategies to inhibit T-bet function have the potential to 
become a double-edged sword in MS by suppressing pathogenic, IFN-γ-producing T (Th17.1) 
cells together with their counterpart CXCR3(T-bet)+ B cells. Small molecule inhibitors of IFN-γ 
signaling (jakinibs)49 and the TLR/myD88 pathway50 are already used in clinics for other 
inflammatory diseases, and are promising candidates for combined suppression of IFN-γ and 
TLR signals to control pathogenic T-bet+ B cells in autoimmune diseases such as MS.
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Background: In MS, pathogenic memory B cells are likely triggered by T 
follicular helper (TFH) cells to infiltrate the brain and develop into antibody-se-
creting cells. Chemokine receptors not only define their brain-homing capacity, 
but also their maturation within germinal centers. How this corresponds to MS 
relapse risk is underexplored.
Objective: To study the impact of pregnancy, as a model for relapse risk, on 
B-cell differentiation in MS.
Methods: Germinal center-like B-cell phenotypes and outgrowth were 
compared between 19 MS patients and 12 healthy controls during pregnancy 
(low risk) and early after delivery (high risk).
Results: Transitional, and not naive mature, B-cell frequencies dropped 
in the third trimester, which was strongest in patients who experienced a 
pre-pregnancy relapse. In the postpartum period, these frequencies raised 
again, while those of memory B cells showed a modest reduction. CXCR4 was 
downregulated and CXCR5, CXCR3 and CCR6 were upregulated on postpartum 
memory B cells, implying enhanced recruitment into germinal center light 
zones for interaction with TFH cells. Postpartum memory B cells of MS patients 
expressed higher CCR6 levels and preferentially developed into plasma cells 
during TFH-like cultures.
Conclusion: These data provide indications how memory B-cell outgrowth 






















MS is a chronic inflammatory and demyelinating disease of the CNS, for which a key role 
for B cells in the pathogenesis has been shown in recent years1. In the relapsing phase of 
MS, naive B cells escape peripheral tolerance checkpoints2 and develop into memory popu-
lations that activate brain-homing, IFN-γ-producing CD4+ T cells3. The latter is supported by 
the reduction in T-cell activation after B cell-depleting therapy in relapsing MS4. This inter-
action of B cells with so-called T follicular helper (TFH) cells occurs within germinal centers 
(GCs) of secondary lymphoid organs. Our group recently showed that B cells, in turn, use 
TH cell-derived IFN-γ to develop into CXCR3
+ populations, which infiltrate the CNS tissue of 
MS patients5. After reaching the CNS, memory B cells are likely reactivated in perivascular 
spaces and ectopic GC-like structures found in the cerebral meninges6 to further mature into 
plasmablasts/plasma cells and contribute to focal inflammation7. 
Besides the homing into inflamed tissue, IFN-γ-mediated induction of B cells results in the 
formation of autoimmune ectopic GCs, as reported in mice. Furthermore, CXCR3 upregula-
tion on B cells contributes to aberrant plasma cell differentiation within GCs8. Other chemo-
kine receptors such as CXCR4 and CXCR5 also orchestrate the GC response by guiding B cells 
into the dark and light zone, respectively. Whereas centroblasts undergo several rounds of 
proliferation and somatic hypermutation in the dark zone, centrocytes interact with follicu-
lar dendritic cells and TFH cells to undergo antigen-specific selection in the light zone
9. The 
presence of CCR6 on B cells has been reported to promote their development and antigen 
responsiveness within the light zone10, 11. Therefore, aberrancies in the expression of these 
chemokine receptors may affect GC B-cell outgrowth into memory and plasmablasts/plasma 
cells, thereby increasing the chance of causing autoimmunity12, 13. Currently, it remains to be 
determined whether and how this associates with relapse risk in MS.
In the natural course of untreated MS patients who are pregnant, relapse risk is reduced 
by approximately 70% in the third trimester14. Although current MS diagnostic and treatment 
strategies likely contribute to an attenuation of this fluctuation15, third trimester and post-
partum period remain a period of relative low and high relapse risk, respectively. Pregnancy 
induces a shift from TH1 to TH2 responses
16 and promotes the expansion of circulating TFH 
cells17, likely affecting the development of GC B cells. Hence, by comparing their develop-
ment in context of chemokine receptor expression between periods of low and high relapse 
risk within patients, insights will be gained into how functional B-cell outgrowth is associated 
with the unpredictable, relapsing MS course. 
In this experimental study, we assessed the frequencies and GC-related chemokine 
receptor profiles of ex vivo B-cell subsets in paired first trimester, third trimester and early 
postpartum blood samples derived from MS patients and healthy controls. In addition, we 
used a TFH-like cell culture system to investigate how in vitro memory B-cell differentiation 
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into plasmablasts or plasma cells differs between periods of relatively low (third trimester) 
and high (early postpartum) relapse risk. Patients with relapses the year preceding preg-




We included 19 pregnant woman with RRMS according to the McDonald criteria18. 
Patient characteristics are displayed in Table 119. Patients did not use any immune modula-
tory medication during the study period (pre-pregnancy, during pregnancy as well as early 
after delivery, except for one who received methylprednisolone prior to pregnancy and IVIg 
treatment during the first trimester postpartum. One patient conceived pregnancy using in 
vitro fertilization and one via intracytoplasmic sperm injection. One patient conceived while 
using leuprolide medication. Three patients gave birth via a cesarean section and all others 
had vaginal deliveries. Nine patients breastfed their child. During the early postpartum high 
risk period, 6 patients developed a clinically manifest relapse. Since we have measured 
these 6 patients separate from the rest of the group, expression levels were not compared 
between these 6 patients and the other non-relapse MS patients or HC. No MRI evaluations 
for disease activity were performed. 
Additionally, 12 age-matched pregnant women were included as healthy controls, who 
did not have central nervous system or inflammatory disease. None of them used immu-
nomodulatory medication before or during the study. For 4/13 women in this group, no 
information about lactation was available. Three used in vitro fertilization and one used 
intracytoplasmic sperm injection to become pregnant. One woman gave cesarean birth and 
one woman developed preeclampsia. All participants were seen at the outpatient clinic of 
Erasmus MC (Rotterdam, The Netherlands) and gave written informed consent. This study 
was approved by the medical ethics committee of Erasmus MC. 
PBMC isolation, flow cytometry and antibodies
PBMCs from patients and controls were collected in the first and third trimester as well 
as 4-8 weeks after delivery. For sample collection, we used Vacutainer CPT® tubes containing 
sodium heparin according to manufacturer’s instructions (BD Biosciences, Erembodegem, 
Belgium). After isolation, cells were taken up in RPMI 1640 (Lonza, Basel, Switzerland) con-
taining 20% fetal calf serum (Lonza) and 10% dimethyl sulfoxide (Sigma-Aldrich, St Louis, MO) 
and stored in liquid nitrogen until further use. Cells were incubated with Fixable Viability 





























BF°° Med PG°°° Special
MS1 33 Yes No No Yes 1 MP (pre-pregnancy)/
IVIg (postpartum)
0
MS2 26 Yes No Yes Yes 0 none 0
MS3 23 Yes No No Yes 1 none 0
MS4 26 Yes No No Yes 1 none 1
MS5 33 Yes No Yes Yes 1 none 0
MS6 37 No No Yes Yes 1 none 1
MS7 37 No No Yes Yes 0 none 1 IVF* + sectio
MS8 33 No No Yes Yes 1 none 0
MS9 26 No No Yes Yes 1 none 1
MS10 29 Yes No Yes Yes 0 none 1 sectio
MS11 30 Yes No Yes Yes 0 none 1
MS12 37 No No No Yes 0 none 0
MS13 33 Yes No No Yes 0 none 0
MS14 22 Yes Yes Yes Yes 1 none 1
MS15 34 No Yes No Yes 1 none 0 Leucrin use
MS16 32 No Yes No Yes 1 none 0
MS17 35 No Yes Yes Yes 0 none 1 ICSI**
MS18 31 No Yes No Yes 0 none 1
MS19 29 No Yes Yes Yes 0 none 1 sectio
HC1 33 n.a. n.a. No Yes 1 n.a. 0
HC2 22 n.a. n.a. No Yes ? n.a. 0
HC3 27 n.a. n.a. Yes Yes 0 n.a. 0
HC4 27 n.a. n.a. Yes Yes 1 n.a. 1 IVF
HC5 33 n.a. n.a. No Yes ? n.a. 0 Pre-eclampsia
HC6 32 n.a. n.a. No Yes 0 n.a. 0 IVF
HC7 34 n.a. n.a. Yes Yes ? n.a. 0
HC8 36 n.a. n.a. No Yes 0 n.a. 0 ICSI
HC9 34 n.a. n.a. Yes Yes 0 n.a. 0 sectio
HC10 25 n.a. n.a. Yes Yes 1 n.a. 0
HC11 33 n.a. n.a. No Yes ? n.a. 0
HC12 41 n.a. n.a. No Yes 1 n.a. 0
HC13 34 n.a. n.a. Yes No 0 n.a. 0 IVF
° = year prior to conception, °° BF = breast feeding, °°° PG = primi gravida (first child), * = in vitro vertilization, ** ICSI 
= intra cytoplasmatic sperm injection. N.a. = not applicable
Table 1. 
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added for 30 min at 4°C: CD27 (BV421, M-T271), CD138 (BV605 and PE-CF594, MI15), CXCR4 
(PE-CF594, 12G5), CXCR5 (PercCP, RF8B2), IgD (PE-CF594, IA6), IgG (APC-H7, G18-145; all 
BD Biosciences), CCR6 (PE, G034E3), CD19 (BV785, HIB19), CD38 (BV605 and PE-Cy7, HIT2), 
CXCR3 (APC and PE-Cy7, G025H7), CXCR4 (APC-Cy7, 12G5) and IgM (BV510, MHM-88; 
all Biolegend, London, UK). For ex vivo phenotyping, cells were measured using an LSRII-
Fortessa flow cytometer. For in vitro cultures, memory (CD19+CD3-CD27+) B cells were puri-
fied using a FACSAria III sorter. Data were analyzed using FACS Diva software, version 8.0.1 
(all BD Biosciences).
Germinal center-like B-cell differentiation assay
In vitro B-cell differentiation assays were performed as recently described5, 20. In short, 
irradiated murine 3T3 fibroblasts expressing human CD40L were co-cultured with sorted 
memory B cells in the presence of IL-21 (50 ng/ml; Thermo Fisher Scientific, Landsmeer, The 
Netherlands). After 6 days of culturing, viable CD19+ cells were analyzed using flow cytome-
try and supernatants were collected and stored at -80°C until further use.
IgM and IgG ELISA 
IgM and IgG levels were determined in supernatants of memory B cells cultured for 6 
days using ELISA. After overnight coating with goat anti-human Ig (1 mg/ml; Southern 
Biotech, Birmingham, USA) at 4°C, flat-bottom 96-well plates (Corning, Tewksbury, USA) were 
washed with PBS/0.05%Tween-20 and subsequently blocked with PBS/5%FCS for 2 h at RT. 
Samples were added for 1.5 h at RT. After washing, peroxidase-conjugated goat anti-human 
IgG (Thermo Fisher Scientific) or rabbit anti-human IgM (Jackson, Uden, The Netherlands) 
were used to detect bound antibody. TMB substrate (Thermo Fisher Scientific) was used to 
reveal peroxidase activity. Reactions were stopped with sulfuric acid and optical densities 
were measured at 450 nm using a BioTek Synergy 2 reader (Winooski, USA). Concentrations 
were calculated using standard curves for IgM and IgG.
Statistical analysis
Graphpad Prism Software, version 8 was used for statistical analysis. Both percentages 
and MFI are displayed as individual data points together with the mean. Wilcoxon signed-
rank test was performed to compare the different gestational periods, Two-way ANOVA was 
performed to compare HC with MS patients, unless stated otherwise. P values < 0.05 were 
considered statistically significant. 
Data availability
The data supporting the findings of this study are available from the corresponding 






















Pregnancy alters the peripheral B-cell compartment resulting in memory 
populations with increased Ig expression in the early postpartum period
To explore whether ex vivo B-cell differentiation profiles are associated with pregnan-
cy-induced relapse risk in MS, we analyzed the proportions of different naive and memory 
populations in paired first trimester, third trimester and early postpartum blood. For this, we 
thawed PBMCs of 19 MS patients and 12 healthy controls (Table 1)19 and distinguished tran-
sitional (CD38highCD27-), naive mature (CD38-/dimCD27-IgM+) as well as IgM+ and IgG+ memory 
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Figure 1. Frequency of circulating naive and memory B-cell subsets during and early after pregnancy in MS pa-
tients and healthy controls. 
(A) Representative gating of viable CD19+ B-cell subsets: transitional (CD38highCD27-), naive mature (CD38-/dimCD27-
IgM+), IgM memory (IgM+CD27+) and IgG memory (IgG+CD27+) B cells. The percentages of transitional B cells, naive 
mature B cells (B) as well as IgM and IgD expression (MFI) on these subsets (C) were compared between paired 
first trimester (1st tri), third trimester (3rd tri) and early postpartum (pp) samples of 13 MS patients (red) and 12 HC 
(blue). Similar analyses were performed for IgM+ and IgG+ memory B cells (D and E). Wilcoxon signed-rank test was 
performed to compared the different gestational periods. * p<0.05, ** p<0.01, *** p<0.001
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In MS patients without a postpartum relapse (n = 13) and healthy controls, the propor-
tion of transitional B cells declined from first to third trimester and recuperated after delivery 
(5.4%, 2.3.% and 6.5% for MS and 5.5% vs 3.1% vs 7.7% for HC, (Figure 1B), as reported 
earlier21. Naive mature B-cell frequencies were not different between periods, resulting in 
elevated naive mature/transitional B-cell ratios per subject (Supplementary Figure 1A). In 
the third trimester, these ratios were even more raised in patients with a relapse one year 
before pregnancy (Supplementary Figure 1B) and were lower in MS patients with an early 
postpartum relapse (n = 6; Table 1 and Supplementary Figure 1C). IgM and not IgD expres-
sion was significantly increased on postpartum transitional B cells, which was not seen for 
naive mature B cells and the most pronounced in MS patients (p = 0.0056, Figure 1C and 
Supplementary Figure 1D). Both IgM+ and IgG+ memory B cells showed a moderate decline 
in frequencies, but a significant increase in Ig surface expression in the postpartum period 
(p = 0.0473 for IgM+ and p = 0.0010 for IgG+; Figure 1D). These differences in expression 
level and memory fractions were not influenced by an early pre-pregnancy or postpartum 
relapse (data not shown and Supplementary Figure 1E and F) or differences in third trimester 
estradiol, progesterone and cortisol levels (data not shown). 
The pregnancy-induced disturbances in naive B-cell development and formation of 
IgMhigh memory B cells ex vivo may imply favored differentiation in GCs during the high risk 
postpartum period22. 
Memory B cells reveal a more GC light zone-related chemokine receptor 
expression profile in postpartum versus third trimester samples
Chemokine receptors selectively regulate GC organization and maturation of B cells 
(Figure 2A). First trimester, third trimester and postpartum B cells were analyzed for the 
expression of CXCR4 and CXCR5, which mediate dark and light zone localization, respectively9, 
as well as CCR6 and CXCR3, which contribute to memory recall and antibody responses8, 23, 
respectively. 
CXCR4 was downregulated, while CXCR5 showed an upregulation on postpartum versus 
third trimester B cells. This was seen for both memory (IgM+ and IgG+; Figure 2B and C) and 
naive mature (Supplementary Figure 1G) B cells. The postpartum rise in CXCR5 was signif-
icant in the MS but not the control group. CXCR4 and CXCR5 levels were higher on naive 
mature than memory B cells (IgM+CD27- > IgM+CD27+ > IgG+CD27+; Supplementary Figure 
2A). In addition to this, CCR6 and CXCR3 were upregulated on postpartum B cells in both 
groups (Figure 2D and E; Supplementary Figure 1H). CCR6 levels were more increased and 
significantly different compared to first trimester B cells in the MS group (p = 0.0126 for 
IgM+ memory and p = 0.0081 for IgG+ memory; Figure 2D and E). For all groups and periods, 
CCR6 was highest expressed on naive mature B cells (IgM+CD27- > IgM+CD27+ > IgG+CD27+), 





















Supplementary Figure 2B ). We found no significant impact of a pre-pregnancy or postpartum 
relapse on chemokine receptor expression (data not shown and Supplementary Figure 3). 
Together with the increased Ig surface levels (Figure 1C and D), the chemokine 
receptor expression profile especially found for postpartum B cells of MS patients 
(CXCR4lowCXCR5highCCR6highCXCR3high) implies an increased potential of these cells to enter 
and further develop in GC light zones. 
Early postpartum memory B cells from MS patients preferentially develop 
into Ig-secreting plasma cells under TFH-like conditions in vitro
Effective B cell memory is generated through the help of TFH cells within the GC light 
zone. After reaching the CNS, memory B cells are likely reactivated to develop into potent 
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Figure 2. Chemokine receptor expression on circulating memory B cells during and early after pregnancy in MS 
patients and healthy controls. 
(A) Schematic display of chemokine receptors involved in GC-dependent organization and maturation of B cells. Ex-
pression of dark zone-associated CXCR4 and light zone-associated CXCR5, CCR6 and CXCR3 was compared between 
IgM+ (B, D) and IgG+ (C, E) memory B cells from first trimester (1st tri), third trimester (3rd tri) and early postpartum 
(pp) samples from 13 MS patients (red) and 12 HC (blue). Wilcoxon signed-rank test was performed to compare 
the different gestational periods. Two-way ANOVA was performed to compare HC with MS patients. * p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001
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responses in the high-risk postpartum period in MS, memory (CD27+) B cells were purified 
from paired third trimester and postpartum samples of 11 MS patients and compared for 
their outgrowth into plasmablasts/plasma cells in vitro. Under IL-21- and CD40L-inducing 
conditions (mimicking a TFH cell response), more antibody-secreting cells (CD38
highCD27high) 
were formed in cultures with postpartum versus third trimester memory B cells (p = 0.0234, 
Figure 3A and B). This was similar to paired memory B-cell samples from healthy controls (n = 
5, 0.1250). When we analyzed plasma cell (CD138+CD38highCD27high) frequencies, these were 
mainly increased for postpartum memory B cells from MS patients, which were significantly 
higher than those from controls (p = 0.001, Figure 3C). For the MS group, IgM+ and not 
IgG+ plasmablasts (CD38highCD27high) seemed to be more induced in both third trimester and 
postpartum memory B-cell cultures Figure 3D). Especially IgM levels were elevated in super-
natants of postpartum memory B-cell cultures, which were not different between patients 
and controls (Figure 3E). 
These results show that memory B cells are highly capable of differentiating into anti-
body-secreting cells early after parturition, which may contribute to the high postpartum 
relapse risk in MS. 
DISCUSSION
Pregnancy causes a transient period of immune suppression, which results in an increased 
relapse risk early after delivery in MS24. Here, we studied how peripheral B-cell differentia-
tion is regulated during pregnancy-associated low and high relapse risk periods in patients 
with MS. The observed differences in IgM, CXCR3, CXCR4, CXCR5 and CCR6 expression levels 
point towards a GC light zone phenotype of postpartum versus third trimester B cells ex vivo. 
This is reflected by the increased capacity of memory B cells to develop into plasma cells 
under TFH-like conditions in vitro. 
Regarding naive B cells, Lima et al21 showed previously that transitional B cell frequencies 
are reduced in the third trimester. We replicated this observation and additionally showed 
kinetics of this observation during pregnancy. Reduced proportions of transitional B cells 
were seen from the first towards the third trimester, resulting in increased naive mature/
transitional B-cell ratios. The pregnancy-induced alterations in B lymphopoiesis are probably 
the result of increased hormone levels in the third trimester17, keeping transitional B cells 
in check due to a lack of multidrug resistance receptor 1 (MDR1)25, a glycoprotein which 
pumps steroids out of cells. We found a similar impact of steroid treatment in patients with 
MS, AQP4-IgG+ neuromyelitis optica spectrum disorder and MOG-IgG-associated disease26. 
Because of the sharp rise in IgMhigh transitional B cells early after delivery, one could spec-





































































































































































Figure 3. Germinal center-dependent antibody-secreting cell outgrowth using memory B cells from paired third 
trimester and early postpartum blood samples.
(A) Representative gating of CD38highCD27high (plasmablasts/plasma cells) and CD138+ (plasma cells) cells after cultur-
ing of memory B cells under TFH-like conditions using IL-21 and 3T3-CD40L for 6 days. Percentages of CD38
highCD27high 
(B), CD138+CD38highCD27high (C) and IgM+ and IgG+ plasmablasts (D; FACS), as well as IgM and IgG secretion (E; ELISA) 
were compared for cultures with third trimester (3rd tri) and early postpartum (pp) memory B cells from 11 MS pa-
tients (red) and 5 HC (blue). Wilcoxon signed-rank test was performed to compare third trimester and postpartum 
samples. Two-way ANOVA was performed to compare HC with MS patients. * p<0.05, *** p<0.001. 
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the GC reaction, to more GC-experienced pathogenic subsets22 that are destined to enter the 
CNS in MS patients. Although we did not touch upon their CNS transmigration capacity in this 
study, we can at least assume that the postpartum increase in CXCR3 expression contributes 
to the local B-cell enrichment in MS.5 This may be further induced by the elevated levels of 
CCR6 found for postpartum B cells of MS patients versus healthy controls. 
The postpartum upregulation of CXCR5 especially seen in MS patients is likely involved 
in B-cell organization rather than recruitment in the CNS9, 27. Our group reported earlier an 
upregulation of CXCR4 during MS onset in non-pregnant patients28. The here found reduction 
in CXCR4 expression during the high relapse risk postpartum period is therefore counterintui-
tive. It may be that autoreactive CXCR4high naive B cells escape from TFH-mediated selection in 
the GC light zone in peripheral lymphoid organs during a primary response13, while CXCR4low 
memory B cells are more prone to interact with TFH cells and develop into long-lived plasma 
cells during a secondary response in the CNS. CCR6 can facilitate such recall responses23 and, 
together with CXCR3, is associated with the production of high affinity antibodies29.
Until now, not much was known about the potential of memory B cells to locally develop 
into plasma cells in MS. Despite the current focus on antibody-independent B-cell functions, 
this is of high relevance as long-lived plasma cells reside within the chronically inflamed MS 
CNS30. The clinical relevance of local Ig production has become apparent from the increased 
risk of CIS to MS conversion in patients with CSF oligoclonal bands31,which are present in 
more than 95% of MS patients and indicates ongoing IgG production in the CNS. Consistently, 
the absence of B cells in brain lesions of MS patients is associated with a lack of CSF oli-
goclonal bands, a lower intrathecal IgG production, and a more favorable outcome32. The 
observation that (short term) anti-CD20 treatment reduces CSF B cell numbers while oligo-
clonal bands persist33 suggests that intrathecal IgG are mainly produced by (CD20-) long-lived 
plasma cells in the CNS. Recently, it has been shown that MS myelin is bound by IgG and 
that IgG immune complexes trigger human microglia, resulting in enhanced production of 
pro-inflammatory cytokines34. 
Our study has some limitations. The relatively low numbers of included subjects ham-
pered a subdivision in MS risk groups based on disease activity before and after pregnancy. 
Sequential data collection of such patients is difficult, but the accumulating evidence for 
the safe continuation during pregnancy of various disease modifying therapies may increase 
options35. Furthermore, we did not perform in vitro B-cell cultures with sera or female hor-
mones. The recent described effects of estradiol and progesterone on preferred outgrowth 
after antigenic triggering of memory B cells and plasma cells in healthy pregnant individuals36 
raises the question whether this is differentially regulated in MS patients. Finally, B-cell EBV 
load could play an additional role in the impact of CXCR3high plasma cell formation20 as seen 





















Together, this work provides new insights into how B-cell development is affected during 
pregnancy and may contribute to an increased postpartum relapse risk in MS. With these 
findings, we reveal a link between chemokine receptor expression profiles and the ability 
of brain-homing memory B cells to differentiate into plasma cells, which should be further 
studied in the near future. This may not only help to decipher the underlying mechanisms of 
local B-cell accumulation and antibody production, but also offer new tools to better predict 
disease activity in patients with MS. 
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Supplementary Figure 1. The naive mature/transitional B cell ratio, frequencies of B cell subsets in MS patients 
with a postpartum relapse and chemokine expression levels on naive mature B cells of HC and MS patients
(A) The naive mature/transitional B cell ratio in the different gestational periods of 12 HC (blue) and 13 MS patients 
(red), which in (B) were separated into MS patients with (n = 8) or without (n = 6) a relapse within 1 year before 
pregnancy. (C) The naive mature/transitional B cell ratio in the 3rd trimester of MS patients with a postpartum re-
lapse (n=6) or without (n=13). (D) IgD expression on transitional and naive mature B cells was compared between 
paired first trimester, third trimester and early postpartum samples of 12 HC (blue) and 13 MS patients (red). (E) 
The percentage of transitional and naive mature B cells in MS patients with a post-pregnancy relapse (n = 6), as well 
as their ratio and the frequency of IgM+ and IgG+ memory B cells. (F) Immunoglobulin expression on memory B cells 
of post-pregnancy relapsing patients (n = 6). (G-H) Expression of dark zone associated CXCR4 and light zone asso-
ciated CXCR5, CCR6 and CXCR3 on naive mature B cells in the first trimester, third trimester and early postpartum 
period for 12 HC (blue) and 13 MS patients (red). Wilcoxon signed-rank test was performed to compare the different 





























































































































































































































































































































































































































































































































































Supplementary Figure 2. Chemokine expression levels on naive mature, IgM+ and IgG+ memory B cells in the third 
trimester and early after delivery.
Expression of dark zone-associated CXCR4 and light zone-associated CXCR5, CCR6 and CXCR3 was compared be-
tween naive mature, IgM+ and IgG+ memory B cells from third trimester and early postpartum samples from 12 HC 
(blue) and 13 MS patients (red). Two-way ANOVA was performed to compare the different B cell subsets within a 
group. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
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Supplementary Figure 3. Chemokine expression levels on naive mature, IgM+ and IgG+ memory B cells in the third 
trimester and early after delivery of post-partum relapsing MS patients 
Expression of dark zone associated CXCR4 and light zone associated CXCR5, CCR6 and CXCR3 on naive mature, IgM+ 
and IgG+ memory B cells in the first trimester, third trimester and early postpartum period for MS patients with a 
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Neuromyelitis optica spectrum disorders (NMOSD) are a group of rare, 
but severe autoimmune diseases characterized by inflammation of the optic 
nerve(s) and/or spinal cord. Although naive B cells are considered key players 
by escaping central tolerance checkpoints, it remains unclear how their com-
position and outgrowth differ in patients with NMOSD. Under complete treat-
ment-naive circumstances, we found that naive mature/transitional B-cell ratios 
were reduced in the blood of 10 patients with aquaporin-4 (AQP4) IgG-positive 
disease (NMOSD) as compared to 11 both age- and gender-matched healthy 
controls, 8 patients with myelin oligodendrocyte glycoprotein-IgG-associated 
disorder (MOGAD) and 10 multiple sclerosis patients. This was the result of 
increased proportions of transitional B cells, which were the highest in NMOSD 
patients with relapses and strongly diminished in a separate group of 9 NMOSD 
and MOGAD patients who received corticosteroid treatment. These findings 
need to be confirmed in longitudinal studies. For purified naive mature B cells 
of 7 NMOSD and MOGAD patients with relapses, TLR9 ligand synergized with 
IFN-γ to enhance plasmablast formation during germinal center-like cultures. 
This was not seen for 11 patients without relapses and 9 healthy controls. In 
the NMOSD group, in vitro plasmablast formation corresponded to total and 
anti-AQP4 IgG secretion, of which the latter was only found for relapsing cases. 
These data indicate that naive B-cell homeostasis is different and selectively 
targeted by corticosteroids in NMOSD patients. This also supports further 
exploration of naive B cells for their use in TLR9-dependent in vitro platforms in 





















Neuromyelitis optica spectrum disorders (NMOSD) are rare and convey a range of severe 
clinical presentations caused by inflammation with preferential involvement of the optic 
nerves and spinal cord (Wingerchuk et al., 2007). Although the exact cause of these diver-
gent presentations remains poorly understood, the dominant role of the B-cell lineage is 
undisputed (Sabatino et al., 2019). In approximately 75% of NMOSD patients, IgG antibodies 
are found that target the neuronal water channel protein aquaporin-4 (AQP4; Saadoun and 
Papadopoulos, 2010). Furthermore, 30-40% of AQP4-IgG-negative NMOSD patients test pos-
itive for antibodies against myelin oligodendrocyte glycoprotein (MOG; Pelt van et al., 2016a; 
Hamid et al., 2017), which are associated with a distinct entity termed MOG-IgG-associated 
disorder (MOGAD).
There are significant differences in clinical features between AQP4-IgG-positive NMOSD 
and MOGAD (Kitley et al., 2012; Pelt van et al., 2016b; Jurynczyk et al., 2017), including 
a higher frequency of and worse recovery from relapses in AQP4-IgG-positive NMOSD. 
Relapses are commonly treated with corticosteroids in both entities. To prevent relapses, 
AQP4-IgG-positive NMOSD patients and relapsing patients with MOGAD are usually treated 
with maintenance therapy. Currently, no biomarkers are available to accurately predict 
relapses and guide treatment decisions. This could be due to the fact that previous studies 
on the immunopathogenesis of NMOSD primarily used patients treated with corticosteroids 
or other maintenance therapy, thereby possibly obliterating disease-relevant B-cell subsets.
Recent findings reveal that AQP4-specific B cells are already present in naive populations 
that escape early tolerance checkpoints (Wilson et al., 2018; Cotzomi et al., 2019). Normally, 
self-reactive clones are counterselected during early B-cell development in the bone marrow 
(central tolerance) and during subsequent maturation of transitional into naive mature B 
cells after entering the circulation (peripheral tolerance). In patients with AQP4-IgG-positive 
NMOSD, naive mature B cells escape both these checkpoints and likely develop into anti-
body-secreting cells in a germinal center-dependent manner (Kowarik et al., 2017; Wilson et 
al., 2018; Cotzomi et al., 2019). In systemic autoimmune disease, which coexists in ~20% of 
AQP4-IgG-positive NMOSD patients (Shahmohammadi et al., 2019), IL-21, IFN-γ and TLR9-
ligand CpG-ODN serve as key triggers of autoreactive germinal center B cells expressing T-box 
transcription factor T-bet (Sindhava et al., 2017; Wang et al., 2018). 
In this study, we aimed to define the impact of AQP4-IgG serostatus, steroid treatment 
and relapse occurrence on naive B-cell development in NMOSD. The composition of the naive 
B-cell pool within the blood was compared between NMOSD, MOGAD and MS groups with 
and without corticosteroid treatment, as well as matched healthy controls. Furthermore, 
naive B-cell outgrowth into (anti-AQP4 or -MOG) IgG-secreting plasmablasts was explored 
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in vitro for patients with and without relapses during T-bet-inducing, germinal center-like 
cultures. 
MATERIALS AND METHODS 
Participants
We included 10 treatment-naive AQP4-IgG-positive NMOSD patients (Wingerchuk et al., 
2015) and 8 treatment-naive patients with MOGAD (all with optic neuritis and/or transverse 
myelitis). These patients did not get immune suppressive therapy before blood sampling; no 
steroids within 1 month and no other maintenance treatment within 3 months. Additionally, 
5 patients with AQP4-IgG-positive NMOSD and 4 patients with MOGAD were included who 
received corticosteroids (i.e. oral prednisone or intravenous methylprednisolone) within 1 
month prior to sampling. In the corticosteroid-treated MOGAD group, 2 patients had an 
NMOSD phenotype, 1 patient presented with acute disseminated encephalomyelitis and 1 
patient was diagnosed with encephalitis. None of the patients included in this study received 
therapy with prolonged immune suppressive activity such as anti-CD20 or any other B cell-di-
rected monoclonal antibodies before sampling. Patient characteristics are shown in Table 1. 
Ex vivo B-cell subset frequencies were compared to age- and gender-matched treat-
ment-naive multiple sclerosis (MS) patients (n = 10) as well as healthy controls (n = 20). As 
a reference group for corticosteroid-treated patients, we included 8 clinically isolated syn-
drome (CIS) patients treated with methylprednisolone within 1 month before sampling and 
diagnosed according to the McDonald 2017 criteria. For the NMOSD and MOGAD groups, 
serum was collected at the same time as peripheral blood mononuclear cells. An NMOSD 
relapse was defined as a new episode of disease activity at least 3 months separated from 
the previous disease episode. All subjects gave written informed consent, and the study was 
approved by the medical ethics committee of Erasmus MC. 
Total IgG ELISA
IgG concentrations in supernatants were determined by ELISA using flat-bottom 96-well 
half-area plates (Corning, Tewksbury, USA) coated overnight at 4°C with goat anti-human Ig (1 
mg/ml; Southern Biotech, Birmingham, USA). Plates were washed with PBS/0.05%Tween-20 
to remove unbound antibody and blocked with PBS/5%FCS for 2 h at RT. Sample and a 
human IgG standard (Sigma-Aldrich/Merck, Darmstadt, Germany) were added for 1.5 h at RT. 
Subsequently, plates were washed with PBS/0.05%Tween-20 and bound IgG was detected 
by peroxidase-conjugated goat anti-human IgG (Thermo Fisher Scientific, Landsmeer, The 
Netherlands). TMB Substrate (Thermo Fisher Scientific) was used to reveal peroxidase activ-




















AQP4- and MOG-IgG cell-based assays 
For determination of AQP4- and MOG-IgG levels in sera and culture supernatants, stan-
dardized cell based assays were used as previously described (Ketelslegers et al., 2011; Pelt 
van et al., 2016a; Pelt van et al., 2016b). In short, either HEK293T transfectants with EGFP-
tagged AQP4-M23 or 1:1 mixtures of LN18 cells transfected with and without full length 
human MOG were incubated with the sample and stained with goat anti-human secondary 
antibody (IgG labeled with APC; Jackson ImmunoResearch, Amsterdam, The Netherlands). 
Our AQP4-IgG cell-based assays showed a mean transfection efficiency (GFP+) of approxi-
mately 35%. Mean fluorescence intensity (MFI) representing the amount of AQP4- or MOG-
IgG bound to the cell surface was compared between transfected (GFP+) and untransfected 
(GFP-) cells within the same experiment using flow cytometry.
# At time of sample collection.
* Steroid treatment within 1 month before sampling (all patients were at least not treated with maintenance med-
ication for 3 months). 
§ All AQP4-IgG and MOG-IgG serum titers were measured within the same experiment using ΔMFI.
ADEM = acute disseminated encephalomyelitis; BS = brainstem (area postrema or cranial nerves); E = encephalitis; 
MP = methylprednisolone (intravenous); ND, not determined; ON = optic neuritis; bilateral = both eyes; P = pred-
nisone (oral); TM = transverse myelitis. 




















Patient 1  41/F  ON + ON  None  7  Yes  7644  NMOSD  Yes 
Patient 2  39/F  TM + 2xTM   None  78  Yes  13365  NMOSD  Yes 
Patient 3  56/F  ON bilateral + ON/BS  None  6  Yes  13736  NMOSD  Yes 
Patient 4  61/F  TM  None  5  No  7469  NMOSD  Yes 
Patient 5  46/M  ON bilateral  None  15  No  545  NMOSD  Yes 
Patient 6  47/F  ON   None  2  No  15437  NMOSD  Yes 
Patient 7  27/F  TM  None  46  No  7874  NMOSD  Yes 
Patient 8  26/F  BS  None  122  No  7262  NMOSD  Yes 
Patient 9  36/F  ON   None  0  No  ND  NMOSD  Yes 
Patient 10  46/F  TM  None  4  No  20533  NMOSD  No 
Patient 11  34/F  TM + TM  P  5  Yes  82  CS‐treated  No 
Patient 12  50/F  TM + 2xTM   MP  13  Yes  17061  CS‐treated  No 
Patient 13  19/F  BS + TM  MP + P  6  Yes  14055  CS‐treated  No 
Patient 14  58/F  TM/ON bilateral  MP + P  2  No  15618  CS‐treated  No 
Patient 15  37/F  BS/ON bilateral  MP + P  4  No  16701  CS‐treated  No 
MOG‐IgG 
Patient 1  38/F  ON + 5xON  None  95  Yes  24237  MOGAD  Yes 
Patient 2  26/M  ON + ON  None  25  Yes  5099  MOGAD  Yes 
Patient 3  25/F  TM + 2xON  None  17  Yes  424  MOGAD  Yes 
Patient 4  32/M  ADEM + TM  MP  326  Yes  1681  CS‐treated  Yes 
Patient 5  52/M  ON   None  10  No  136  MOGAD  Yes 
Patient 6  40/F  ON bilateral  None  10  No  1234  MOGAD  Yes 
Patient 7  56/F  TM  None  18  No  696  MOGAD  Yes 
Patient 8  37/M  TM/ON  MP  1  No  6495  CS‐treated  Yes 
Patient 9  26/F  ON bilateral  MP + P  1  No  2058  CS‐treated  Yes 
Patient 10  25/F  ON bilateral + 3xON   None  201  Yes  6617  MOGAD  No 
Patient 11    32/M  E + E  MP  181  Yes  21  CS‐treated  No 
Patient 12  29/M  TM  None  51  No  1200  MOGAD  No 
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Cell isolation, antibodies and flow cytometry
Peripheral blood mononuclear cells were collected using Vacutainer CPT® tubes con-
taining sodium heparin according to the manufacturer’s instructions (BD Biosciences, 
Erembodegem, Belgium). After centrifugation, cells were taken up in RPMI 1640 (Lonza, 
Basel, Switzerland) containing 40% fetal calf serum (Lonza) and 20% dimethyl sulfoxide 
(Sigma-Aldrich, St Louis, MO) and stored in liquid nitrogen until further use. Ex vivo naive 
mature (CD19+CD38dim/-CD27-IgG-IgA-) B cells were purified for in vitro cultures using a BD 
FACSAria III cell sorter. For immunophenotyping, cells were incubated with Fixable Viability 
Stain 700 (BD Biosciences) for 15 min and monoclonal antibodies for 30 min at 4°C. The 
following FACS antibodies were used: CD24 (BV605, ML5), CD27 (BV421, M-T271), IgD (PE-
CF594, IA6), IgG (APC-H7, G18-145; BD Biosciences), CD19 (BV785, HIB19), CD38 (PE-Cy7, 
HIT2), IgM (BV510, MHM-88), T-bet (PE-Cy7, 4B10; Biolegend, London, UK) and IgA (FITC, 
IS11-8E10; Miltenyi Biotec, Bergisch Gladbach, Germany). For intracellular T-bet staining, 
cells were fixed with 2% paraformaldehyde (Merck, Schiphol-Rijk, the Netherlands) and 
permeabilized using PBS pH7.4 containing 0.3% BSA and 0.5% saponin (Sigma-Aldrich). All 
measurements were conducted with an LSRII-Fortessa flow cytometer and analyzed using 
FACS Diva software, version 8.0.1 (BD Biosciences). For both ex vivo and in vitro analyses, we 
first gated on viable CD19+ B cells.
Germinal center-like B-cell differentiation assay
Germinal center-like B cell cultures were performed as recently described (van Langelaar 
et al., 2019). In short, irradiated murine 3T3 fibroblasts expressing human CD40L were 
co-cultured with sorted naive mature (CD27-CD38dim/-IgG-IgA-) B cells in the presence of IL-21 
(50 ng/ml; Thermo Fisher Scientific) with and without IFN-γ (50 ng/ml; Peprotech, Huissen, 
The Netherlands) and CpG-ODN (10 μg/ml; InvivoGen, San Diego, USA). After 11 days of 
culturing, cells were stained for flow cytometry and supernatants were stored and analyzed 
for the presence of AQP4- and MOG-IgG.
Statistical analysis
Statistical analysis was performed using Graphpad Prism Software, version 5.04. Kruskal-
Wallis and Dunn’s post-hoc tests were performed for comparing multiple groups. Mann-
Whitney U-tests were used for comparing two groups. Paired datasets were assessed using 
Wilcoxon signed-rank tests. Correlations between variables were tested using the Spearman 
rank or Pearson coefficients, depending on results of the D’Agostino & Pearson omnibus 






















The raw data that support the here described findings are available from the correspond-
ing author upon reasonable request. 
RESULTS
Naive mature/transitional B-cell ratios are reduced in the blood of 
treatment-naive AQP4-IgG-positive NMOSD patients 
First, we assessed the proportions of naive and memory B-cell subsets in the blood of 
NMOSD patients without any form of previous immune suppressive treatment. Because the 
female-to-male ratio is higher in AQP4- than MOG-IgG-associated disease (see Table 1; (Pelt 
van et al., 2016a), we selected healthy controls who were age- and gender-matched either to 
treatment-naive patients with NMOSD (n = 11) or MOGAD (n = 9). The proportion of transi-
tional B cells (CD38++CD27-) and not naive mature (CD38dim/-CD27-IgM+) B cells (Timmermans 
et al., 2016; Heeringa et al., 2018) was elevated in NMOSD versus healthy controls (mean 
16.2% vs 5.6% for transitional B cells and 47.3% vs 41.5% for naive mature B cells, respec-
tively), which resulted in lowered naive mature/transitional B-cell ratios (Fig. 1A and B). This 
classification of naive B cells was confirmed using IgD and CD24 (Supplementary Fig. 1). No 
differences were seen between the MOGAD and healthy control group (Fig. 1C and D). Two 
out of three NMOSD patients with relapses showed extremely high frequencies of transi-
tional B cells (35% and 44% of the total B-cell pool, Fig. 1B). Naive mature/transitional B-cell 
ratios were lower in NMOSD compared to MOGAD (P < 0.01; Fig. 1F). 
Germinal center-independent natural effector (CD38dim/-CD27+IgM+IgD+) memory 
B cells (Berkowska et al., 2011) were significantly reduced in the NMOSD versus healthy 
control group (lowest in two relapsing cases with the highest percentage of transitional 
B cells; Supplementary Fig. 2A and B). A similar trend was found in the MOGAD group 
(Supplementary Fig. 2B). The proportions of germinal center-dependent IgM-only B cells 
(CD38dim/-CD27+IgM+IgD-) and IgG+ (both CD27+ and CD27-) B cells (Berkowska et al., 2011) 
(Supplementary Fig. 2B) or plasmablasts (CD38++CD27++; Supplementary Fig. 3A), did not 
differ between groups. None of the populations and ratios correlated to AQP4- or MOG-IgG 
serum levels (Table 1) in the NMOSD groups (data not shown).
Corticosteroid treatment corresponds to increased naive mature/
transitional B-cell ratios in AQP4- and MOG-IgG-positive disease 
To study the impact of corticosteroids as a standard treatment of acute relapses, we 
compared our results to B-cell subsets from the blood of 9 AQP4-IgG or MOG-IgG-positive 
patients who only received corticosteroids and no other forms of immunosuppressive 
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Figure 1. Transitional and naive mature B-cell frequencies in the blood of different NMOSD, MOGAD, MS and 
healthy control groups.
Representative gating, proportions and ratios of transitional (CD38++CD27-) and naive mature (CD38dim/-CD27-) B cells 
from blood of treatment-naive patients with NMOSD (n = 10; A,B) or MOGAD (n = 8; C,D). The fractions of transition-
al and naive mature B cells and their ratios were compared to a separate age- and gender-matched healthy control 
group (for NMOSD, n = 11; for MOGAD, n = 9). (E) Gating example for the detection of transitional and naive mature 
B cells in the blood from corticosteroid-treated patients with NMOSD or MOGAD (CS-treated). (F) Naive mature/
transitional B-cell ratios in the blood of treatment-naive NMOSD or MOGAD, CS-treated NMOSD or MOGAD (n = 9), 
treatment-naive MS (n = 10) and healthy control (HC; n = 20) groups. (G) Correlation of naive mature/transitional 




















treatment. In this group, naive mature/transitional B-cell ratios were significantly elevated 
(fold change vs NMOSD: 14.8, P < 0.0001; Fig. 1E and F), which correlated positively with time 
since start of corticosteroid treatment (r = 0.86 and P = 0.002, Fig. 1G). These elevated ratios 
were the result of an almost complete absence of transitional B cells (Fig. 1E, Supplementary 
Fig. 4). The association of corticosteroid treatment with transitional and not naive mature 
B cells was confirmed in an additional cohort of patients with a clinically isolated syndrome 
(Supplementary Fig. 5). In the steroid-treated NMOSD and MOGAD group, the proportion of 
natural effector B cells was similar to healthy controls and correlated to time since start of 
treatment (r = 0.71, P = 0.02; Supplementary Fig. 2C and D). Corticosteroid treatment did not 
affect plasmablast, IgM-only and IgG+ (CD27-/CD27+) B-cell frequencies (Supplementary Fig. 
3B and data not shown). 
TLR9 ligand synergizes with IFN-γ to promote naive mature B cell to 
plasmablast formation only for AQP4- or MOG-IgG-positive patients with 
relapses
To assess how the B-cell germinal center-like differentiation pathway is regulated in 
NMOSD, we purified naive mature B cells from the peripheral blood of 9 AQP4-IgG-positive 
patients, 9 MOG-IgG-positive patients and 9 healthy controls and cultured these populations 
in the presence of IL-21 and CD40L-3T3 cells with and without IFN-γ and TLR9 ligand CpG-
ODN. The percentage of viable CD38++CD27++ plasmablasts was analyzed after 11 days using 
flow cytometry (Fig. 2A). To further substantiate the clinical relevance of this model, we 
explored the functional association of in vitro-generated plasmablasts with disease activity 
within the continuum of relapse risk. 
For all tested subjects, IFN-γ induced the development of plasmablasts (Fig. 2B), which 
was similar between the groups. However, in both NMOSD and MOGAD patients with 
relapses (n = 7), the addition of CpG-ODN to IFN-γ-containing cultures significantly increased 
plasmablast formation (Fig. 2B; mean, IFN-γ: 19.8%, IFN-γ+CpG: 34.9%, P = 0.0156). The 
opposite was found in patients without relapses (n = 11; IFN-γ: 15.8%; IFN-γ+CpG: 12.8%, 
P = 0.0137). Although disease duration was longer for relapsing compared to non-relapsing 
patients (median 43 vs 17 months, respectively), relapsing patients experienced their first 
relapse within a median time of 10 months since onset. In 6 out of 7 relapsing patients, 
immune suppressive treatment was initiated after the first relapse, whereas 6 out of 11 
monophasic patients were treated from onset onwards. For naive mature B cells of healthy 
controls, these frequencies were identical for both conditions (IFN-γ: 20.9%, IFN-γ+CpG: 
20.4%). Intracellular T-bet levels were upregulated by IFN-γ and further induced by CpG-ODN 
(Fig. 2C). Since this was comparable between the groups, other factors probably mediate the 
observed effect of CpG-ODN on in vitro plasmablast formation. The proportions of ex vivo 
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Figure 2. In vitro plasmablast outgrowth for naive mature B cells from subgroups with and without relapses under 
different germinal center-like conditions.
(A) Representative gating of viable plasmablasts (CD38++CD27++) cultured from naive mature B cells of an NMOSD 
patient with and without relapses. Cells were triggered with CD40L-3T3, IL-21, IFN-γ and/or TLR9 ligand CpG-ODN 
for 11 days. Both the percentage of in vitro-generated plasmablasts (B) and intracellular T-bet expression (C) were 
determined for cultured naive mature B cells from the blood of NMOSD or MOGAD subgroups with (n = 7) or with-
out relapses (n = 11), as well as healthy controls (n = 9). For 1 patient with MOGAD, we only obtained sufficient cell 




















B-cell subsets and plasmablasts did not differ between the groups with or without relapses 
(Supplementary Fig. 6). 
In both the NMOSD and MOGAD group, in vitro secretion of total IgG was significantly 
increased after the addition of CpG-ODN (Fig. 3A and Supplementary Fig. 7). For the NMOSD 
group, this positively correlated with in vitro plasmablast formation (Fig. 3B). The increase 
in both plasmablast formation and IgG secretion was the most pronounced in the 2 NMOSD 
patients with relapses (Fig. 3B). We detected anti-AQP4 IgG in naive mature B-cell culture 
supernatants of all 3 relapsing but in none of 6 non-relapsing NMOSD patients (Fig. 3C). 
Anti-AQP4 IgG secretion was enhanced by CpG-ODN for 2 out of 3 relapsing patients; for 
one relapsing case with very high levels in culture (ΔMFI, IFN-γ: 24442, IFN-γ+CpG: 34725, 
negative control: 33) and one relapsing case with very low levels in culture (ΔMFI, IFN-γ: 57, 
IFN-γ+CpG: 94, negative control: 54). In culture supernatants of naive mature B cells of 4 
































































































































































Figure 3. IgG secretion by in vitro-generated plasmablasts using naive mature B cells from subgroups with and 
without relapses. 
(A) Total IgG secretion was measured in germinal center-like cultures with naive mature B cells from patients with 
NMOSD (n = 7) or MOGAD (n = 6; 11 days). In each subgroup, two patients had relapsing disease (open symbols). 
Data were compared between IFN-γ- and both IFN-γ- and CpG-ODN-inducing conditions (A) and correlated to in 
vitro plasmablast (CD38++CD27++) formation (B). (C) Detection of anti-AQP4-IgG and -MOG-IgG in naive mature B-cell 
culture supernatants (11 days) for patients with NMOSD or MOGAD. AQP4-IgG levels were elevated in IFN-γ-con-
taining cultures with CpG-ODN for 2 NMOSD patients with relapses.
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(Fig. 3C; ΔMFI, positive control: 7322). In this group, total IgG levels did not correlate with in 
vitro plasmablast formation (Fig. 3B).
DISCUSSION
AQP4-IgG production by peripheral B cells is an important driver of NMOSD (Hauser et 
al., 2008; Bar-Or et al., 2010; Kim et al., 2011). Since central B-cell tolerance mechanisms 
are defective in NMOSD (Kinnunen et al., 2013; Cotzomi et al., 2019), the selection of AQP4-
specific B cells is already disturbed at the earliest stage in the bone marrow. We now show 
that the composition and functional outgrowth of circulating naive B cells is different in 
NMOSD patients, which seems to be linked to corticosteroid treatment, relapse occurrence 
and AQP4-IgG secretion.
The selective enrichment of transitional B cells in the blood of AQP4-IgG-positive NMOSD 
patients is likely caused by higher fractions of poly- and autoreactive clones that escaped 
selection within the bone marrow (Cotzomi et al., 2019). We now find that transitional B 
cells are almost completely absent in the blood of corticosteroid-treated patients. Since 
the patients described by Cotzomi et al. received immunotherapy including corticosteroids, 
AQP4-specific B cells and other unique clones may have been missed in their analysis. This 
effect of steroids on transitional B cells is probably explained by their lack of multidrug 
resistance receptor 1 (Wirths and Lanzavecchia, 2005), a glycoprotein that pumps a wide 
range of substances including corticosteroids out of the cell (Brinkmann and Eichelbaum, 
2001). Transitional B cells were abrogated by steroid treatment in patients with NMOSD 
and MOGAD. This correlated to time since start of treatment in clinically isolated syndrome 
patients as well, implicating that corticosteroids have a generic impact on these early B-cell 
emigrants. 
In a previous study, the proportion of circulating CD27+ memory B cells was found to be 
reduced in NMOSD patients (Kowarik et al., 2017). We find that frequencies of germinal 
center-independent CD27+IgM+IgD+ memory B cells are lower in NMOSD patients and recov-
ered after corticosteroid treatment. These data suggest that AQP4-specific naive mature B 
cells preferentially enter the germinal center to undergo proliferation and somatic hyper-
mutation. Consistent with this, under germinal center-like conditions in vitro, AQP4-specific 
plasmablast development occurred more for naive than memory B cells and did not require 
antigen (Wilson et al., 2018), and somatic hypermutation was shown to be essential for 
generating AQP4-specific antibodies (Cotzomi et al., 2019). We did not find any increase 
in circulating memory B-cell subsets, including those lacking CD27 expression (Kowarik et 
al., 2017). This implies that within germinal centers, AQP4-specific naive B cells develop 




















circulating plasmablasts are expanded in NMOSD, which seemed to be irrespective of steroid 
usage (Chihara et al., 2011; Kowarik et al., 2017). In the current study, no differences in ex 
vivo CD38++CD27++ plasmablasts were found, similar to the observations by Wilson et al. The 
vulnerability of plasmablasts for freeze-thaw cycles (Kyu et al., 2009) can be a confounding 
factor, although this was similar for all subjects in this study. Another factor is that plasmab-
lasts probably further mature and reside within the bone marrow or inflamed tissues to 
produce AQP4-specific antibodies (Bennett et al., 2015; Wilson et al., 2018). 
Whereas the ability of ex vivo plasmablasts to produce AQP4-IgG is highly controversial 
(Chihara et al., 2011; Wilson et al., 2018), the development of naive B cells into antibody-se-
creting cells has become widely accepted. In the study by Cotzomi et al., none of the recom-
binant anti-AQP4 IgGs reverted back to unmutated precursors were able to bind to AQP4, 
indicating that naive mature B cells need to enter germinal centers to develop into anti-AQP4 
IgG producers. Recently, we found that IFN-γ induces naive mature B cells to develop into 
plasmablasts during germinal center-like cultures (van Langelaar et al., 2019). The same is 
true for naive mature B cells of NMOSD patients (this study). However, in contrast to MS 
patients (van Langelaar et al., 2019), the addition of CpG-ODN had an inducing effect on in 
vitro plasmablast outgrowth for NMOSD patients with recorded relapses. This difference in 
in vitro naive mature B-cell outgrowth is likely related to the impaired central B-cell tolerance 
found in NMOSD and not in MS (Cotzomi et al., 2019). Based on the data in this study it is 
tempting to speculate that the elevated frequencies of (autoreactive) transitional B cells in 
patients with a high relapse risk causes preferential development of naive mature B cells into 
AQP4-IgG-secreting plasmablasts within secondary lymphoid organs. However, our findings 
should be interpreted cautiously due to low patient numbers and inherent differences in the 
clinical course between NMOSD, MOGAD and MS. 
CpG-ODN alone is known to suppress (Jackson et al., 2014), but synergizes with IFN-γ 
to potentiate autoreactive T-bet+ B cells (Rivera-Correa et al., 2017). T-bet expression does 
not seem to mediate the difference in IFN-γ- and CpG-ODN-induced plasmablast induction 
in vitro between relapsing and non-relapsing NMOSD groups. An intriguing scenario may be 
that IFN-γ enhances IL-6 production by B cells (Arkatkar et al., 2017), leading to TLR9 upreg-
ulation (Carvalho et al., 2011). TLR ligation has been previously associated with the activa-
tion of transcription factor X-box binding protein 1 (XBP-1; Martinon et al., 2010), which 
enhances IgG secretion (Iwakoshi et al., 2003)2003 and links to the IL-6-driven survival of 
AQP4-IgG-secreting plasmablasts (Chihara et al., 2011). 
A limitation of this study is the relatively low sample size. The results obtained here 
need to be confirmed in longitudinal studies and in additional cohorts. Nonetheless, to our 
knowledge, this is the first study that assessed the phenotype and responsiveness of naive 
B cells of NMOSD patients without immunomodulatory treatment and compared these to 
MOGAD, MS and healthy control groups. The impact of steroids on transitional but not on 
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naive mature B cells could be a mechanistic explanation why NMOSD relapses recur after 
discontinuation of steroid treatment. Our findings also provide a rationale for exploring the 
underlying mechanisms of naive B-cell development in patients with active or stable dis-
ease. Further assessment of CpG-ODN-mediated outgrowth of naive B cells under germinal 
center-like, IFN-γ-containing in vitro conditions may be a new approach to predict NMOSD 
relapses. 
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Supplementary Figure 1. Expression of CD24, IgD and IgM on transitional and naive mature B cells in the blood.
154

















































































































































































































Supplementary Figure 2. Presence of ex vivo memory B-cell subsets in the blood of untreated and CS-treated 
NMOSD, MOGAD, MS and HC subgroups.
Gating strategy for the identification of IgM-only (CD27+IgM+IgD-), natural effector (CD27+IgM+IgD+) and IgG+ (both 
CD27- and CD27+) memory B cells from the blood of a treatment-naive (A) and a corticosteroid (CS)-treated (C) 
AQP4-IgG positive NMOSD patient. Fractions were compared between NMOSD (n = 10) and MOGAD (n = 8) and 
age- and gender-matched healthy controls (HC) for each group (for NMOSD, n = 11; for MOGAD, n = 9; B). (D) Frac-
tions of natural effector memory B cells in CS-naive NMOSD, MOGAD, MS, and HC, as well as CS-treated NMOSD and 





































































































Supplementary Figure 3. Frequencies of ex vivo plasmablasts in the blood of untreated and CS-treated NMOSD, 
MOGAD, MS and HC subgroups. 
Representative gating and frequencies of circulating plasmablasts (CD38++CD27++) in treatment-naive (A) and cor-
ticosteroid (CS)-treated (B) NMOSD and MOGAD patients. Fractions of ex vivo plasmablasts within the total CD19+ 
pool were compared between CS-naive NMOSD (n = 10), CS-naive MOGAD (n = 8), CS-treated NMOSD or MOGAD (n 
















































Supplementary Figure 4. Composition of the naive B-cell pool in the blood of untreated and CS-treated NMOSD, 
MOGAD, MS and HC subgroups. 
Proportions of circulating transitional and naive mature B cells within the total CD19+ pool were assessed in CS-na-
ive NMOSD (n = 10), CIS-naive MOGAD (n = 8), CS-treated NMOSD or MOGAD (n = 9), MS (n = 10) and HC (n = 20) 
groups.
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Supplementary Figure 5. The impact of CS treatment on the presence of transitional and naive mature B cells in 
the blood. 
Proportions of circulating transitional and naive mature B cells were correlated to time since start of CS treatment 























































































































































































Supplementary Figure 6. Presence of ex vivo B-cell subsets in relapsing and non-relapsing NMOSD and MOGAD 
subgroups. 
Proportions of naive and memory B-cell subsets as well as plasmablasts (CD38++CD27++) were analyzed in the blood 

























Supplementary Figure 7. Validation of the differences in IgG secretion by in vitro-generated plasmablasts between 
NMOSD and MOGAD subgroups. 
Plasmablasts were generated from naive mature B cells of a relapsing (solid box) and non-relapsing (open box) 
NMOSD and MOGAD patient under IFN-γ and/or CpG-ODN-inducing germinal center-like conditions. IgG secretion 

















Multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) and myelin 
oligodendrocyte glycoprotein Ig associated disease (MOGAD) are autoinflammatory diseases 
of the central nervous system (CNS) differing in incidence, pathogenesis and clinical fea-
tures1-5. These diseases are mediated by pathogenic lymphocytes, which are triggered in the 
periphery and contribute to local inflammation and demyelination. This was summarized in 
chapter 1. 
In this thesis, we assessed the antigen specificity, local recruitment and development of 
such lymphocytes to increase our understanding of the immunopathology of these diseases 
and find new ways to improve disease prediction and current treatment regimes. In this final 
chapter, the most important findings will be discussed and directions for future studies will 
be proposed. 
Antigen-specific T-cell responses in MS
In chapter 2, we assessed antigen-specific CD4+ and CD8+ T-cell responses using cell lines 
generated from cerebrospinal fluid (CSF) of early-stage MS patients. We used autologous 
Epstein Barr virus (EBV)-immortalized B-lymphoblastoid cell lines (BLCL) as antigen presenting 
cell (APC)6, 7. BLCL were transfected using a plasmid vector containing open reading frames8 
of one of eight MS candidate autoantigens (MSAg), selected based on previous reports9-19. 
With use of this system, we showed that none of these CD4+ or CD8+ CSF T cell lines (TCL) 
showed substantial reactivity towards any of the selected oligodendrocyte (myelin associ-
ated glycoprotein (MAG), myelin oligodendrocyte glycoprotein (MOG), proteolipid protein 
(PLP) and myelin basic protein(MBP)), glial (Kir4.1 (inwards rectifying potassium channel) 
and S100 calcium binding protein (S100B)) or neuronal (contactin-2 (CNTN2), neurofascin 
155-kD isoform (NF155)) antigens. These results are in sharp contrast to studies on periph-
eral blood derived T-cell studies9-19. This inconsistency can be explained by methodological 
differences, amongst others mononuclear cell (MNC) source, culture characteristics, used 
autoantigens and read out systems. These confounders will be discussed hereafter. 
Historically, the majority of research on T-cell antigen specificity in MS has been per-
formed using peripheral blood mononuclear cells (PBMC). CSF contains immune cells specif-
ically trafficking between brain parenchyma and the cervical lymph nodes20-23. Therefore, CSF 
MNC and PBMC differ in terms of phenotype and T cell receptor repertoire24 and since MS 
pathology is confined to the CNS, antigen-specific T cells are likely to be enriched here25. The 
lack of antigen specific responses found in our study is in line with the report by Wuest et al, 
who also used CSF derived T cells and autologous dendritic cells pulsed with CNS antigens as 
APC26. In contrast to Wuest et al, we generated short lived TCL27 in order to perform repeated 
analysis and validation experiments. Since in subjects with chronic immune responses like 
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MS, T cell exhaustion may occur28, 29 possibly causing selective outgrowth of our TCL and 
obliterating relevant responses. In contrast, techniques have been developed to facilitate 
prediction of T cell antigen-specificity on single cell level. For instance, by sequencing indi-
vidual TCR bound to labeled major histocompatibility complex (MHC)-tetramers with known 
epitopes. Combining these TCR sequences and correlating them to their specificity will 
eventually enable prediction of T cell antigen-specificities based on TCR sequence30. Even 
more recently, an algorithm has been developed also including mRNA and protein levels in 
combination with CDR3 sequence31. Future studies might use these techniques to determine 
antigen specificities for individual brain infiltrating T cells in MS directly ex vivo to circumvent 
culture induced alterations. 
An important issue to consider when attempting to prevent culture induced alterations 
is the presence of post-translational modifications32. In our study, BLCL expressed full 
length proteins, enabling post-translational modification by autologous APC. Alternatively, 
post-translational modifications are present in studies using brain derived proteins for anti-
genic stimulation10, 11. However, the use of brain-derived proteins as antigen requires highly 
pure protein fractions to prevent xenoreactivity against contaminants, leaving the possibility 
that these observed responses were false positive. When using peptides, post-translational 
modifications are absent, possibly skewing T cell responses. In order to compare T cell 
responses to different peptide levels with our MSAg BLCL-APC system, we used a measles 
virus fusion (MVF) protein specific TCL and MVF-nucleofected BLCL. Our MVF-BLCL induced 
similar levels of T cell responses compared to MVF antigen concentrations of 1 μM. This 
is in contrast to most studies using often high, non-physiological concentrations (25-250 
μM)33 of peptides to stimulate T cells, increasing the likelihood low-avidity TCR responses15, 
25, 33-35. Cells carrying these TCR are likely not to be activated in physiological circumstances. 
Different types of peptides can be used as well; some studies used synthetic overlapping 
peptides9, 12-17 or in silico predicted human leukocyte antigen (HLA) class I or class II binding 
peptides14, 36, 37. Selecting peptides based on prediction models inevitably introduces a bias 
for the selected HLA haplotypes. The same is true for tetramers38, 39. This can result in HLA-
haplotype-associated skewing of antigen-specific responses40-44. In our study, we used autol-
ogous EBV-BLCLs circumventing HLA-haplotype selection. The capacity of BLCL-APC system 
to detect autoantigen-specific responses, if present, has been shown in type 1 diabetes45-47. 
In light of the limitations associated with protein or peptide usage for detecting antigen spe-
cific responses, the use of our autologous APC system with endogenous expression of MSAg 
to trigger both antigen-specific CD4+ and CD8+ T cell responses is preferable.
To detect antigen specific responses, we used intracellular cytokine staining. In our CSF 
CD4+ and CD8+ TCL, we only stained for IFN-γ. This cytokine was chosen since both CD4+ 
(Th1) and CD8+ T cells have been reported to produce this in high levels48, 49. Furthermore, 








system using this cytokine was preferable. However, single staining for IFN-γ omits detection 
of other cytokines. For instance, granulocyte-macrophage colony-stimulating factor (GM-
CSF) has been reported to be an important contributor to MS immunopathology50, 51 and 
IFN- γ coproduction has been shown to be important in MS in chapter 3. Future studies are 
recommended to include antibodies targeting multiple cytokines when studying MS antigen 
specific T cell responses. 
Undeniably, the candidate antigens included in our screening panel affect outcome. 
Since publication of our article, some antigens have been shown to be the target of humoral 
responses (which necessitates CD4+ T cell help) in MS patients, including Kir4.152 , neuro-
fascin53 and PLP54. In contrast, S100B has recently been shown to be a more relevant bio-
marker in NMOSD compared to MS55 and a recent report states that MOG is not associated 
with adult MS56. New candidate antigens have been proposed since our paper has been 
published. For instance, CD4+ autoreactive T cells towards self-peptides (mainly HLA-DR2a 
and DR2b derived)43 have been described in patients carrying MS risk haplotype HLA-DR15. 
Interestingly, these CD4+ cells can cross react with EBV and bacterium Akkermansia, found 
in gut microbiome previously shown to be enriched in MS patients57 and a target of MS 
oligoclonal band (OCB) IgG58. Also in patients without the HLA-DR15-haplotype, autoreac-
tive CD4+ T cells with cross reactivity towards gut microbiome peptides have been shown to 
infiltrate the CNS59. These results provide the possibility that cross reactivity contributes to 
previously described autoimmune T cell responses in MS. In a follow up study using the BLCL-
APC system and MS associated antigen panel, T cells obtained from white matter lesions 
end-stage MS donors did not show CNS antigen-specific responses60. Interestingly, a strong 
reactivity of CD8+ T cells towards non-transfected BLCL was detected, suggesting a local EBV-
specific response in MS lesions.
For future studies after antigen specificity of T cells in MS, it would be of interest to 
include T cells obtain from leptomeningeal follicles, structures often present in MS (and dis-
cussed later in this chapter)61, 62. Furthermore, TCR derived from brain infiltrating T cells can 
be analyzed and cloned into TCR-null T cells to perform antigen-discovery experiments. In 
conclusion, auto-reactive T cells are likely to be involved in MS pathology, although the exact 
target of these cells remains enigmatic.
Highlights
 – Autologous BLCL are suitable as antigen presenting cell for studying reactivity of 
both CD4+ and CD8+ T cells to pre-defined candidate antigens 
 – No significant antigen-specific T cell response was detected against a panel of eight 
candidate MS-associated auto-antigens
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Recruitment of pathogenic T and B-cell subsets to the MS central nervous 
system
Th1-like Th17 cells 
In chapter 3, we investigated the frequency and distribution of IFN-γ, IL-17A and GM-CSF 
producing CD4+ T cell subsets in patients with CIS and MS. IL-17 producing CD4+ T cells (Th17) 
are traditionally characterized by expression of the ROR-γt transcription factor in combina-
tion with C-C motif chemokine receptor CCR6, whereas Th1 cells express C-X-C chemokine 
receptor CXCR3 via transcription factor T-bet63, 64. In peripheral blood of early onset CIS and 
RRMS patients, we observed lower frequencies of highly activated (HLA-DR+CD38+) CD4+ T 
cells expressing both CXCR3 and CCR6 as well as T-bet and ROR-γt. CXCR3 and CCR6 facilitate 
Figure 1. Model of distinct CNS-homing, T-bet-expressing B and T cell subsets in early MS. 
 CXCR3+IgG(1)+ B cells and Th17.1 cells migrate across the blood brain barrier with use of adhesion molecules, 
including VLA-4/VCAM-1 interaction among others. VCAM-1 is enriched on endothelial cells of brain vessels under 
inflammatory conditions. CXCL10 (cognate ligand for CXCR3) is upregulated in the inflamed CNS, which mediates the 
local attraction of these types of pathogenic lymphocytes. Classical Th17 do not express CXCR3 and are therefore 
not recruited by MS specific upregulation of this chemokine. In MS patients treated with natalizumab, we found 
that both subsets selectively accumulate in the peripheral blood. Their accumulation, re-activation and proliferation 








different migration routes into the CNS65. CCR6 expression primarily enables migration across 
the choroid plexus66, whereas CXCR3 migration is initiated towards its ligand C-X-C motif 
ligand CXCL10, that is highly produced in the MS brain parenchyma and CSF67-69. T-bet knock-
out animals were shown to be resistant for EAE induction due to downregulation of IFN-γ 
and upregulation of regulatory IL-1070. EAE was aggravated in mice deficient for STAT1, a 
signaling molecule upstream of T-bet71. 
In our study, IFN-γ was co-expressed with GM-CSF and less so with IL-17 in CCR6+CXCR3+ 
Th cells, which is in sharp contrast to mice72. GM-CSF can infiltrate the CNS via diffusion and 
active transport73 and is able to attract lymphocytes from the circulation74. Furthermore, 
both GM-CSF and IFN-γ contribute to breakdown of the blood brain barrier (BBB) by inducing 
local immune responses75, 76 and modifying BBB tight junctions77 respectively. BBB disruption 
is important in the early phase of MS since it facilitates infiltration of pathogenic immune 
subsets78, 79. Consistent with this, blocking of GM-CSF has been shown to prevent EAE disease 
onset in mice80. 
In line with their reduced proportions in the peripheral blood, short-term T cell cultures 
of CSF mononuclear cells from patients with early MS contained significantly more Th1-like 
Th17 cells (chapter 3). Furthermore, in these cultures, effector to central memory (EM/CM) 
ratios were significantly higher for Th1-like Th17 compared to Th1 and Th17 cells. After PMA/
ionomycin stimulation, CSF Th1-like Th17 cells produced more IFN-γ and GM-CSF compared 
to their counterparts in the peripheral blood, confirming the high pro-inflammatory capacity 
of this brain-homing subset. Their local enrichment was confirmed by ex vivo analysis of 
late-stage MS CSF and brain tissues. The proportion of Th1-like Th17 cells was also increased 
in brain tissues from controls but to a much lower extent. Under inflammatory conditions, all 
memory CD4+ T-cell subsets are able to migrate across the BBB81. In contrast, in non-inflam-
matory conditions, CXCR3+ T cells (including Th1-like Th17 cells) show an increased migra-
tory potential81. Of all the memory CD4+ T cells analyzed in our study, Th1-like Th17 cells 
and in particular the CXCR4- Th17.1 (discussed later in more detail) preferentially crossed 
non-inflamed hBEC monolayers in vitro even without the addition of CXCL10. Since CXCL10 
is not expressed in MS normal appearing white matter or healthy control brain tissue69, it is 
tempting to speculate that this subset triggers MS disease onset. 
Based on our analyses of ex vivo blood from natalizumab-treated patients, in which leu-
kocyte transmigration into the CNS is impaired, and paired blood and CSF samples of treat-
ment-naive patients, we confirmed that mainly Th17.1 cells are locally enriched in the early 
phase of MS. For these analyses, we included CCR4 as a third marker to subdivide Th1-like 
Th17 cells into Th17.1 (CCR4-/dim; IFN-γhighGM-CSFhighIL-17low) and Th17 DP (CCR4+; IFN-γlowGM-
CSFlowIL-17int) subsets. In contrast to non-responders to natalizumab (demonstrated by the 
ongoing clinical relapses), Th17.1 and not Th17 or Th17 DP cells selectively accumulated 
in the blood of patients who responded to natalizumab treatment. This suggests that the 
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blockade of this brain-homing subset contributes to the beneficial therapeutic effects. Due 
to the presence of anti-natalizumab antibodies in unresponsive patients82, it would be worth-
while identifying mechanisms by which migration of Th17.1 cells into the CNS can be blocked 
in other ways. Recent work postulates that natalizumab resistance may be caused by certain 
single nucleotide polymorphisms83, but further research providing immunological support 
for this statement is required. 
The selective increase of Th17.1 cells in the blood of clinical responders could explain 
partly results of a recent study, in which Th17.1 cells were moderately enriched in the twins 
with MS compared to non-affected twins84. Of the 43 patients included in this study, 21 used 
immune modulatory drugs, including natalizumab. However, the details on which twins 
where using which particular drugs were not available. A follow-up study including treat-
ment-naive monozygotic MS discordant twins will provide more direct insights in the effects 
of genetic and epigenetic factors on Th17.1 and other T-cell subsets. The pathogenicity of 
Th17.1 cells has been shown in other autoimmune and neurological diseases as well, includ-
ing myasthenia gravis85, sarcoidosis86, systemic lupus erythematosus87 and Graves’ disease88. 
In patients with neurodegenerative Huntington’s disease, Th17.1 cells seemed to be associ-
ated with the initiation and not progression of the disease, since this subset was enriched in 
the CSF of patients with preceding onset of clinical disease89. More insights into the induction 
and activation of Th17.1 cells are warranted to understand how this pathogenic subset con-
tributes to CNS immunopathology. One important aspect may be the fraction of follicular T 
helper cells, which have recently been reported to be enriched in MS CSF90. Follicular T cells 
not only get signals from B cells, but also trigger germinal center (GC) B cells to develop into 
memory and antibody-secreting cells. In MS patients, pathogenic T- and B-cell subsets likely 
interact both in the periphery and the CNS to mediate the pathogenesis. 
CXCR3+ memory B cells
In chapter 4, the frequencies and brain-infiltrating capacity of CXCR3+ B cells in MS patients 
were assessed. Particularly in mice, this B-cell population is known to be highly pathogenic 
and involved in other models of CNS inflammation and autoimmunity91. In accordance with 
Th17.1 cells in chapter 3, the proportion of IgG+CXCR3+ B cells in peripheral blood was sig-
nificantly reduced in treatment-naive MS patients compared to age-and-gender matched 
HC. When looking in deceased end-stage MS patients, CXCR3+ B cells were reduced in the 
peripheral blood and enriched in CSF, leptomeninges and brain parenchyma. CXCR3+ IgG+ B 
cells accumulated in the blood of MS patients treated with natalizumab, supporting the fact 
that memory subsets enter the CNS in a VLA-4-dependent manner92. Interestingly, the pro-
portions of IgG+CXCR3+ B cells positively correlated to those of Th17.1 and not Th1 or Th17 
cells. The accumulating CXCR3+ memory B-cell populations in natalizumab-treated patients 








oligoclonal bands (OCB)93, 94. This corresponded to the expression of T-bet, which induces 
IgG2a (the murine equivalent of human IgG1) switching in murine B cells95-97. When assessed 
in vitro, CXCR3high IgG1+B cells preferentially crossed confluent monolayers of human brain 
endothelial cells towards CXCL10 as compared to IgM+ and IgG2+ memory B cells. The dis-
ease-contributing role of IgG1 and T-bet expressing B cells has been shown in other autoim-
mune diseases, for instance in Sjogren’s syndrome and systemic lupus erythematosus98, 99. 
The selective recruitment of CXCR3+ B cells or plasmablasts towards the diseases sites has 
been shown previously in NMOSD patients100 and in a viral encephalomyelitis model91. 
IFN-γ has been shown earlier to induce CXCR3 expression on B cells101. We assessed the 
effect of IFN-γ on T-bet and CXCR3 expression by peripheral blood B cells of MS patients 
and healthy controls in vitro in TFH-like cultures to assess GC responses in vitro. IFN-γ upreg-
ulated T-bet and consecutive T-bet mediated CXCR3 expression in MS B cells to a larger 
extent compared to HC B cells. No enhanced T-bet or CXCR3 expression was seen in absence 
of IFN-γ. To analyze the impact of IFN-γ on the antigen-presenting function of B cells, we 
performed autologous T-cell co-cultures with B cells taking up Th1-associated Salmonella 
typhimurium bacteria via surface IgG. This crosslinking-based method was reported earlier 
to induce BCR-mediated uptake and antigen presentation102. During co-cultures with and 
without IFN-γ blocking antibody, we showed that IFN-γ production by autologous Th cells 
upregulates CXCR3 on IgG+ B cells. Proliferation and activation of co-cultured autologous T 
cells was reduced after IFN-γ blockade. These in vitro findings are in line with the described 
crucial role of T-bet+ B cells in the animal model autoimmune responses in systemic lupus 
erythematosus103, facilitating production of autoantibodies and GC generation. Another 
study reported that IFN-γ mediates GC-dependent development of autoreactive B cells in 
mice104. We observed an increase in plasmablast differentiation in vitro after addition of 
IFN-γ to culture medium. 
The effects of IFN-γ on B cells can be influenced by Toll-like receptor (TLR) stimulation105, 
106. TLR9 recognizes unmethylated CpG repeats in DNA sequences of pathogens and TLR9 
triggering has been shown to induce T-bet expression in B cells107 and enhance regulatory 
functions in the absence of IFN-γ108, 109. In naive, and not memory, MS B cells CpG-ODN syn-
ergized with IFN-γ to further enhance T-bet expression under TFH-like culture conditions (Fig. 
4). In addition, this TLR9 triggering blocked plasmablast development, but induced IgG1+ 
memory formation. This implies that both stimuli contribute to the formation of IgG1⁺ 
memory B cells. The high sensitivity of B cells from MS patients to IFN-γ and CpG110, prob-
ably facilitates migration of CXCR3highIgG+ subsets into the CNS. CXCR3highIgG+ B cell possibly 
migrate into the leptomeningeal follicle-like structures that have been reported frequently 
in MS patients61, 111, 112. Recent reports have shown that their presence correlates with demy-
elination, both subpial113, 114 and in the spinal cord115. Furthermore, our meningeal samples 
of end-stage MS patients contained significant numbers of CXCR3+ B cells. T-bet+ B cells have 
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recently been described to be present in follicle like structures in kidney of SLE mice103 and 
patients116. Once IgG1+CXCR3+ memory B cells have crossed the BBB, local re-activation can 
be sufficient to induce development of tissue-resident antibody secreting cells (ASC) in MS 
chronically inflamed CNS117. Future research is warranted to assess the antigenic target of 
these ASC. A possible target of local immune responses in the MS CNS might be EBV sug-
gested by a recent report on EBNA1- and EBNA2-specific IgG derived from MS brain118 and 
the observation that memory B cells with high EBV load show increased expression of CXCR3, 
facilitating CNS homing119. 
CXCL10 in MS
Both CXCR3+ cell types discussed here, Th17.1 cells and IgG1-T-bet+ B cells, preferentially 
migrate towards CXCL10 in our in vitro experiments. It is tempting to speculate this, at least 
partly, contributes to the correlation of CXCL10 levels with MS disease course. An alterna-
tive name for CXCL10 is interferon gamma-induced protein 1067, 120. However, it can also be 
produced upon TNF-α stimulation or after exposure to proteins from bacteria or virusses121, 
122. CXCL10 can be produced by various cell types, including lymphocytes, fibroblasts and 
endothelial cells. In MS patients, various cell types have been shown to produce higher levels 
of CXCL10 after IFN-γ and LPS stimulation compared to controls123. Like mentioned before, 
CXCL10 is abundant in MS CNS67-69. CXCL10 has been shown to be important for microglial acti-
vation in an EAE model124 and oligodendrocytes in MS brain express more CXCL10-receptor 
CXCR3 compared to oligodendrocytes from control brain125. In viral models, IFN-γ produced 
in the CNS induces CXCL10, attracting CXCR3+ T cells and damaging tight-junctions of the 
BBB, creating a feedforward loop with ongoing infiltration of pathogenic lymphocytes126, 
127. In MS, similar mechanisms could occur, further supported by the significant decrease 
of CSF CXCL10 levels in patients that have been successfully treated with natalizumab128, 
potentially hampering this cascade. GM-CSF production, for instance by IFN-γ and GM-CSF 
co-producing Th17.1 cells, might further damage the BBB74. In light of correlations of clinical 
MS course with CXCL10 levels, preventing CXCR3+ lymphocytes from entering the CNS by 
hampering CXCL10 mediated migration is therefore an interesting target for MS therapy. It 
has been reported that interferon-β increases peripheral levels of CXCL10129, thereby likely 
suppressing the gradient-mediated migration of CXCR3+ cells. Furthermore, nano-antibodies 
have been developed recently to selectively block CXCL10130. Future studies analyzing effect 
of these treatments on selective migration of Th17.1 and IgG1CXCR3+ B cells are warranted to 
investigate whether this can reduce disease activity, for instance in patients not responding 









 – Out of all memory CD4+ T- and B-cell subsets analyzed, Th17.1 and CXCR3+ B cells are 
selectively recruited to the CNS of MS patients
 – The increased brain-homing capacity of both subsets is confirmed in patients treated 
with natalizumab and in vitro using human brain endothelial monolayers 
 – IFN-γ is highly produced by Th17.1 cells and synergizes with TLR9 ligand CpG-ODN to 
induce CXCR3 expression and class switching in differentiating human B cells 
GC-like differentiation of B cells in MS: impact of pregnancy and comparison 
to AQP4-IgG+ NMOSD and MOGAD 
The final part of this thesis was devoted to development of pathogenic B cells and 
plasmablasts in neuro immunological disease. For this, we studied differentiation of naive B 
cells after entrance of the germinal center reaction in high- and low relapse risk MS as well as 
in the other demyelinating neuro immunological disorders AQP4-IgG+ NMOSD and MOGAD. 
Figure 2. In vitro recall B cell response. 
TFH-like conditions with CD40L and IL-21 using sorted memory B cells from 3
rd trimester and early postpartum from 
MS patients and HC.
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MS relapse risk is reduced during pregnancy and increases again early after delivery131, 132,, 
resulting in a low-relapse risk 3rd trimester and a high relapse risk post-partum. In chapter 
5, we find clues that the capacity of third trimester memory B cells to infiltrate the CNS and 
differentiate into ASC is attenuated, thereby potentially contributing to the low relapse risk 
during this period. 
First, we assessed ex vivo B cell subset distribution in different pregnancy stages. We 
observed reduced proportions of transitional B cells during pregnancy, most pronounced in 
3rd trimester, replicating earlier reports133. This reduction was seen in both MS patients and 
matched controls, rendering this a generic effect of pregnancy for instance mediated by a 
generic pregnancy-associated factor, such as increased circulating hormone levels117. This 
reduction might result in reduced numbers of autoreactive naive mature B cells. In normal 
situations in MS, primary B cell responses give rise to memory B cells, that can infiltrate brain 
parenchyma with use of the right receptors or integrins. It has been hypothesized that after 
local reactivation and recall B cell response, these cells develop into tissue resident ASC79. 
However, chemokine receptors also contribute to B cell localization in the GC134. In our ex 
vivo analysis, B cells that were obtained from 3rd trimester MS patients were likely to express 
chemokine receptors that retained cells into the GC-dark zones, thereby preventing devel-
opment of GC-dependent memory B cells. In contrast, in postpartum B cells we observed 
reduced expression of CXCR4, enhanced expression of CXCR5134 on IgM and IgG memory B 
cells as well as naive mature B cells facilitating migration to GC-light zones. The upregulation 
of CXCR5 expression was only significant in MS. Postpartum B cells expressed more CCR6, 
associated with memory recall response135 and CXCR3, contributing to antibody responses136 
respectively. CCR6 expression was enhanced more strongly on MS B cells. Together, chemo-
kine receptor expression of postpartum B cells was CXCR3highCXCR4lowCXCR5highCCR6high, facil-
itating TFH interaction in GC-light zones and memory B cell development. Immunoglobulin 
expression was altered by pregnancy as well. IgM was significantly higher on postpartum 
translational B cells, most pronounced in MS. Ex vivo expression of surface Ig was increased 
postpartum for both IgM and IgG memory cells. IgMhigh memory B cells primarily originate 
from GC137, again suggesting preferential GC-dependent memory cell formation postpartum. 
In our in TFH-like cultures, we found that memory B cells from postpartum blood samples 
of MS patients were more prone to differentiate into plasma cells. This resulted in increased 
production of IgM and IgG, which was not different between patients and controls. This sim-
ilarity seems counterintuitive due to increased numbers of ASC in MS. However, it might be 
possible that affinity of MS antibodies was higher, due to altered chemokine receptor expres-
sion profile and increased CD138 expression. Future studies confirming this are warranted. 
Local antibody deposition is a pathological characteristic of MS white matter lesions138, 
and a recent report showed that intrathecal IgG complexes may break human microglial 








CNS recruitment. The relevance of IgGs for MS is further highlighted by the high proportion 
(95%) of patients with oligoclonal bands at diagnosis140, which associates with lesional B cell 
infiltration and activity in autopsy studies141. Patients without OCB have in general less brain 
atrophy142 and disability143. Hence, the here described alterations in chemokine receptor 
expression on memory B cells may prevent local ASC formation and therefore contribute to 
the reduced relapse occurrence during pregnancy. 
Before entering the GC for further maturation, autoreactive B-cell clones are negatively 
selected during central and peripheral tolerance checkpoints. In MS, only the peripheral 
checkpoints are defective144, whereas in NMOSD both central and peripheral tolerance 
checkpoints are affected145, 146. Whether these checkpoints are impaired and contribute to 
the pathogenesis in patients with MOGAD is currently unknown. In chapter 6 we studied 
the naïve B cells and germinal center responses in NMOSD and MOGAD patients (Fig. 3). 
In treatment-naive NMOSD patients, transitional B cells were significantly upregulated. 
Figure 3. Representation of naive B cell to plasmablast differentiation in AQP4-IgG+ NMOSD and MOGAD patients 
with relapsing disease. 
A) In the blood of AQP4-IgG+ NMOSD patients, transitional B cells show increased frequencies and are targeted 
by steroid treatment. B) TFH-like cultures, mimicking in vivo GC-reactions, induce plasmablast outgrowth and Ig 
production. 
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Interestingly, this upregulation seemed associated with disease activity, since it was most 
pronounced in patients experiencing a relapse close to cell sampling. It is very likely that the 
central checkpoint deficits in NMOSD results in increased release of autoreactive transitional 
B cells into the circulation146. Since B cell depleting CD20 antibody rituximab was recently 
shown to be effective in preventing NMOSD relapses147, 148 and transitional B cells are the 
first to recover149, studies should focus on analyzing the long term effect of this treatment in 
NMOSD. In patients with MOGAD, the proportion of transitional B cells was not increased, 
which may imply that central tolerance checkpoints are not affected. Of note, while preg-
nancy reduces MS disease activity (as discussed earlier), relapse risk has been reported to 
be aggravated in pregnant NMOSD patients150, 151, although this more recently has been 
questioned due to lack of sufficient data152. This implies differential regulation of transitional 
B cells in the NMOSD peri-partum period. In NMOSD and MOGAD as well as CIS patients, 
steroid treatment reduced transitional B cell levels to a large extent. The lack of multi-drug 
resistant gene 1 (MDR1) in this subset probably renders cells more vulnerable for steroid-in-
duced cell death153, 154, explaining the treatment success of steroids in dampening acute 
disease activity as well as the frequent and quick relapses occurring after this treatment 
in NMOSD and MOGAD patients without maintenance therapy 155-157. Interestingly, in the 
high-level steroid hormone carrying pregnant woman (chapter 5), low levels of transitional B 
cells were observed as well. In treatment-naive NMOSD patients, proportions of circulating 
GC-independent CD27+IgM+IgD+ memory (natural effector) B cells were reduced compared to 
healthy controls and MOGAD patients, suggesting preferential GC-entrance of B cells. After 
steroid treatment, the frequencies of natural effector B cells returned to baseline levels. 
No differences were observed in ASC frequencies ex vivo, which may be explained by ASC 
homing to inflamed sites or bone marrow2, 145. Another reason may be the fact that we used 
frozen PBMC for our study. Future studies using non-frozen cells would be valuable, since 
freeze-thaw cycles affect plasmablasts158 and, in other models like viral infections159, such 
freezing effects can be different between patients and healthy individuals. 
The earlier described TFH-like culture system was used in NMOSD and MOGAD (chapter 
6) and MS (chapter 4) patients to investigate primary B cell responses (Fig. 4). For induc-
ing primary B cell responses, naive mature B cells were cultured in the presence of IL-21 
and CD-40-3T3 cells. Additionally, 1/3 of cultures received IFN-γ and 1/3 received IFN-γ 
together with TLR9 triggering CpG-ODN. In HC and treatment-naive MS patients included in 
chapter 4, plasmablast outgrowth was induced upon IFN-γ stimulation under these TFH-like 
conditions. In cultures with both IFN-γ and CpG-ODN, more IgG+-memory B cells and less 
plasmablasts were induced. For naive mature B cells from NMOSD and MOGAD patients 
(chapter 6), the addition of CpG-ODN to IFN-γ-containing cultures yielded alternative effects; 
only in patients with relapsing disease, irrespective of serotype (MOG-/AQP4-IgG), IFN-γ and 








only. Plasmablast outgrowth was reduced upon CpG addition in patients with stable disease, 
which was in line with effects on HC and MS patient B cells as shown in chapter 4 (Fig. 
4). T-bet was upregulated by both IFN-γ and CpG-ODN in both relapsing and non-relapsing 
groups. In NMOSD, IFN-γ possibly induces IL-6 production by B cells160, with consequent TLR9 
upregulation161. IL-6 facilitates survival of plasmablasts162, 163 and induces the expansion of 
circulating TFH cells in NMOSD164, possibly creating a feedforward loop by further enabling 
B-cell differentiation into ASC. In this particular aspect, MOGAD seems to be more similar to 
NMOSD compared to MS, since increased ASC outgrowth upon CpG stimulation in patients 
with active disease is seen in this group as well. However, in our studies using MS B cells, 
samples were not separated based on disease activity. It might be interesting to separate 
MS patients with active and more stable disease and observe whether this synergistic effect 
is NMOSD/MOGAD specific or more associated with disease activity. Furthermore, it might 
be of additional value to compare sample B cells from NMOSD patients with and without 
Figure 4. Investigating in vitro primary B cell responses in demyelinating disease.
TFH-like conditions were simulated with CD40L and IL-21. IFN-γ and CpG was added to some cultures using sorted 
memory B cells from MS patients and NMOSD and MOGAD patients with stable and relapsing disease. 
174





additional autoimmune disease, present in 20% of all patients165, since this can affect cell 
characteristics, for instance T-bet induction116, as well. 
Antibody production by peripheral B cells is presumed to be an important driver of 
NMOSD166-168. The importance of IgG in NMOSD pathology is demonstrated by the correla-
tion between antibody titers and disability169 and the reduced AQP4-IgG serum levels after 
successful anti-CD20 therapy170, 171. Naive mature B cells from NMOSD patients gave rise to 
AQP4-IgG producing B cells from relapsing NMOSD in the most basic culture condition (+ 
CD40L and IL-21) even in absence of antigen (Fig. 3B). This supports the idea that AQP4 
specific B cells can produce AQP4-IgG in the periphery that eventually cause pathology in the 
CNS100, 162, 172, 173. Cotzomi et al146 reported somatic hypermutation, and therefore GC-reactions, 
are indispensable to generate functional (i.e. detected by the cell based assays in our study) 
AQP4 antibodies. In contrast, exposing naive mature B cells from patients with MOGAD to 
TFH-like culture conditions did not result in disease-specific (i.e. MOG) IgGs.
Main findings
 – In the early postpartum (high relapse risk) period, memory B cells of MS patients 
show a chemokine receptor expression pattern that reflects localization in the GC 
light zones and an increased capacity to develop into ASC
 – Naive B-cell composition and outgrowth into ASC is associated with disease activity 
and AQP4-IgG production in patients with NMOSD
This thesis was devoted to development, antigen specificity and local recruitment of 
lymphocytes in CNS autoimmunity. Although many questions remain and need to be investi-
gated, here we identified relevant T- and B-cell subsets and triggers that are involved in MS, 
NMOSD and MOGAD. Since we used primarily patient material it is hard to prove causation. 
Combining research in human samples with studies using animal models in which many fac-
tors can be controlled, will be valuable. New techniques based on information technology 
and mathematical models, might add even more. We argue that future research into the 
development and reactivity of the here discussed pathogenic subsets will result in valu-
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APC antigen presenting cell
APRIL  a proliferation inducing ligand
AQP4  aquaporin 4
ASC  antibody secreting cell
BBB  blood brain barrier
BCR  B cell receptor
BLCL  EBV transformed B cell
CCR/L  c-c motif chemokine receptor/ligand
CD  cluster of differentiation
CD40L  CD40 ligand 
CDMS  clinically definite multiple sclerosis
CIS  clinically isolated syndrome
CM  central memory
cMSAg  candidate MS associated antigen
CNS  central nervous system
CpG-ODN CpG oligodeoxynucleotides
CSF  cerebrospinal fluid
CTN2  contactin 2
CXCR/-L  CXC chemokine receptor/ligand
EAE  experimental autoimmune encephalomyelitis 
EBNA  Epstein-Barr nuclear antigen
EBV  Epstein-Barr virus
ELISA  enzyme-linked immune sorbent assay
EM  effector memory
FACS  Fluorescence activated cell sorting
GC  germinal center
GM-CSF  granulocyte macrophage colony-stimulating factor
HC  healthy control
HEK  Human embryonic kidney cell
HLA  human leukocyte antigen
IFN  interferon
Ig  Immunoglobulin 
IL  interleukin
KIR4.1  potassium inwardly-rectifying channel
MAG  myelin associated glycoprotein
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MBP  myelin basic protein
MFI  mean/median fluorescence intensity
MHC  major histocompatibility complex
MNC  mononuclear cell
MOG  myelin oligodendrocyte glycoprotein
MOGAD  myelin oligodendrocyte glycoprotein IgG associated disease
MS  multiple sclerosis
MVF  measles virus fusion protein
NFASC 155 kd isoform of neurofascin
NMOSD  neuromyelitis optica spectrum disorders
OCB  oligoclonal bands
ORF  open reading frame
PB  plasmablast
PBMC  peripheral blood mononuclear cell
PC  plasma cell
PLP  proteolipid protein
PP  post-partum
PPMS  primary progressive MS
PRR  pattern recognition receptor
RRMS  relapsing remitting multiple slerosis
S100B  S100 calcium binding protein B
SLE  systemic lupus erythematosus
T-bet  T-box transcription factor
TCC  T cell clone
TCL  T cell line
TCR  T cell receptor
Tfh  follicular T helper cell
Th  T helper cell
TLR  toll like receptor








Multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) and myelin 
oligodendrocyte glycoprotein (MOG) antibody disease (MOGAD) are demyelinating diseases 
of the central nervous system (CNS). Although these diseases differ in clinical features, an 
aberrant response of lymphocytes is thought to be driving the pathogenesis of all three dis-
orders. In this thesis, specificity, local recruitment and development of lymphocyte subsets 
involved in the pathogenesis of these diseases have been studied. 
Chapter 1 outlined the current state of knowledge of MS, NMOSD and MOGAD epidemi-
ology and risk factors. The similarities and differences between diseases are discussed as are 
the different views on pathogenesis which have changed significantly over the years. 
In Chapter 2, we studied the antigen specificity of cerebrospinal fluid (CSF) derived T 
cell lines in MS. As antigen-presenting cells, we used autologous B cells immortalized with 
EBV and transfected with a selection of MS-associated antigens (MSAg; contactin-2, inward 
rectifying potassium channel protein, myelin associated glycoprotein, myelin basic protein, 
myelin oligodendrocyte glycoprotein, neurofascin, proteolipid protein, protein S100B). This 
physiologically advantageous model was shown to be useful for triggering both antigen-spe-
cific CD4+ and CD8+ T cells. However, no significant responses were detected against the 
MSAg of choice.
In chapter 3, we found that a functionally distinct Th1-like Th17 subset termed Th17.1 was 
selectively associated with early disease activity in MS patients. This IFN-γhighGM-CSFhighIL-
17low CD4+ T cell subset was less present in the peripheral blood of patients who rapidly 
develop MS, enriched in MS CSF and brain tissues and highly capable of migrating across con-
fluent human brain endothelial monolayers in vitro. Interestingly, in RRMS patients treated 
with natalizumab, only Th17.1 cells accumulated in the blood of clinical responders. This 
was not seen in non-responders, supporting the role of this brain-homing T-cell subset in 
inducing MS disease activity. 
Regarding B cells, we showed in Chapter 4 that IFN-γ-related CXCR3+ populations were 
significantly enriched in MS CSF, meninges and brain compared to paired blood. The brain-in-
filtrating capacity of CXCR3+ B cells was underlined both in vitro and ex vivo using the same 
transmigration systems and blood samples from natalizumab-treated patients as in Chapter 
3. During TFH-like cultures with naive B-cells IFN-γ mainly triggered plasmablast formation, 
while the addition of both IFN-γ and Toll like receptor (TLR) 9 ligand (CpG-ODN) resulted in 
switching to IgG1. 
Chapter 5 addressed B-cell differentiation in pregnant MS patients and healthy controls 
in the context of relapse risk. When comparing B cells between the high relapse risk period 
(4-8 weeks after delivery) and low relapse risk period (third trimester of pregnancy), memory 
B cells showed an altered chemokine receptor expression profile related to increased 
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migration into the CNS and preferential localization in the TFH cell-containing germinal center 
light zone. In addition, we found that postpartum memory B cells are more able to differen-
tiate into plasma cells in a TFH-dependent manner in vitro, which may contribute to their final 
maturation in the CNS. 
In Chapter 6 we observed high frequencies of transitional B cells in treatment naive 
patients with NMOSD compared to patients with MOGAD, MS and healthy controls. These 
high frequencies were most prominent in patient samples obtained close to relapse. Steroid 
treatment reduced proportions of transitional B cells in NMOSD, MOGAD and MS. In vitro, 
germinal center-like cultures containing IFN-γ induced plasmablast outgrowth. However, 
only in relapsing NMOSD and MOGAD patients, CpG-ODN synergized with IFN-γ to further 
enhance plasmablast outgrowth. In patients with stable disease, addition of CpG-ODN to 
culture medium reduced plasmablast proportions. AQP4 specific IgG could be found in the 
supernatant of patients with relapsing NMOSD. MOG specific IgG was not found. In conclu-
sion, naive B cell homeostasis is altered in NMOSD and affected by corticosteroids. 
Chapter 7 summarized results, compared outcomes between different studies and pro-








Multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) en myeline 
oligodendrocyt glycoproteïne (MOG) antistof geassocieerde ziekte (MOGAD) zijn demye-
liniserende ziekten van het centrale zenuwstelsel (CZS). Hoewel deze ziekte verschillen in 
pathologie, incidentie en patiëntkarakteristieken, hebben ze gemeenschappelijk dat er een 
afwijkende reactie van lymfocyten ten grondslag ligt aan de immunopathologie van de ziek-
ten. In dit proefschrift is gekeken naar specificiteit, lokale verrijking en ontwikkeling van ver-
schillende groepen lymfocyten die zijn betrokken bij de pathogenese van deze drie ziekten. 
Hoofdstuk 1 introduceert de huidige stand van zaken van de wetenschap omtrent MS, 
NMOSD en MOGAD en de betrokken lymfocyten. Gelijkenissen en verschillen tussen deze 
ziekten worden behandeld alsook de veranderende kijk op de pathogenese door de jaren 
heen, aangezien daar de nodige wijzigingen in zijn opgetreden. 
Hoofdstuk 2 kijkt naar de antigeen specificiteit van T cel lijnen die zijn gehaald uit hersen-
vocht van patiënten met MS. Om dit goed te kunnen bestuderen, is er gebruik gemaakt 
van autologe B cellen die onsterfelijk gemaakt zijn middels EBV infectie en via transductie 
één van een geselecteerd panel van kandidaat antigeen tot expressie brengen (contactin-2, 
kaliumkanaaleiwit, myeline geassocieerd glycoproteïne, myeline basiseiwit, myeline oligo-
dendrocyt glycoproteïne, neurofascine, proteolipide eiwit en S100B eiwit). Deze manier van 
antigeen presentatie maakte het uitlokken van antigeen specifieke responsen bij zowel CD4+ 
als CD8+ T cellen mogelijk. Er werd geen significante antigeen specifieke reactiviteit van de T 
cel lijnen gevonden tegen dit panel van kandidaat MS antigenen. 
In hoofdstuk 3 vonden we dat aanwezigheid van de specifieke Th17.1 subset, die zowel 
op Th1 als Th17 lijkt, gecorreleerd was met vroege ziekteactiviteit in MS. De subset produ-
ceert significante hoeveelheden IFN-γ en GM-CSF en een kleine hoeveelheid IL-17. Th17.1 
waren verlaagd aanwezig in het bloed van patiënten die snel MS ontwikkelden, verrijkt in 
MS hersenvocht en breinweefsel en hadden een groot migrerend vermogen over een cel-
laag met brein endotheelcellen in vitro. In het bloed van patiënten die werden behandeld 
met natalizumab, een VLA4 antistof, werd een selectieve ophoping van dit celtype gezien 
waarschijnlijk door verminderde migratie naar het CZS. In patiënten die ondanks natali-
zumab behandeling toch een nieuwe aanval kregen, vond geen ophoping van Th17.1 plaats, 
suggererend dat niet effectieve blokkade van de Th17.1 in deze patiënten bijdraagt aan de 
ontwikkeling van MS schubs. 
Kijkend naar B cellen in hoofdstuk 4, ontdekten we dat een CXCR3+ celtype selectief 
verrijkt was in het CZS (hersenvocht, meningen en hersenweefsel) vergeleken met bloed. 
Het migrerend vermogen van deze cellen naar het brein werd ondersteund door door 
vergelijkbare in vitro en ex vivo bevindingen als in hoofdstuk 3. Tijdens in vitro kweken met 
TFH-condities zorgde toevoeging van IFN-γ vooral voor het ontstaan van plasmablasten. Als 
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daarbovenop nog Toll like receptor (TLR) 9 ligand CpG-ODN werd toegevoegd, trad voor-
namelijk isotype verandering naar IgG1 op. 
Hoofdstuk 5 bestudeerde B cellen in zwangere MS patiënten en gezonde controles als 
model van ziekte activiteit. Bij het vergelijken van B cellen tijdens periodes van hoge ziekte 
activiteit (4-8 weken na bevalling) en lage ziekte activiteit (derde trimester van de zwanger-
schap) viel een verschil op tussen de chemokine receptoren die de geheugen B cellen tot 
expressie brachten. Postpartum faciliteerden deze receptoren migratie naar het brein alsook 
lokalisatie in de lichte zone van de kiemcelcentrumreactie. Daarnaast vonden we dat B cellen 
die verkregen waren van postpartum MS patiënten makkelijker differentieerden tot plasma 
cellen in vitro in kweken die de aanwezigheid van folliculaire T-helpercellen nabootsen. Dit 
draagt mogelijk bij tot hun differentiatie tot mature cellen in het CZS. 
In hoofdstuk 6 ontdekten we dat in onbehandelde patiënten met NMOSD hoge percent-
ages transitionele B cellen aanwezig zijn in vergelijking met onbehandelde MS en MOGAD 
patiënten en gezonde controles. Deze waren het meest uitgesproken aanwezig bij patiënten 
die kort voor of na bloedafname een ziekteaanval kregen. Deze B cell subset werd specifiek 
verlaagd in patiënten die behandeld waren met steroïden. In vitro ontstonden er in aan-
wezigheid van IFN-γ in kweken van alle patiënten plasmablasten. Echter, alleen in patiënten 
met een recente ziekteaanval werd het aantal plasmablasten verder verhoogd na toevoeging 
van een TLR9 ligand. In patiënten met stabiele ziekte werd de plasmablast differentiatie hier-
door juist verminderd. In het supernatant van deze kweken van sommige NMOSD patiënten 
met recidiverende ziekteaanvallen konden AQP4 specifieke antistoffen worden aangetoond. 
De aanwezigheid en ontwikkeling van naïeve B cellen in NMOSD patiënten verschilt ten 
opzichte van controles en patiënten met andere neuroimmunologische ziekten. Dit wordt 
beïnvloed door corticosteroïden.
In hoofdstuk 7 werden de resultaten samengevat, de uitkomsten vergeleken en 
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